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ABSTRACT
Androgen deprivation therapy (ADT) is a cornerstone treatment option for 
men with metastatic or locally advanced prostate cancer, however, treatment 
with ADT has been associated with increased incidence of adverse 
cardiovascular events. Strategies to investigate and monitor cardiovascular 
risk, as well as to reduce such treatment-related morbidity are urgently 
required in this population.
Study 1 of this thesis investigated the differences in endothelial function 
between men with advanced prostate cancer treated with ADT and matched 
controls using a case-control design. Flow-mediated dilatation (FMD) and 
glyceryl-trinitrate (GTN)-mediated dilatation of the brachial artery were 
assessed in 20 men (69 ± 7 years) with prostate cancer treated with ADT for 
a median of 22 months (range 6-133 months) and compared against 20 
controls (69 ± 5 years) matched for age, history of cardiovascular disease 
and physical activity levels. FMD was reduced in men on ADT compared to 
controls (P <0.05) but no differences were observed between groups for 
GTN-mediated dilatation (P >0.05). These findings provide novel data to 
suggest endothelial function is impaired in men with prostate cancer treated 
with ADT, which is in agreement with evidence of increased cardiovascular 
risk in this population.
Study 2 investigated the effects of a 12-week lifestyle intervention including 
supervised exercise training and dietary advice on markers of cardiovascular 
health and general well-being in men treated with ADT for prostate cancer. 
Fifty men treated with ADT for >6 months were randomly allocated to receive 
the intervention or usual care. Assessments of vascular function, blood 
pressure, body composition, exercise tolerance and psychological well-being 
were undertaken prior to randomisation (baseline) and after completion of the 
intervention (end-point), with a follow-up assessment completed a further 12 
weeks after end-point assessments. Statistically significant differences 
between groups were observed for changes in skeletal muscle mass, body 
fat percentage, exercise tolerance, quality of life and fatigue (P <0.05). In 
addition, clinically meaningful effect sizes were observed for the difference 
between groups for the change between baseline and end-point in FMD and 
diastolic blood pressure (d >0.51), with post-hoc analysis demonstrating a 
statistically significant change in FMD in men in the intervention group (P = 
0.038). These findings support evidence that diet and exercise can improve 
general well-being of patients treated with ADT, and provide novel data on 
the effects of such an intervention on cardiovascular health.
xvi
1.0 INTRODUCTION
The concept of cancer survivorship has been redefined over the years. When 
cancer was considered incurable, the term "survivor” described family 
members who survived the loss of loved ones to cancer (Leigh, 1996). More 
recently however the term "cancer survivorJ' has been used to describe any 
person living with or beyond cancer (Macmillan Cancer Support, 2008). An 
individual will be considered a cancer survivor from the time of cancer 
diagnosis through the remaining years of life.
Data for the UK shows the number of people meeting this definition has 
steadily increased over the past decade (Maddams et al., 2009) and is 
projected to continue to rise over the next 20 years (Mistry et al., 2011). 
There are currently 1.8 million cancer survivors in England and 2 million 
across the whole of the UK, but in consideration of the growing and aging 
population and the improvements in cancer survival rates, these numbers are 
expected to rise by 3% per year; it has been estimated that there will be 3 
million cancer survivors in England by 2030 (National Cancer Survivorship 
Initiative, 2013). Accordingly, there is growing incentive to develop strategies 
to support and care for this population. This has led to the Department of 
Health, in collaboration with Macmillan Cancer Support, developing a 
National Cancer Survivorship Initiative (NCSI) in the UK, which was launched 
in January 2010. The NCSI has sought to engage patients, clinicians, policy 
makers and members of the research community to review and develop the 
most effective models of services, care and cancer support to address the 
physical, psychological, social and economic needs of cancer survivors 
(Richards et al., 2011).
Increasing attention to accommodate these needs of individuals with cancer 
is clearly warranted in consideration of the relatively poorer health and well­
being reported among cancer survivors. Comparing the health of individuals 
with a previous cancer diagnosis to individuals who had never been treated
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for cancer, the 2008 national population-based survey in the UK found that 
cancer survivors had worse general health, with greater on-going health 
problems, resulting in greater use of health services (Elliott et al., 2011). 
These data are further supported by evidence of increased prevalence of 
depression (Massie, 2004; Burgess et al., 2005), osteoporosis (Khan et al., 
2011; Reuss-Borst et al., 2012), heart failure (Hooning et al., 2007; Chen et 
al., 2012) and coronary artery disease (Krone, 2010; Zoller et al., 2012) in 
cancer survivors.
The incidence of cardiovascular disease among cancer survivors is one area 
of growing concern with increasing evidence describing greater 
cardiovascular risk among patients with different site-specific cancers 
(Hooning et al., 2007; Yusuf et al., 2008; Keating et al., 2010; Fu et al., 2011; 
Daher et al., 2012; Weaver et al., 2013). Studies have shown increased 
prevalence of cardiovascular risk factors (Daher et al., 2012; Weaver et al., 
2013) and increased incidence of cardiovascular events among cancer 
survivors (Hooning et al., 2007; Keating et al., 2010; Fu et al., 2011). 
Moreover, cardiovascular disease is now considered a leading cause of 
death for patients with cancers of the breast, prostate, colon-rectum and 
endometrium (Baade et al., 2006; Patnaik et al., 2011; Shikanov et al., 2012; 
Ward et al., 2012)
Although the evidence describing an increase in cardiovascular risk in cancer 
survivors has continued to grow this has been primarily focussed around 
traditional cardiovascular risk factors (e.g. blood pressure, body composition, 
lipid profile), with limited data currently available on changes in more novel 
markers of cardiovascular risk (e.g. markers of vascular inflammation, 
endothelial progenitor cells, endothelial function) in this population. Such a 
paucity of data in this area could mean that there is limited understanding of 
the increase in cardiovascular risk in cancer survivors, while possible means 
of monitoring cardiovascular health in this patient group are also not being 
utilised. Furthermore, strategies to reduce cardiovascular risk in cancer 
survivors are currently also sparse. Although drug therapies have been 
described for the treatment of cardiovascular complications such as heart
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failure, hypertension, thromboembolism and arrhythmias occurring after 
treatment with radioactive or chemotherapeutic agents (Yeh and Bickford,
2009), such additional treatment regimens must be used with care due to the 
possible further side-effects that are inherent in individual drug therapies 
(Lamy, 1988; Tomlinson and Mangione, 2005; Born and Patrono, 2006) or 
that can result from interactions between drugs. Accordingly, the use of non- 
pharmacological therapies to reduce the risk of cardiovascular disease could 
provide a preferable treatment pathway as an adjunct to individual cancer 
therapeutic strategies.
In disease-free individuals and other patient groups, lifestyle interventions 
including diet and exercise have been shown to lead to reductions in 
cardiovascular risk (Myers, 2003; Green et al., 2008) and reduced incidence 
of cardiovascular events and mortality (Lee et al., 1999; Hamer et al., 2012), 
yet evidence for the benefits of such strategies in cancer survivors is sparse. 
The possible use of lifestyle interventions to reduce cardiovascular risk has 
been specifically described for patients with prostate or breast cancer 
(Galvao et al., 2009; Knobf and Coviello, 2012), and has been noted in 
reviews of possible benefits of lifestyle changes in cancer survivors (Schmitz 
et al., 2010; Rock et al., 2012; Sabiston and Brunet, 2012), however, 
evidence to support such claims remains very limited. Where evidence exists, 
it is strongest in breast cancer survivors.
Further research is clearly warranted into the mechanisms of development, 
monitoring and management of cardiovascular risk in cancer survivors. With 
the projected increase in the number of cancer survivors, such research 
could help to reduce the burden of comorbidity upon patients and the burden 
of treatment costs on health-care providers. As such, such research is in line 
with the latest guidance on improving outcomes for cancer survivors recently 
published by the NCSI (Department of Health, 2013).
In this regard, investigations in men with prostate cancer treated with long­
term androgen deprivation therapy (ADT) are of particular interest. The 
widespread use of this form of treatment, which has itself been associated 
with numerous side-effects including the deterioration of cardiovascular
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health, means that a large number of men are potentially at risk, with 
attendant morbidity and treatment costs.
The studies described in this thesis aim to fill some of the gaps in knowledge 
which exist in this area. In the first part, concluding with the cross-sectional 
study of the effects of treatment of prostate cancer with ADT on endothelial 
function, prostate cancer and its treatment are considered with particular 
regards to the potential effects of ADT on cardiovascular risk. In the second 
part, concluding with the intervention study of the effects of supervised 
exercise training and dietary advice on markers of cardiovascular risk in men 
treated with ADT for prostate cancer, the effects of a 12 week lifestyle 
intervention including supervised exercise training and dietary advice on 
markers of cardiovascular health and general quality of life are examined. 
The final discussion at the end of this thesis aims to bring together the 
findings of these two studies and consider the implications for further 
research into the management of cardiovascular health in prostate cancer 
survivors in the future.
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2.0 REVIEW OF LITERATURE: Study 1
2.1 Cancer
Cancer can be defined as a molecular disease characterised by progressive 
accumulation of a mass of cells, as a result of excessive reproduction of cells 
not compensated by cell loss; these cells progressively invade and damage 
the tissues and organs of the host (Lowitz and Casciato, 2012). Cancer cells 
develop as a result of alterations in cellular signalling caused by mutations of 
the primary nucleotide sequence of cellular deoxyribonucleic acid (DNA). 
Mutations that develop in genes responsible for cellular growth (oncogenes 
or tumour suppressor genes) or preserving DNA repair (so-called 'caretaker' 
gene) might not influence cell function, but can lead to increased cellular 
proliferation and subsequent tumour development (neoplasm). These 
mutations can be the result of various mechanisms, which can include 
imprecise DNA repair, random replication errors, messenger ribonucleic acid 
(mRNA) processing errors, exposure to carcinogens, or incorporation of 
exogenous DNA into the genome (O'Dwyer and Frattini, 2010).
Tumours can be classified as benign or malignant. Benign (non-cancerous) 
tumours will remain localised and encapsulated and are considered safe 
unless they impede vital tissues or organs. Conversely, malignant tumours 
possess the ability to spread from the original tumour site to infiltrate other 
tissues and organs around the body. This spread is termed metastasis, and 
can lead to secondary tumour development, possibly affecting the function of 
tissue / organs at the new site (Clancy and McVicar, 2009).
There are different types of cancer, with the defining characteristic of each 
being the types of cell in which the cancer originates. While the term 
carcinoma is used to describe cancers of epithelial origin (e.g. the skin or 
tissues that line or cover internal organs), sarcoma describes cancers that 
originate from tissues of mesodermal components, namely bone, cartilage, 
fat, muscle, blood vessels or other connective or supportive tissues. Other
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types of cancer include leukaemia (cancers starting in blood forming tissues, 
e.g. bone marrow), lymphoma and myeloma (cancer beginning in the cells of 
the immune system) and gliomata, central nervous system cancers (cancers 
originating in the tissues of the brain or spinal cord; National Cancer Institute, 
2012).
Although current knowledge of cancer is based on many recent scientific 
discoveries, cancer has been known about since the time of Hippocrates 
(460 BC - 377 BC) when it was termed karcinos (Porter, 1997). Later, Galen 
(130 AD - 200 AD) considered cancer a species of inflammation, while 
endorsing the Hippocratic counsel view that deep or hidden cancers should 
not be treated. The hypothesis from these early scholars was that a tumour 
might form because of too much blood in the veins, or as a transmutation of a 
scirrhus formed by a flux of black bile mixed with blood.
2.1.1 Cancer incidence and mortality
Currently cancer is more prevalent than ever, with an estimated 12.7 million 
new cancer cases and 7.6 million cancer deaths occurring worldwide in 2008 
(International Agency for Research on Cancer, 2009a). This represents a 
continual increase in both cancer diagnosis and mortality through the past 20 
years, with 10.9 million new cases and 6.7 million deaths reported in 2002,
10.1 million new cases and 6.2 million deaths in 2000 and 8.1 million new 
cases and 5.2 million deaths in 1990 (Parkin et al., 1999; Parkin, 2001; 
Parkin et al., 2005). It has been predicted that this trend for increasing cancer 
incidence will continue through the next two decades with an estimated 22.2 
million new cases worldwide by 2030 (Bray et al., 2012).
Similarly, in the UK cancer incidence and mortality have continued to 
increase. In the most recent data presented by the Office for National 
Statistics (2012), there were 324,579 new cancer cases and 157,275 cancer 
deaths in 2010 alone. This represents an 18% increase in new cancer cases 
and a 2% increase in cancer deaths since 2001. Maddams et al. (2009) 
estimated that there would be around 2 million cancer survivors in the UK at
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the end of 2008. Moreover, they suggested that approximately one in three 
people in the UK would be diagnosed with cancer in their lifetime and one in 
four would die from it.
This pattern of increasing cancer incidence is mirrored by the growing 
financial burden of the disease. Cancer spending in the UK in 2009-2010 was 
£5.86 billion, accounting for 5.6% of total health spending for the year 
(Sullivan et al., 2011). In the USA cancer spending has increased from $27 
billion in 1990 to $90 billion in 2008. It is predicted that by 2020 it will reach 
$173 billion, a rise of >600% in 30 years (Mariotto et al., 2011).
These data highlight the need for more strategies to reduce the burden of 
cancer. As the number of people living beyond a diagnosis of cancer 
continues to rise, it is important that their needs for maintaining quality of life 
can be met in a cost-effective manner.
2.2 The prostate
The prostate gland is described in Dorlands Medical Dictionary (2007) as "a 
gland In the male that surrounds the bladder neck and urethra. It consists of 
a median lobe and two lateral lobes, and is made up partly of glandular 
matter whose ducts empty into the prostatic part of the urethra, and partly of 
muscular fibres that encircle the urethra".
The prostate is doughnut shaped, and about the size of a golf ball, measuring 
approximately 4 cm across, 3 cm in height and 2 cm deep (Figure 2.1). The 
anatomy of the prostate is widely known by the zonal subdivisions first 
described by McNeal (1968) which uses the urethra as the primary anatomic 
reference point. The central zone constitutes about 25% of the prostate gland 
and is located at the base of the prostate surrounding the ejaculatory ducts. 
The peripheral zone makes up around 70% of the glandular prostate and is 
described as the sub-capsular portion of the posterior aspect of the prostate 
gland that surround the distal urethra. The transitional zones accounts for 
around 5% of the prostate and are located along the proximal urethra.
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Prostate size increases in three main phases throughout life; from birth to 
puberty it expands slowly, from puberty to approximately 30 years of age it 
expands rapidly and after 45 years of age further growth can also take place 
(Tortora and Derrickson, 2006). In normal function the prostate secretes an 
alkaline fluid that neutralizes acidic vaginal secretions, thus increasing sperm 
motility by creating a slightly alkaline environment. Additionally, the prostate 
secretes clotting enzymes, including prostate-specific antigen (PSA), and 
fibrinolysin into semen prior to ejaculation. Clotting enzymes interact with 
fibrinogen from the seminal vesicles to produce fibrin which clots semen, and 
hence helps to ensure ejaculate remains in the female reproductive tract after 
withdrawal of the penis. Subsequently, the fibrin-degrading capacity of 
fibrinolysin breaks the clot down to release mobile sperm within the 
reproductive tract (Sherwood, 2007).
Glandular elements 
of prostate
Openings of 
ejaculatory ducts
Prostatic utricle
Openings of 
ducts of glandular 
elements of prostate
Fibromuscular
stroma
(smooth muscle and 
fibrous connective tissue
- Deep perineal pouch
Internal urethral sphincter 
(smooth muscle)
Prostate
External urethral 
sphincter (skeletal muscle)
 Perineal membrane
Prostatic sinuses
Seminal colliculus
Urethral crest
Figure 2.1. The prostate. Image taken from Drake et al. (2010)
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2.3 Prostate cancer
The majority of malignancies of the prostate are a form of carcinoma termed 
adenocarcinomas (cancers developing in glandular cells lining certain 
internal organs and that have gland-like properties). Other forms of prostate 
cancer can include small-cell carcinoma or prostate sarcoma, however both 
of these forms of prostate cancer are rare accounting for about 1% and 0.1% 
of prostate malignancies, respectively (Nuttings et al., 1997; Pace et al.,
2010).
Approximately 70% of prostatic adenocarcinomas form in the peripheral zone 
of the gland, around 20% arise in the transitional zone and fewer than 10% 
arise in the central zone (Byar and Mostofi, 1972). Local tumour growth 
results in invasion of the prostate gland and surrounding tissues, with the 
seminal vesicles, bladder and rectum the most common sites for infiltration. 
Metastases of the spine are most common although all parts of the skeleton 
could be affected bringing about potential pathological fractures, spinal cord 
compression, or neurological symptoms dependent upon metastases location 
(Neal and Hoskin, 2003; Mehta et al., 2007).
Although prostatic tumours can remain latent and are discovered only at 
autopsy (Damber and Aus, 2008), the implications of symptomatic disease 
can be physiologically and psychologically damaging for the patient. 
Presenting symptoms can include: prostatic obstruction of urine affecting 
frequency, hesitancy, poor stream, nocturia and terminal dribble; 
haematospermia; bone pain or infrequently spinal cord compression as an 
effect of bone metastases; hypercalcemia and general symptoms of 
malignancy including malaise, anorexia and weight loss (Neal and Hoskin, 
2003), although currently, the commonest presentation is with an elevated 
serum PSA concentration identified during opportunistic screening.
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2.3.1 Prostate cancer risk factors
Prostate cancer incidence is known to increase with age with the majority of 
men presenting between 60-80 years, and only rarely will men less than 50 
years be diagnosed with the disease (Mehta et al., 2007). Furthermore, 
family genetics have been linked to prostate cancer risk. In a study of cancer 
incidence in 44,788 pairs of twins from Sweden, Denmark and Finland, 42% 
of prostate cancer cases were attributed to inheritable risk, more than shown 
with any other form of cancer (Lichtenstein et al., 2000). These results are in 
agreement with others also showing high genetic risk in prostate cancer 
development (Steinberg et al., 1990; Page et al., 1997; Ahn et al., 2008). 
Indeed, Steinberg et al. (1990) reported that males with one, two or three 
first-degree relatives affected by prostate cancer would themselves have 
their risk for the disease increased by a factor of 2, 5 or 11, respectively.
Prostate cancer incidence has also been associated with several additional 
risk factors, although this is an area in which further research is clearly 
warranted as there is much contradictory evidence. Serum androgen 
concentrations have been linked to prostate cancer risk, however there is 
little consensus on the details of such an association. In the largest meta­
analysis performed on the relationship between sex hormones and prostate 
cancer risk, the Endogenous Hormone and Prostate Cancer Collaborative 
Group reported no link between the risk of prostate cancer and serum 
concentrations of total testosterone, free testosterone or 5a- 
dihydrotestosterone (DHT). Pooling data from 18 studies, including more 
than 10,000 men (3,886 with prostate cancer and 6,438 controls), a 
moderate inverse relationship was found however between sex-hormone 
binding globulin (SHBG) and prostate cancer risk (Roddam et al., 2008). Men 
in the highest fifth of SHBG concentrations had a risk ratio (RR) for the 
development of prostate cancer of 0.86 (95% Cl, 0.75-0.98) compared to 
men in the lowest fifth of SHBG, although this relationship did not achieve 
statistical significance. Notably, more recent studies in this area have 
reported alternative findings that do not fully support these results. Later in 
2008, Weiss et al. (2008) found no relationship between any serum sex
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hormones and prostate cancer risk, but did report an increase in disease risk 
with increased testosterone:SHBG ratio. Moreover, Daniels et al. (2010) 
found a strong relationship between increasing estrone concentrations and 
prostate cancer risk, but did not find disease incidence to be linked to any 
other sex hormones. Unfortunately, comparisons between these studies are 
complicated because of differences in the sex hormones investigated. 
Although both Weiss et al. and Daniels et al. contradicted the finding of an 
association between SHBG and disease risk, the evidence of relationships 
between testosterone:SHBG ratio and estrone concentrations with prostate 
cancer also cannot be confirmed as neither of these markers were reported 
in the other studies. These conflicting findings could be the result of 
differences between studies in sample size, or potentially influenced by 
different factors being used for adjustment of results for each study.
Lifestyle is also considered highly important in development of prostate 
cancer. High incidence rates (>31.0 cases per 100,000) in westernised 
countries such as Australia, Northern America and Western Europe, and 
lower incidence (<9.8 per 100,000) in parts of Africa and much of Asia 
suggest an environmental effect (Hsing et al., 2000; Quinn and Babb, 2002; 
Parkin et al., 2005; Garcia et al., 2007). This is further evidenced by the 
increased prostate cancer incidence among migrants moving from areas of 
low disease prevalence to areas of high disease prevalence (Shimizu et al., 
1991; Nasseri et al., 2007).
Dietary factors have been widely cited in this change in disease risk (Nelson 
et al., 2003). Data from the Health Professionals Follow-up study, a 
prospective cohort study involving 51,529 men, demonstrated that 
consumption of animal fat, especially from red meat, was linked with 
advanced cancers after 2 years of follow-up (Giovannucci et al., 1993), while 
after 10 years of follow-up there was a strong association between intake of 
red meat or processed meats and incidence of metastatic prostate cancer 
(Michaud et al., 2001). These findings are supported by others who also 
report a positive association between consumption of red and processed 
meats and risk of prostate cancer diagnosis (Rodriguez et al., 2006; Sinha et
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al., 2009; Ukoli et al., 2009). Although mechanisms behind this association 
have not been identified, it is hypothesized that cooking methods might be 
influential (Nelson et al., 2003). Studies in rats have shown eating meat 
cooked at high temperatures or broiled on charcoal grills can cause prostate 
cancer through the effects of heterocyclic aromatic amine and polycyclic 
aromatic hydrocarbon carcinogens formed in the cooking process (Stuart et 
al., 2000). These carcinogens have been reported to induce genetic damage 
resulting in cellular apoptosis or mutation, with the latter of these outcomes 
thought to be key in cancer development (Gooderham et al., 2002).
Additionally, calcium intake has been related to risk of prostate cancer 
incidence (Chan et al., 2001; Ahn et al., 2007). Chan et al. (2001) reported 
that in a cohort of 20,885 men, those who had a daily calcium intake >600 
mg per day, had a 32% higher risk of prostate cancer (95% Cl, 1.08-1.63) 
compared with men consuming <150 mg. Similarly, Ahn et al. (2007) 
described a 34% increased risk (95% Cl, 0.93-1.94) of prostate cancer in 
men consuming >2,000 mg per day compared to those consuming <1,000 
mg per day. However, the mechanisms underlying such an association are 
unclear and these findings have been contradicted by others who have 
reported no effect or a benefit of calcium intake on prostate cancer risk (Koh 
etal., 2006; Williams et al., 2012). Assessing the association between dietary 
calcium and prostate cancer in a sample of 500 men, Williams et al. (2012) 
reported lower disease risk in men in the highest tertile of calcium intake from 
food (median intake = 1,093 mg per day) compared to those in the lowest 
tertile of calcium from food (median intake 367.3 mg per; Odds ratio (OR) = 
0.37; 95% Cl, 0.15-0.90). Although the smaller sample size of the study by 
Williams et al. (2012) suggests this finding might be the result of a sampling 
issue, the fact that the statistically significant findings focus on calcium from 
food instead of total calcium is of interest, and thus these contradictory 
findings suggest further research in this area is clearly warranted.
Obesity is also recognised as a risk factor for prostate cancer with excess 
body fat reported to influence disease incidence, progression and mortality 
(Cooper-Buschemeyer and Freedland, 2007). Increasing body mass index
12
(BMI) has been positively associated with increased risk of prostate cancer in 
several large cohort studies including more than a million men (Andersson et 
al., 1997; Engeland et al., 2003). Moreover, investigations into whether or not 
BMI influences disease stage or grade at diagnosis demonstrated that men 
with a higher BMI were less likely to be diagnosed with localised disease, but 
were more likely to have high-grade or metastatic/fatal disease (Rodriguez et 
al., 2007; De Nunzio et al., 2011). This propensity towards higher-grade 
disease could be the result of several factors. Greater difficulty in diagnosis 
of prostate cancer in the obese could lead to a detection bias in which 
tumours are diagnosed only at more advanced stages in men with higher 
BMI (Cooper-Buschemeyer and Freedland, 2007). Additionally, there is 
evidence of physiological effects of increased adiposity predisposing 
overweight individuals to develop higher-grade cancers. Although, as 
previously described, there is some contradictory evidence of an association 
between serum androgens and total prostate cancer risk, lower pre-diagnosis 
serum androgens concentrations, as can be found with obesity, have been 
linked to increased risk for future high-grade disease (Platz et al., 2005; 
Severi et al., 2006). Furthermore, analyses of serum concentrations of 
oestradiol at diagnosis have demonstrated possible evidence of a positive 
association with more aggressive disease. Oestradiol concentrations have 
been shown to be increased in obese men due to high aromatase activity in 
adipose tissue (Vermeulen et al., 2002), and higher oestradiol has been 
linked to greater risk of more aggressive prostate cancer. Salonia et al. (2011) 
demonstrated that oestradiol concentrations >50 pg ml'1 were associated 
with a 3.24 fold increased risk of high-grade prostate cancer.
Although the evidence reviewed above suggests a strong relationship 
between BMI and prostate cancer, other studies have reported no 
relationship between BMI and disease risk (Lund Nilsen and Vatten, 1999). 
Part of the lack of agreement in results could be because of differences in 
body composition between study samples. Fowke et al. (2012) demonstrated 
that increases in disease risk with increasing BMI and waist circumference 
were mediated by measurement of total body fat free mass. It was suggested
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that this association was probably the result of measures of fat free mass 
reflecting shared genetic, hormonal and nutritional factors for maintenance of 
lean body mass and prostate carcinogenesis.
2.3.2 Prostate cancer epidemiology
International data for the year 2008 showed that prostate cancer was the 
second most frequently diagnosed cancer in men (after lung cancer) with 
13.8% of new male cancers diagnosed being of the prostate, a total of
913.000 new cases (International Agency for Research on Cancer, 2009b). 
Through the past five decades, disease incidence has continued to steadily 
rise in many nations through both the developed and developing world (Hsing 
et al., 2000; Quinn and Babb, 2002; Quaglia et al., 2003; Kvale et al., 2007; 
International Agency for Research on Cancer, 2009b), with worldwide mean 
age-adjusted disease incidence increasing 1.1% annually from 1985 to 2002 
(Parkin et al., 2005). Recent data for England demonstrate prostate cancer 
more than doubled between 1992 and 2010, with 15,705 registered new 
cases in 1992 increasing to 34,892 new cases in 2010 (Office for National 
Statistics, 2012).
Currently, prostate cancer is the sixth highest cause of male death attributed 
to cancer worldwide (behind cancers of the lung, liver, stomach, colon-rectum 
and oesophagus) with 258,000 cases annually (International Agency for 
Research on Cancer, 2009a). However, despite the worldwide incidence of 
prostate cancer continuing to rise, mortality rates have stabilised or begun to 
decline in many westernised nations (Oliver et al., 2001; Baade et al., 2004; 
Hussain et al., 2008). This pattern has been evident in England and Wales 
where despite disease mortality rates more than doubling from 4421 in 1979 
to 9169 in 2004, the greatest proportion of this increase was between 1979 
and 1992, where there was an estimated mean increase of 1.72 deaths per
100.000 population per year (from 46.33 per 100,000 to 67.33 per 100,000). 
This trend was reversed from 1992 to 2004 with an estimated annual decline 
in mortality rates of 1.61 per 100,000, to 49.64 deaths per 100,000, or a total
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fall of 26% in absolute terms (Hussain et al., 2008). These trends were 
reflected across the UK as a whole, as is displayed in Figure 2.2 which 
shows prostate cancer incidence and mortality rates for the UK from 1975- 
2010.
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Figure 2.2, Age-standardised incidence and mortality rates per 100,000 male 
population for prostate cancer in the UK from 1975-2010. Data obtained from 
Cancer Research UK (2013).
It must therefore be asked, what factors account for these widespread 
changes in prostate cancer incidence and mortality? Consensus from several 
authors considering this conundrum appears to be that while increased 
screening for PSA has led to dramatic increases in incidence, advances in 
disease treatment could be playing an integral role in changes in mortality 
rates (Albertson, 2003; Baade et al., 2004; Damber, 2004). Earlier disease 
detection combined with more aggressive treatment could be responsible for
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the decline in cancer related mortality. Indeed, it has been reported that men 
diagnosed with prostate cancer have a risk of dying from cardiovascular 
disease of equivalent levels to the risk of dying from prostate cancer 
(Ketchandji, etal., 2009).
2.4 Cardiovascular disease
The cardiovascular system includes the heart and the networks of blood 
vessels (Oxford Medical Dictionary, 2007). This system is responsible for the 
circulation of blood around the body, which supplies nutrients and oxygen to 
the tissues in addition to removing waste products. Disruption to the 
homeostasis within this system can lead to the development of 
cardiovascular disease including conditions such as ischemic heart disease, 
heart failure, arrhythmias or vascular diseases, which can lead to clinically 
significant morbidity or mortality (Griffin and Topol, 2009).
Cardiovascular disease is the number one cause of death globally 
accounting for an estimated 17.3 million deaths in 2008 alone, representing 
30% of deaths worldwide (World Health Organization, 2013), yet this global 
burden is continuing to rise. More recent data for Europe shows that 
cardiovascular disease was responsible for 47% of all deaths in 2012 
(European Heart Network, 2013). Moreover, the World Health Organization 
predicts that by 2030 cardiovascular disease will be responsible for 23.3 
million deaths worldwide (World Health Organization, 2013).
Such mortality rates are of little surprise in consideration of the widespread 
incidence of cardiovascular disease. In the recent review of heart disease 
and stroke statistics for the American Heart Association, Go et al. (2013) 
reported that around 11%, 35%, 70% and 85% for people aged 20-39 years, 
40-59 years, 60-79 years and over 80 years, respectively, had been 
diagnosed with some form of cardiovascular disease (including coronary 
heart disease, heart failure, stroke and hypertension). Similarly, data for 
Great Britain also demonstrates high rates of cardiovascular disease 
incidence (British Heart Foundation, 2012). Data for the year 2010 shows
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coronary heart disease or stroke had been diagnosed in 2%, 12%, 28% and 
33% of individuals aged 16-44 years, 45-64 years, 65-74 years or over 75 
years, respectively.
Consequently, with such high prevalence rates for cardiovascular disease the 
economic costs are also high. Data from the British Heart Foundation (2012) 
shows that in 2009 cardiovascular disease cost the UK health care system 
around £9 billion, representing a cost per capita of £141. Hospital care 
account for around 50% of these costs with drug treatments making up 
approximately 23%. Furthermore, it was estimated that the cost of lost 
production for cardiovascular disease morbidity or mortality was over £6 
billion for the year 2009.
2.4.1 Cardiovascular disease risk factors
The development of cardiovascular disease can be the result of both 
modifiable and non-modifiable factors. Modifiable risk factors are considered 
behavioural and include physical inactivity, unhealthy diet, tobacco use and 
harmful use of alcohol. These four behaviours can lead to key physiological 
changes that increase cardiovascular disease risk by promoting the 
development of raised blood pressure, overweight or obesity, 
hyperglycaemia and hyperlidemia (World Health Organization, 2013). It has 
been reported that modifiable risk factors account for approximately 80% of 
the incidence of coronary heart disease and cerebrovascular disease (World 
Health Organization, 2011). The link between each of these risk factors and 
the development of cardiovascular disease is reviewed in greater detail later 
in this chapter (2.8.7 Cardiovascular risk).
Non-modifiable cardiovascular disease risk factors include attributes that will 
influence the chance of cardiovascular disease development, but are not 
within the control of an individual. Being of advanced age is one such risk 
factor. In the Framingham Heart Study age is considered the most important 
determinant of the 10 year risk of cardiovascular disease (D'Agostino et al., 
2008). The American Heart Association (2013) report that the risk of having a
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stroke approximately doubles for each decade of life after 55 years. Such 
increases in risk can be partly explained by structural and functional 
adaptations in the cardiovascular system occuring with age (Priebe, 2000). 
Priebe (2000) reported that aging is associated with changes in cardiac and 
vascular function, with reduced contractile efficiency in the heart and greater 
vascular stiffness shown with age.
Being of male gender has been considered to be important in cardiovascular 
risk, with men having a greater risk than premenopausal women but a similar 
risk to post-menopausal women (World Heart Federation, 2013). It has been 
reported that differences in iron concentrations may be important in this 
discrepancy in risk of cardiovascular events explaining the changing risk in 
women with menopause (Kiechl et al., 1997). In addition, differences 
between genders for components of the metabolic syndrome including insulin 
resistance, adiposity, dyslipidemia, and hypertension have also been 
reported to potentially influence the development of cardiovascular disease 
(Regit-Zagrosek etal., 2006). Current evidence on both of these mechanisms 
remains limited however, and thus further research in this area is required to 
substantiate these data.
Ethnicity has also been reported to influence cardiovascular risk. The British 
Heart Foundation (2010) reported that incidence of myocardial infarctions 
was higher in South Asian individuals than in non-South Asians, while 
incidence of stroke was highest in people of a black ethnic group compared 
to those of a white ethnic group. There could be both physiological and socio­
economic reasons for these discrepancies between ethnic groups however. 
Physiologically, individuals from different ethnic groups will store fat in 
different places influencing the subsequent cardiovascular risk accrued. 
Although conversely, it is also reported that very few people from ethnic 
minority groups attend cardiac rehabilitation programmes, thus increasing 
their risk of subsequent events.
In addition, family history can also influence an individuals risk of developing 
cardiovascular disease. The World Heart Federation (2013) state that an 
individual's risk of developing heart disease will be increased if a first-degree
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male relative has suffered a myocardial infarction before the age of 55, or a 
first-degree female relative has suffered one before the age of 65. They 
report that if both parents have suffered from heart disease before the age of 
55, the risk of their children developing heart disease can be increased by 50% 
from the general population. This familial link could be partly attriuted to a 
genetic component in the development of hypertension, abnormal lipid 
concentrations and diabetes (Siervogel, 1983; Klein et al., 1996; Soutar and 
Naoumova, 2007), although, additional genetic links have also been 
speculated upon (Tymchuk et al., 2006). In-fact, Hamer et al., (2009) 
reported that only a small portion (15%) of the increase in cardiovascular risk 
associated with a family history was accounted for by conventional risk 
factors (blood pressure, cholesterol, adiposity), suggesting an important role 
for such additional genetic mechanisms.
The Interheart study undertook a case-control investigation across 52 
countries to examine the contribution of risk factors for the development of 
acute myocardial infarction (Yusuf et al., 2004). It was reported that nine 
potentially modifiable risk factors (smoking, abnormal lipids, hypertension, 
abdominal obesity, diabetes, psychosocial factors, consumption of fruits and 
vegetables, alcohol intake and regular physical activity) accounted for more 
than 90% of the risk.
Data from the British Heart Foundation (2012) provides the most recent 
evidence for the prevalence of cardiovascular risk factors across the UK, with 
the findings showing that many risk factors are widespread. Data for men 
aged 65 years or older demonstrates both behavioural and physiological risk 
factors are widely apparent. Behavioural data shows physical inactivity, 
excessive alcohol intake and cigarette smoking were shown in 45%, 22% 
and 13% of the population. Consequently, physiological risk factors including 
high blood pressure, high cholesterol concentrations, obesity and diabetes 
were also evident in 70%, 45%, 26% and 15% of men of such an age group, 
respectively.
Although it is concerning that cardiovascular risk factors are so abundant, 
evidence that such a large proportion of the risk of cardiovascular disease
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can be accrued through factors that are modifiable is encouraging for the 
prevention of such diseases in prostate cancer survivors in whom incidence 
has been shown to be raised. Attention must therefore turn to investigating 
whether modifying risk factors in such a population can decrease 
cardiovascular risk, in addition to maintaining general health and overall 
quality of life. The NCSI has stated that with increasing numbers of people 
living beyond a cancer diagnosis dealing with the concerns of these patients 
and the consequences of their treatment must become a priority (Richards et 
al., 2011). Greater research into patient physical and mental well-being after 
diagnosis and the development of strategies to ensure patients can maintain 
or improve their standard of living are clearly warranted.
2.5 Prostate cancer diagnosis and staging
2.5.1 Prostate-specific antigen
Described by Pal et al. (2012) as a serine protease that serves as a marker 
unique to the prostate, PSA is an enzyme produced by the glandular 
epithelium of the prostate. In normal function PSA is secreted into seminal 
plasma where, via interactions with semenogelin I, semenogelin II and 
fibronection, it causes liquefaction of the seminal plasma clot after ejaculation 
(Diamandis, 1998). However, in light of the potential prognostic value of high 
PSA concentrations in men with prostate cancer the clinical importance of 
this enzyme has increased. First described by Hara et al. (1966), it wasn't 
until 1980 that the clinical use of PSA as a blood-borne marker of prostate 
cancer was first described (Papsidero et al., 1980). These discoveries led to 
increasing use of PSA testing for tracking the progression of patients with 
confirmed disease, and then subsequently for screening asymptomatic 
patients (Loeb and Catalona, 2007).
Increased testing for PSA has been strongly linked to the rise in prostate 
cancer diagnoses (Farkas et al., 1998; Barchielli et al., 1999; Hankey et al., 
1999; Coldman et al., 2003; Larrahaga et al., 2010). PSA testing has 
facilitated men being diagnosed younger and with earlier stage disease than
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was apparent in the pre-PSA era (Diamandis, 1998; Barchielli et al., 1999; 
Carsin et al., 2010). In spite of these developments, one major issue of 
contention remaining with PSA testing is whether or not the improvements in 
disease detection actually translate into benefits in prostate cancer-specific 
or all-cause mortality (Concato et al., 2006; Albertsen, 2010). Although there 
is evidence linking PSA screening to decreased prostate cancer mortality 
rates (Oberaigner et al., 2006; Schroder et al., 2009) a greater volume of 
literature describes contradictory findings, suggesting other factors could, at 
least in part, be responsible for changes in prostate cancer mortality rates 
(Lu-Yao et al., 2002; Lu-Yao et al., 2008; Marcella et al., 2008; Andriole et al., 
2009; Carsin et al., 2010). What has become apparent since PSA testing has 
become more widely used, is that men are now initiating radical treatments 
for prostate cancer earlier and staying on treatments longer (Cooperberg et 
al., 2003; Hussain et al., 2008) increasing the possibility of treatment- 
associated morbidities such as the increase in cardiovascular risk factors 
reported in men on long-term ADT (Bourke etal., 2012).
Natural fluctuations in PSA concentrations mean a single high PSA value 
cannot be used conclusively to diagnose prostate cancer. PSA 
concentrations will increase with age, with upper limits of normative values of
2.5 ng-ml'1, 3.5 ng-ml'1, 4.5 ng-ml'1 and 5.5 ng-ml'1 proposed for men aged 
<50, 50-59, 60-69 and 70-79 years, respectively (Mehta et al., 2007). 
Furthermore, PSA values can be increased in patients with benign prostatic 
hyperplasia, infection and chronic inflammation (Shariat etal., 2008).
A PSA cut-off of 4 ng-ml'1 was previously considered suggestive of increased 
risk of prostate cancer and warranted further investigation. This PSA 
concentration has sensitivity for prostate cancer detection of 72.1% and a 
specificity of 93.2% (Mistry and Cable, 2003). However, this cut-off level was 
highly questioned after studies reported histologically confirmed prostate 
cancer in patients with PSA <4 ng-ml"1 (Catalona et al., 1997; Tornblom et al., 
1999; Thompson et al., 2004). Catalona et al. (1997) reported prostate 
cancer was detected in 22% of men with PSA between 2.6 and 4 ng-ml'1, 
while data from Thompson et al. (2004) suggests that among men aged 62 -
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91 years there is no lower PSA threshold below which prostate cancer can 
be ruled out with high confidence. These findings have led to the most recent 
European Association of Urology guidelines on prostate cancer stating that a 
PSA threshold indicating the highest risk of prostate cancer still needs to be 
defined, and that use of further investigation is warranted in patients with 
raised PSA, or in whom prostate cancer is suspected despite low PSA 
concentration (Heidenreich etal., 2011).
2.5.2 Digital rectal examination
First described in 1905 by Young (1905, as cited in Brawley et al., 2009), 
digital rectal examination (DRE) was for a long time considered the only 
method for prostate cancer screening. Examinations involve a trained 
professional palpating the surface of the gland to assess symmetry and 
texture (Waldman, 2006). Within this process stands a weakness however, 
as it has been shown that up to 40% of prostatic carcinomas form anterior to 
the midline of the prostate making them undetectable by DRE (Littrup et al., 
1992). In addition, DRE is limited by the difficulty in detecting small-size 
tumours (Waldman, 2006) and the subjective nature of the test leading to 
potential inter-observer variability (Gosselaar et al., 2008).
When used alone, DRE provides an insensitive method of prostate cancer 
detection, as is evident in the work by Thompson et al. (1984) who reported 
that up to two-thirds of patients in whom prostate cancer was detected by 
DRE had disease that had spread beyond the prostate at time of diagnosis. 
However, in modern practice DRE is often performed in addition to PSA 
screening as an additional means of confirming or refuting the presence of 
carcinoma and as a means of detecting non-PSA secreting tumours (Borley 
and Feneley, 2009).
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2.5.3 Transrectal ultrasound and prostate biopsies
Using a 7.5 mHz ultrasound probe inserted into the anus the prostate gland 
and seminal vesicles can be imaged to determine the outline and volume of 
the prostate (Borley and Feneley, 2009). Although not suitable for the 
detection of early stage disease, transrectal ultrasound (TRUS) can identify 
calcifications, abscesses and cysts, with defects in the periprostatic fat layer 
symptomatic of extracapsular disease (Mehta et al., 2007).
In addition to the merits of solely imaging the prostate, TRUS is used to guide 
needle biopsies to specific sites. Under local anaesthetic 10-12 biopsy 
specimens, dependent upon glandular volume, can be taken from regions 
around the prostate (Damber and Aus, 2008). These samples subsequently 
undergo microscopic analysis of cellular disease spread allowing 
determination of a Gleason score (discussed in 2.5.4 Classification). 
Samples are predominantly obtained from the periphery of the prostate, with 
limited benefit shown for biopsies of the transitional zone because of 
infrequent cancer development in this region (Pelzer et al., 2005). This 
process is not without risk however, with complications including 
haematospermia, urinary retention, haematuria, rectal bleeding, and sepsis 
reported in men post-prostatectomy (de Jesus et al., 2006; Chiang et al., 
2007).
Improvements in cancer detection rate of 31% have been reported using the 
10-12 samples technique compared with the more traditional sextant 
technique (6 samples) which was widely used until the late 1990's and early 
2000's (Eichler et al., 2006). In patients with no signs of cancer in initial 
biopsies, but in whom cancer is still suspected, saturation biopsies can be 
performed. Saturation biopsies will require 20 or more samples from across 
the gland or from specific targeted regions identified by ultrasound imaging in 
which a cancer is suspected (Borley and Feneley, 2009).
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2.5.4 Classification
After cancer detection, clinical staging is performed using the tumour, node, 
metastasis (TNM) classification system and Gleason score. This information 
informs clinicians on the development and spread of the disease and will be 
considered when deciding on the most appropriate treatment.
The TNM system has been used for staging prostate cancer since the 1940's, 
with updates and improvements subsequently applied to the original design 
leading to the publishing of the sixth edition in 2002 (Chang and Amin, 2008). 
The tumour (T) element of the staging refers to the presence and spread of 
the primary tumour. Node (N) details the extent of regional lymph node 
involvement. Metastasis (M) describes the existence of any distant 
metastasis. Table 2.1 displays the TNM staging classification as described by 
Chang and Amin (2008), with definitions of each stage provided.
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Table 2.1. Definition of the tumour, node, metastasis system of prostate cancer staging. 
Table reproduced from Chang and Amin (2008)
Primary Tumour (T)
Clinical
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
T1 Clinically inapparent tumour neither palpable nor visible by imaging
T1a Tumour incidental histologic finding in 5% or less of tissue resected
T1b Tumour incidental histologic finding in more than 5% of tissue resected
T1c Tumour identified by needle biopsy (e.g. because of elevated PSA)
T2 Tumour confined within prostate*
T2a Tumour involves one-half of one lobe or less
T2b Tumour involves more than one-half of one lobe but not both lobes
T2c Tumour involves both lobes
T3 Tumour extends through the prostate capsule**
T3a Extracapsular extension (unilateral or bilateral)
T3b Tumour invades seminal vesicle(s)
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: external
sphincter, bladder, rectum, levator muscles, and/or pelvic wall
* Note: Tumour found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging
is classified as T1c. ** Note: Invasion into the prostate apex or into (but not beyond) the prostatic capsule is
classified not as T3 but as T2.
Regional Lymph Nodes (N)
Clinical
NX Regional lymph nodes were not assessed
NO No regional lymph node metastasis
N1 Metastasis in regional lymph node(s)
Distant Metastasis (M)*
MX Distant metastasis cannot be assessed (not evaluated by any modality)
MO No distant metastasis
M1 Distant metastasis
M1a Non-regional lymph node(s)
M1b Bone(s)
M1c Other site(s) with or without bone disease
* Note: When more than one site of metastasis is present, the most advanced category is used.
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The Gleason system was originally described by Dr Donald Gleason in 1966 
and uses a grading system based on microscopic interpretation of stained 
prostatic tissue obtained from biopsy samples (Humphrey, 2004). Five 
grading patterns of carcinoma can be generated scoring from 1 to 5. Scores 
are given for the most prevalent, and second most prevalent levels of 
carcinoma in the sample that are subsequently summed to give a score from 
2 to 10, with higher scores indicative of the most aggressive cancers. For a 
cancer grading pattern to be counted it must occupy more than 5% of the 
sample, while if only one grading pattern is present in a sample this score is 
doubled to give the final Gleason score (Heidenreich et al., 2008).
2.5.5 Risk Stratification
Clinical staging, PSA concentrations and Gleason score have also been used 
to stratify the risk of disease progression in patients with localised and locally 
advanced disease. The National Institute for Health and Clinical Excellence 
(NICE, 2008) provide guideline data for categorising low, intermediate and 
high risk patients (Table 2.2).
Table 2.2. Risk stratification for men with localised prostate cancer
PSA Gleason
score
Clinical stage
Low risk <10 ng-ml"1 and <6 and T1-T2a
Intermediate risk 10-20 ng-ml'1 or 7 or T2b-T2c
High risk >20 ng-ml'1 or 8-10 or T3-T4*
Definition: PSA- Prostate-specific antigen
* Clinical stage T3-T4 represents locally advanced prostate cancer
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2.6 Treatments
The treatment of prostate cancer has continued to evolve over many years 
with new techniques often building upon theory and practice rooted in history 
(Sriprasad et al., 2009). Improved methods of disease detection can mean 
that patients are now spending longer undergoing treatment than they would 
have in the past. Deciding on the most appropriate form of treatment for each 
patient will depend on balancing the benefits of that form of treatment against 
the possible negatives of withholding other treatments or treatment side 
effects
2.6.1 Expectant management
Expectant management of prostate cancer is undertaken in-sight of several 
important facts, 1) a large number of cancers will remain dormant and 
asymptomatic, 2) if cancers progress, this will take place at different rates, 
and 3) radical treatment does not come without side effects. 'Watchful 
waiting' or 'active monitoring' could therefore be preferential options in some 
patients in which radical treatment is not suitable or not necessary. Although 
these terms are sometimes used interchangeably they refer to different forms 
of deferred treatment. Watchful waiting is a suitable option for patients who 
are asymptomatic but who have locally advanced disease that is considered 
incurable. These patients are often elderly and are likely to have a cancer 
that will not affect their life expectancy (Mehta et al., 2007). Watchful waiting 
is effectively keeping treatment to control the cancer in reserve until it is 
needed (Cancer Research UK, 2009).
Conversely, active monitoring is more appropriate for younger, fitter men 
diagnosed with early prostate cancer who wish to avoid the negative side 
effects of radical treatment. Klotz (2005) suggested that men with low risk 
disease (PSA <10ng ml'1, biopsy Gleason score <6, stage T1c-T2a, life 
expectancy >10 years) are good candidates for this form of management. 
Patients under active monitoring will be reviewed regularly with PSA tests 
every 1-3 months, regular DRE and biopsies taken at least every 2-3 years.
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Radical treatment to cure the cancer will be planned should progression 
occur (Cancer Research UK, 2009). Criteria for initiation of secondary 
therapy will be chosen at the discretion of the clinician and the patient with 
PSA concentrations and biopsy results used to guide this decision making 
process (Dall'Era et al., 2008; van den Bergh et al., 2010).
Active monitoring is of considerable use in modern medicine with the 
increasing number of patients diagnosed with early-stage cancers since the 
introduction of PSA testing. Use of active monitoring helps lower the number 
of cases of over-treatment where patients with low stage disease would have 
previously undergone radical therapy that might have proved to have been 
unnecessary (Miller et al., 2006). Use of active monitoring allows the patient 
to be monitored to assess whether or not progression is occurring and thus 
whether radical therapy is needed.
Investigations of mortality rates in patients undergoing expectant 
management do not fully support the efficacy of delayed treatment however, 
with evidence of better disease-specific outcomes and survival in patients 
treated more aggressively. Although one of the largest studies investigating 
disease progression and mortality in men with clinically localised prostate 
cancer reported stable mortality rates 15 years after diagnosis, supporting 
the notion of treatment with watchful waiting until clinically necessary 
(Albertsen et al., 2005), these findings are not fully supported by others. 
Randomised controlled studies of disease progression between men with 
localised disease randomly allocated to watchful waiting or radical 
prostatectomy show reduced disease progression, disease-specific mortality 
and overall mortality over follow-up periods of up to 8 years in men 
randomised to receive prostatectomy (Holmberg et al., 2002; Bill-Axelson et 
al., 2005).
2.6.2 Radical prostatectomy
Radical prostatectomy is the surgical removal of the prostate gland and 
seminal vesicles. This treatment option is performed with curative intent in
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patients with T1 or T2 disease confined within the prostate (Mehta et al., 
2007). The technique for prostatectomy has been developed since it was first 
performed by Covillard in 1639, who removed prostatic tissue during a 
lithotomy (Jones, 1936). Although at least nine different approaches to the 
prostate have been described, it is mainly the retropubic approach that is 
used in modern practice with laparoscopic and robotic techniques becoming 
more common place (Sriprasad et al., 2009). Perineal prostatectomies were 
common practice with surgeons trained prior to 1975, however, with the 
introduction of pelvic lymphadenectomies for staging purposes, retropubic 
approaches became preferable. The perineal approach does have 
advantages of reduced morbidity, operation time, and blood loss, making it 
suitable for older patients or those with high anaesthetic risk. Furthermore, 
this approach could be favourable in patients with high amounts of abdominal 
fat, or with previous lower abdominal pathologies or surgery where the 
retropubic approach might be inadvisable (Gillitzer and Thuroff, 2002).
Urinary incontinence and impotence can be long-term side effects 
experienced by patients after both forms of prostatectomy (Gillitzer and 
Thuroff, 2002). In a study of 203 patients undergoing prostatectomy, Smither 
et al. (2007) reported moderate or severe incontinence in 74% of patients 2 
weeks after the operation. Symptoms decreased over time, yet remained in 
12% of patients at 18 weeks, and in 4% after 54 weeks. Similarly, Talcott et 
al. (1997) reported that impotence was prolific in men after prostatectomy. At 
baseline 26% of patients reported erections inadequate for intercourse, 
however, 3 months after prostatectomy 97% of men were reported to be 
impotent, and 90% were still impotent 12 months after surgery.
Although radical prostatectomy is performed with curative intent, a large 
number of patients experience disease recurrence as a result of tumour 
reappearance in the prostate bed or through disease spread to lymph nodes 
or distant sites. In a study of disease-specific survival rates, Freedland et al. 
(2005) evaluated data from 5096 men over a mean duration from surgery of 
6 years. Results identified biochemical recurrence, defined as a single post­
operative PSA >0.2 ng-ml"1, in 979 men (19%). In a subset of 379 men with
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recurrence entering the study, the authors report recurrence occurring at a 
mean of 3.5 years following surgery. Similar results were reported by 
Roberts et al. (2001) who described biochemical recurrence, defined as PSA 
>0.4 ng-ml'1, in 879 men (31% of a total of 2079) occurring at a mean of 2.9 
years after surgery.
2.6.3 Radiotherapy
Radiotherapy involves the delivery of doses of ionizing radiation to a 
cancerous tumour, with the aim of causing DNA damage to the cancer cells 
preventing further growth and leading to cell death when cellular division is 
attempted. Developed more than 100 years ago following the discovery that 
x-rays had potential therapeutic properties (Sriprasad et al., 2009), 
radiotherapy now provides a modality for treatment of patients with early 
stage disease confined to the prostate and those with advanced disease 
suffering from metastatic spread and increased pain.
Radical radiotherapy, used for the treatment of early stage prostate cancer, is 
performed using either external beam radiation therapy (EBRT) or internal 
radiation therapy (brachytherapy). EBRT is the most commonly used form of 
radical radiotherapy (Volpe and Watkins, 2006) with high-energy ionizing 
radiation beams delivered to the prostate gland over a course of therapy 
lasting 4-7 weeks. Radiation produced from a radioactive source or 
electromagnetic energy is delivered to target sites on the patient at external 
doses of 65 to 78 Gy, providing daily fractions of around 1.8-2.0 Gy per day. 
In addition to standard EBRT, conformal radiotherapy and intensity 
modulated radiotherapy are both available options that allow the shape and 
intensity of the radiation beam to be modified to optimise radioactive delivery 
to the tumour while minimising the exposure of surrounding tissues. Studies 
are on-going to investigate the most effective technique (Cancer Research 
UK, 2010b).
Brachytherapy is the implantation of radioactive 'seeds' into the prostate 
gland. Using ultrasound guidance, Iodine-125 or Palladium-103 radioisotopes
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are inserted through a transperineal approach to pre-planned locations within 
the prostate (Hilaris et al., 2000). Patients can receive between 80 and 100 
seeds in an operation expected to last around an hour, with this rapid 
delivery of radiation considered one of the strengths of brachytherapy 
compared with the daily treatment schedules of up to seven weeks 
experienced with EBRT. Radiation doses delivered with brachytherapy 
depend on the positioning of the seeds inside the prostate gland. Use of 
peripheral loading allows radiation doses at the centre of the prostate to 
remain below twice the prescription dose lowering the incidence of urinary 
complications (Wallner, 2000).
Radical radiotherapy is performed with a curative intent, yet disease 
recurrence is not uncommon. Although studies investigating biochemical 
recurrence after radiotherapy have varied in the form of radiotherapy patients 
have been exposed to and duration of follow-up, disease recurrence in 20-50% 
of patients has been reported (Eastham et al., 1997; Hanks et al., 1997; 
D'Amico et al., 2003; Alicikus et al., 2010). Disease progression prior to 
treatment is evidently an important factor in determining the rates of disease 
recurrence (Hanks et al., 1997; Alicikus et al., 2010). In patients presenting 
with localised disease and PSA <10 ng-ml'1 disease-free survival was 
reported in around 80% of those treated with radical radiotherapy.
Conversely, radiotherapy in patients with locally advanced disease and pre­
treatment PSA >20 ng-ml'1 has been reported to be less effective and
disease recurrence is evident in 40-50% of cases.
Side effects associated with radical radiotherapy have decreased from the 
considerable burden of the early techniques, however men undergoing EBRT 
and brachytherapy do still experience considerable treatment related 
morbidities. Erectile dysfunction, infertility and incontinence are reported by 
many patients after radiation treatment (Macmillan Cancer Support, 2010). 
Furthermore, patients can experience increased fatigue as a side effect of 
radiotherapy which has been associated with activation of the
proinflammatory cytokine network during treatment (Bower et al., 2009).
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Radiotherapy in the treatment of advanced cancer is used to control 
secondary tumours and to relieve pain. In patients with specific areas of 
disease spread, EBRT delivered to secondary tumours can kill cancerous 
cells, shrinking the cancer and decreasing pain experienced at that site. In 
patients suffering pain from multiple sites of metastatic spread, palliative 
radiotherapy is offered. The injection of the radioisotope Strontium 89 allows 
radiation to circulate throughout the body providing pain relief and slowing 
the rate of metastatic growth (Cancer research UK, 2010a).
2.6.4 Androgen deprivation therapy (ADT)
ADT has developed from the early work of Huggins and Hodges (1941), who 
won the Nobel-prize for first describing the androgen dependence of prostate 
cancer cells. The primary objective of ADT is to deprive the prostate of 
androgens. In normal function 90-95% of testosterone is produced in the 
testes, with the remaining 5-10% synthesized by the adrenal glands. 
Stimulation of testosterone production at the testes comes via a hormone 
cascade initiated with the pulsatile release of luteinizing-hormone releasing 
hormone (LHRH) from the hypothalamus. LHRH binds to the anterior pituitary 
promoting luteinizing-hormone (LH) release into the bloodstream. 
Subsequently, LH acts to regulate the rate of testosterone synthesis from 
cholesterol which takes place in the Leydig cells of the testis.
Testosterone is converted to DHT by prostatic tissue through conversion by 
5a-reductase isoforms, making DHT the predominant androgen within the 
prostate (in other tissues testosterone can be converted to oestradiol by 
aromatase). DHT binds androgen receptors resulting in changes in gene 
expression, and specifically, stimulation of the fibroblast growth factor gene in 
the human prostate cancer cell. Stimulation of this gene initiates cell 
development and cancer progression (Harris et al., 2009; Pommerville and 
de Boer, 2010). Further promotion of the cancer cell growth also comes 
through the same metabolic pathway from follicle stimulating hormone (FSH). 
Produced by the anterior pituitary after the binding of LHRH, FSH stimulates
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the Leydig cells to increase LH binding in addition to directly stimulating 
cancer cell growth through binding with receptors on the prostate.
Inhibition of this cascade of events at one or more stages is achieved using 
ADT. ADT aims to prevent hormone-sensitive tumour development, and 
preferably, decrease tumour size, with decreases in intracellular DHT of >80% 
needed to shrink the size of the tumour through cellular apoptosis (Kyprianou 
and Isaacs, 1987, as cited in Tammela, 2004). This process is not curative 
however, with many cancers eventually becoming hormone refractory 
(otherwise known as castration resistant), meaning continued evidence of 
cancer progression in-spite of castrate testosterone concentrations. It has 
been speculated that the progression to hormone-refractory prostate cancer 
could in-fact be reliant upon production of intratumoral androgens 
(Montgomery et al., 2008). While systemic testosterone concentrations 
remain at castrate levels, activity of enzymes involved in steroidogenesis and 
androgen catabolism is maintained in the metastatic tumour allowing 
production of sufficient testosterone concentrations within the tumour to 
activate androgen-receptor target genes and maintain tumour cell survival.
Treatment with ADT can eliminate gonadal testosterone production using 
orchiectomy or LHRH-analogues, with serum total testosterone <50 ng dl'1 
(<1.74 nmolT1) the target for surgically or medically castrated patients (Harris 
et al., 2009). Alternatively, administration of anti-androgens can block the 
action of existing testosterone (Tammela, 2004). Hormonal therapies 
available in the UK for medical castration are shown in Table 2.3.
Table 2.3, Hormonal therapies available in the UK.
LHRH Agonists LHRH Antagonists Anti-androgen
Leuprorelin Abarelix Bicalutamide
Goserelin Cetrorelix Flutamide
Buserelin Degarelix Cyproterone acetate
Triptorelin Nilutamide
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2.6.4.1 Orchiectomy
Orchiectomy is the surgical removal of the testicles which can be performed 
either as a complete removal or in a subcapsular fashion leaving the tunica 
albuginea (Mehta et al., 2007). The irreversible nature of the operation 
makes orchiectomy an unattractive option to many men who choose to 
undergo medical castration instead. Surgical castration reduces testosterone 
to castrate levels within 12 hours resulting in a rapid decrease in tumour 
burden, glandular atrophy and involution of the prostate, with decreased 
cellular proliferation and increased cellular apoptosis also noted within 3 days 
(Harris et al., 2009).
2.6.4.2 Luteinizing-hormone releasing hormone analogues
LHRH-analogues can be divided into LHRH-agonists and LHRH-antagonists. 
Agonists are the original chemical castration method first licensed in 1986 
after evidence of their use as an effective therapeutic agent was first 
published in 1982 (Tolis et al., 1982). Administered via injection or 
subcutaneous implant at 1-3 month intervals, agonists bind and stimulate 
LHRH-receptors resulting in chronic receptor stimulation desensitizing 
pituitary LH release through feedback inhibition of the hypothalamic-pituitary 
axis (Pommerville and de Boer, 2010). The result of this desensitization is 
decreased LH release, and thus a reduction in serum testosterone, with 
castrate levels often reached within 1-3 weeks of commencing treatment 
(Moreau et al., 2006).
A side effect experienced by patients undergoing LHRH agonist treatment is 
'tumour flare1 in response to the increase in circulating testosterone found in 
the first 1-2 weeks of therapy, prior to receptor desensitization (Thompson, 
2001). Tumour flare is often characterised by accelerated disease 
progression and, in patients with advanced cancer or bony metastases, can 
be of concern as severe pain and potential spinal cord compression can be 
experienced. The advent of the anti-androgen therapy (discussed in 2.6.4.3 
Anti-androgens) has brought a solution to the issue however, with patients
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commencing LHRH-agonist therapy simultaneously prescribed anti­
androgens for the first 2 weeks (Pommerville and de Boer, 2010).
LHRH-antagonists act by blocking, but not stimulating, the LHRH-receptors 
resulting in an immediate fall in LH and testosterone and avoiding tumour 
flare (Pommerville and de Boer, 2010). Castrate levels of serum testosterone 
can be achieved within a single day of antagonist therapy which is similar to 
the decline in testosterone seen with orchiectomy (Tammela, 2004).
2.6.4.3 Anti-androgens
Anti-androgens prevent the action of androgens by binding to androgen 
receptors in the target tissue to prevent the binding of DHT and testosterone 
(Suzuki et al., 2008). Unlike therapy with LHRH-analogues, anti-androgen 
therapy will maintain circulating androgens at normal or increased 
concentrations, decreasing the onset of side effects often seen with 
androgen depletion. Side effects with anti-androgens can still include 
hepatotoxicity and thromboembolic complications with long-term steroidal 
anti-androgen use, while gynecomastia is highly prevalent with both steroidal 
and non-steroidal therapy.
Anti-androgen use in the initial weeks of LHRH-agonist therapy can prevent 
tumour flare by preventing binding of circulating androgens. Anti-androgens 
are also increasingly being used as monotherapy, with Bicalutamide shown 
to provide similar survival benefits to castration therapy (Iversen et al., 1998).
2.6.4.4 Maximum androgen blockade
First described in the early 1980's by Labrie et al. (1982), maximum 
androgen blockade, otherwise referred to as complete androgen blockade or 
combined androgen blockade, uses a combination of methods to both 
decrease testosterone production (orchiectomy or LHRH analogues) and 
prevent testosterone action (anti-androgen). The addition of an anti-androgen
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inhibits both adrenal androgens and the small quantities produced by the 
testes during LHRH agonist treatment.
2.6.4.5 Neoadjuvant or adjuvant ADT
In addition to being used as a primary therapy, ADT is also often employed 
as part of a multi-modal approach, along with radiotherapy or prostatectomy, 
for treatment of localised or locally advanced prostate cancer. Hormonal 
therapy can be used either before (neoadjuvant hormonal therapy, NHT) or 
at the same time as (adjuvant hormonal therapy, AHT) the primary treatment 
option, with different benefits gained from the different treatment schedules.
NHT prior to radiotherapy is performed to decrease tumour volume, thus 
enabling optimal radiation doses to be delivered to the prostate, yet 
minimising the exposure to surrounding tissues. NHT prior to prostatectomy 
reduces margin positivity improving the coverage of the cancerous area by 
surgery and lowering the incidence of extracapsular disease (Lee et al., 
1999a).
Use of AHT is performed under the premise that while surgery or radiation 
will eradicate the primary tumour, the hormonal treatment will eliminate 
micro-metastases. The benefit of this greater systemic therapy is a reduction 
in both local disease recurrence and distant metastases (See, 2003).
In the Cochrane Review on NHT and AHT for localised and locally advanced 
prostate cancer the wide-ranging benefits of the different treatment options 
are described (Kumar et al., 2009). Although NHT prior to prostatectomy was 
not associated with any overall survival advantage, there were reductions in 
positive surgical margins and pathological improvements including lymph 
node involvements, pathological staging and organ confined rates, showing 
evidence of reduced disease spread as a result of hormonal therapy. 
Considering NHT prior to radiotherapy, Kumar et al. (2009) found evidence of 
survival benefits for patients with Gleason score 2-6 cancer in one study 
(Pilepich et al., 2001), although these results were contradicted by the
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findings of others. Evidence of improvements in both clinical disease-free 
survival and biochemical disease-free survival were both consistently 
reported.
Three studies were included in the review for investigations into the benefits 
of AHT with prostatectomy (Messing et al., 1999; Wirth et al., 2004; McLoed 
et al., 2005). Only Messing et al. (1999) reported improvements in overall 
survival with immediate receipt of AHT after prostatectomy compared to a 
control group who received hormones only after signs of disease progression 
were evident. All three studies reported improvements in disease-free and 
progression-free survival. Combined AHT and radiotherapy was reviewed in 
four studies (Zagars et al., 1988; Bolla et al., 2002; McLoed et al., 2005; 
Pilepich et al., 2005) with improvements in overall survival, disease-free 
survival and disease reoccurrence reported in all studies.
It should be noted that there are possible disadvantages to the use of ADT 
with radiation or surgery. In addition to increasing the toxicity of treatment 
and thus increasing the risk of side effects, there is also a rise in the cost of 
providing the therapy (Kumar et al., 2009). Furthermore, the early use of ADT 
can lead to the possible emergence of resistant clones increasing the 
possibility of hormone refractory disease should the disease progress. 
Additionally, use of NHT can lead to a possible delay in definitive local 
treatment as a result of the pre-treatment with ADT (Lee et al., 1999a).
2.6.4.6 Trends in ADT use
Since its inception, use of ADT has markedly increased making it now the 
mainstay treatment for men with advanced and metastatic prostate cancer. 
Nearly 50% of men diagnosed with prostate cancer will undergo ADT at 
some stage after diagnosis (Meng et al., 2002). Originally performed using 
surgical castration and/or diethylstilbestrol, the advancement in depot 
formulations of LHRH-agonists have made these the primary form of ADT, 
replacing diethylstilbestrol and reducing the use of surgical castration 
(Perlmutter and Lepor, 2007). This is evident in the results reported by
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Carson et al. (2010) for trends in treatment between 1991 and 1999 for 
patients with metastatic cancer on the Surveillance, Epidemiology and End 
Results (SEER) project. Use of surgical castration decreased from being 
used in 48.1% of patients in 1991 to only being accepted by 10% in 1999, 
while treatment with LHRH-agonists increased from 27.2% to 60.7% over the 
same time period.
Despite primarily being considered a form of therapy for patients with 
advanced disease there is also a trend for increased use of hormonal 
treatment using LHRH-agonists for patients with localised cancer. Further 
results from the SEER project support this data, showing that between 1991 
and 1999 use of LHRH-agonists for treatment of men with localised disease 
increased from 11.5% of patients up to 41.1% of patients, while use of 
orchiectomy fell from 12% to 1.8% over the same time period (Shahinian et 
al., 2005).
Data on the overall use of ADT in England and Wales is provided by Hussain 
et al. (2008). Between 1987 and 2004 use of LHRH analogues increased by 
17,810 prescriptions per year (from 14.5 cases per 100,000 population per 
year to 1089.8 per 100,000), while between 1982 and 2004 anti-androgen 
therapy increased by 7,508 prescription per year (from 0 to 515.9 cases per 
100,000). Orchiectomy shows a reverse of this trend however; between 1991 
and 2004 surgical castration decreased from 28.07 cases per 100,000 to 
2.45 cases per 100,000 in men aged 55-74 years, and fell from 106.58 per
100,000 to 15.17 per 100,000 over the same period in men aged >75 years.
2.6.4.7 ADT and prostate cancer mortality
Although it has been suggested that increasing use of ADT might be 
contributing to the reduction in prostate cancer mortality (Demers et al., 2001; 
Damber, 2004) there is limited evidence to support a direct mortality benefit 
of ADT. Currently data is available describing improvements in disease- 
specific mortality when ADT is used as neoadjuvant or adjuvant treatment 
alongside surgery or radiotherapy, as was discussed in 2.6.4.5 Neoadjuvant
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or adjuvant ADT. However, evidence from studies directly evaluating survival 
benefits from ADT by comparing ADT monotherapy against no treatment is 
sparse, primarily because as patients become symptomatic they start ADT to 
achieve palliation of symptoms. Hence, the studies evaluating the benefits of 
ADT have focussed on comparing immediate initiation of treatment against 
deferring treatment until symptomatic disease progression for overall survival 
advantage (Studer et al., 2006; Keating et al., 2008; DiBlasio et al., 2009). 
Although results from these studies are still inconclusive on the best time to 
commence ADT, the recent review of the subject by Kunath et al. (2013) 
concluded that the best survival advantage was found in those with early 
initiation of ADT (Hazard ratio (HR) = 0.57; 95% Cl, 0.37-0.90 for early 
compared to late ADT). Similarly, in the Cochrane review of early versus 
deferred treatment it was reported that improvements in survival were 
apparent at 1, 2, 5 and 10 years after diagnosis with early treatment, 
however, only the difference in survival between groups at 10 years achieved 
statistical significance (OR = 1.5; 95% Cl, 1.04-2.16) (Wilt et al., 2001).
Treatment with ADT has also been shown to be related to prolonging the 
time for cancer progression. In a comparison of men who received ADT 
(LHRH-agonists, anti-androgens or orchiectomy) or no ADT for 10 years after 
radical prostatectomy, Siddiqui et al. (2011) reported that ADT was protective 
against PSA failure and clinical recurrence. HR of 0.17, 0.29, 0.36 and 0.35 
were reported for PSA failure, local recurrence, systemic progression and 
death from prostate cancer, respectively. In an additional analysis comparing 
disease progression between men receiving ADT in the form of LHRH- 
agonists against those who underwent orchiectomy, there was little 
difference between the groups except for lower PSA progression in men 
treated surgically.
2.7 Testosterone
Testosterone is a cholesterol-based steroid hormone which exerts numerous 
effects on the male body throughout the life cycle (Marieb and Hoehn, 2010).
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Starting during foetal development, testosterone is responsible for the 
differentiation of the foetal genitourinary tract leading to the male foetus 
developing Leydig cells, which begin testosterone production and 
subsequently lead to the masculinisation of the external genitalia. After birth, 
testosterone is responsible for the development of secondary sexual 
characteristics and anabolic processes during puberty, including growth of 
body and facial hair, increased muscle mass, testicular growth and sperm 
production (Marieb and Hoehn, 2010). Once physical maturity is achieved 
testosterone still has important homeostatic functions including 
spermatogenesis, maintenance of muscle mass and aiding erectile function 
(Ganong, 2005).
As previously described (2.6.4 Androgen deprivation therapy), testosterone is 
predominantly produced in males by the testes. After production testosterone 
diffuses into the blood circulation where it can be found as bioavailable 
testosterone (accounts for 20-50% of serum testosterone) or biologically 
inactive testosterone (the remaining 50-80%) (Jones, 2013). Bioavailable 
testosterone is made up of testosterone bound to albumin (approximately 20- 
50% of total serum testosterone) and free testosterone (approximately 2-3% 
of total testosterone). Bioavailable testosterone is available for biological 
actions due to the weak binding with albumin or the unbound nature of free 
testosterone. Conversely, biologically inactive testosterone is not available 
for metabolism in tissues. This testosterone will be bound with SHBG, with 
the strength of the bind inhibiting its use in other biological actions (Jones, 
2013).
Bioavailable testosterone can lead to changes in the behaviour of cells in 
different targets tissues with these actions often mediated through binding of 
androgen receptors (Kadi, 2008). Androgen receptors are ligand-responsive 
transcription regulators which, when bound to circulating androgens, will 
commence a signalling cascade resulting in the development and 
maintenance of the male phenotype and male reproductive function (Li and 
Al-Azzawi, 2009). After binding to testosterone or DHT the androgen receptor 
undergoes nuclear translocation, increased phosphorylation and interaction
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with DNA, prior to the receptor binding to the androgen-response element 
within the target gene where the subsequent cellular actions will be initiated 
(Li and Al-Azzawi, 2009).
2.7.1 Hypogonadism
In men with low testosterone concentrations, hypogonadism can be 
diagnosed. Male hypogonadism is defined by The European Association of 
Urology as a clinical syndrome caused by androgen deficiency which may 
adversely affect multiple organ functions and quality of life (Dohle et al., 
2012). Hypogonadism can be classified as primary or secondary depending 
upon the clinical defects leading to its development.
Primary hypogonadism, otherwise known as hypergonadotropic 
hypogonadism, is caused by testicular failure resulting in low serum 
testosterone and high LH and FSH concentrations. Primary hypogonadism 
can develop from testicular injury, tumour or infection; genetic defects 
affecting testicular development (e.g. Klinefelter syndrome); alcohol abuse; or 
after treatment with chemotherapy or radiotherapy (Dandona and Rosenberg, 
2010).
Secondary hypogonadism is a result of a defect at one or more levels of the 
hypothalamic-pituitary-gonadal axis. Secondary hypogonadism is association 
with low serum testosterone, in addition to normal or low FSH and LH 
concentrations. Hence, secondary hypogonadism is also known as 
hypogonadotropic hypogonadism. This form of hypogonadism can be caused 
by hypothalamic or pituitary disorders, hyperprolactinaemeia or Kallmann 
syndrome. Furthermore, certain medications and illnesses can also lead to 
development of secondary hypogonadism (Dandona and Rosenberg, 2010).
Hypogonadism is prevalent among middle and older aged men, although 
reported prevalence rates vary between studies. Approximately 39% of men 
in the Hypogonadism in Males (HIM) study were reported as hypogonadal 
(Mulligan et al., 2006) but the rate of hypogonadism in the Massachusetts
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Male Aging Study (MMAS) was found to be between 6% and 12%, with 
several men meeting criteria for hypogonadism on only 1 of the 2 
assessment dates (Araujo et al., 2004). The variation in findings could be the 
result of differences in the age groups of men in each study or use of 
different criteria to define hypogonadism. While the HIM study enrolled men 
aged >45 years and defined hypogonadism as total testosterone <300 ng-dl'1 
or current androgen treatment, in the MMAS participants were aged 40-69 
years and hypogonadism was diagnosed after the presence of hypogonadal 
symptoms and total testosterone <200 ng-dl"1.
Incidence of hypogonadism increases with age. In the Baltimore Longitudinal 
Study on aging hypogonadism (defined as total testosterone <325 ng-dl'1) 
was diagnosed in 12%, 19%, 28% and 49% of men in their 50's, 60's, 70's 
and 80's respectively (Harman et al., 2001). Likewise, in the HIM study 
hypogonadism was reported in 34% of men aged 45-54 years and 50% of 
men aged >85 years, a patient's risk of hypogonadism increased by 17% for 
every 10 year increase in age (Mulligan et al., 2006).
Differences between studies in defining the criteria for hypogonadism are 
wide-spread throughout the literature and can be often explained by whether 
a study is investigating biochemical hypogonadism or clinical hypogonadism. 
While biochemical hypogonadism can be reported in men with low 
testosterone concentrations, The Endocrine Society suggests clinical 
hypogonadism should only be diagnosed in patients who consistently show 
signs and symptoms of hypogonadism (discussed below) in addition to low 
testosterone levels (Bhasin et al., 2010).
Further confusing matters in the reporting of hypogonadism is the 
concentration of testosterone considered low or inadequate. Although The 
Endocrine Society suggests 300 ng-dl'1 (10.4 nmolT1) is the lower limit of 
normal measures of total testosterone (Bhasin et al., 2010), The American 
Association of Clinical Endocrinologists recommends 200 ng-dl'1 (6.9 nmolT1; 
Petak et al., 2002). Conversely, the consensus statement of the International 
Society of Andrology, the International Society for the Study of Ageing Males, 
European Association of Urology, European Academy of Andrology and the
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American Society of Andrology recommends that patients with serum total 
testosterone <230 ng-dl'1 (8 nmolT1) will usually benefit from testosterone 
treatment (Wang et al., 2008).
Importantly, all authorities suggest that measures of testosterone should be 
performed on more than one occasion and should be standardised for time of 
day. Diurnal variations in testosterone concentrations have led to the 
recommendation that testosterone is measured in the morning, when it is 
considered highest and most reproducible (Brambilla et al., 2009; Dohle et al., 
2012).
2.8 Sequelae of ADT
Treatment with ADT is designed to induce hypogonadotropic hypogonadal 
testosterone concentrations. As reported above (2.6.4 Androgen deprivation 
therapy), serum total testosterone levels <50 ng-dl'1 (<1.74 nmol I'1) are the 
target for surgically or medically castrated patients (Harris et al., 2009). 
Considering this rapid development of hypogonadal testosterone 
concentrations it is of no surprise that men on ADT experience many of the 
symptoms of hypogonadism. Reduced libido, erectile dysfunction, 
gynaecomastia, hot flushes, fatigue, changes in mood and decreased bone 
mineral content are all primary clinical symptoms of hypogonadism (Dohle et 
al., 2012) and have all been side effects associated with ADT; which can lead 
to a reduction in patients' overall quality of life (Casey et al., 2012).
2.8.1 Sexual health
Sexual health side effects are one of the most significant occurrences in men 
on ADT, with loss of sexual function rated as one of the biggest factors in 
determining decreased quality of life in this patient group (Walker and 
Robinson, 2010). Decreased sexual health is characterised by decreased 
libido and erectile dysfunction (Thompson et al., 2003; Stempkowski, 2006; 
Mohile et al., 2009). Androgens play a critical role in the development and
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maintenance of erections in penile tissue, and thus ADT greatly inhibits this 
action, with these side effects usually presenting within 12 months of starting 
treatment (Mohile et al., 2009). In a study of 395 men on ADT, DiBlasio et al. 
(2008) reported 57 patients (14.4%) presented with erectile dysfunction, of 
which 70% had new onset erectile dysfunction after starting hormone therapy. 
Moreover, only 2.5% of patients reported normal libido after the initiation of 
ADT. These results are supported by Basaria et al. (2002), who reported that 
men on ADT had lower scores on the Watts sexual function questionnaire, 
had a lower frequency of spontaneous early morning erections and had more 
difficulty in gaining and maintaining erections than control groups of men with 
prostate cancer not on ADT and healthy age-matched controls. Furthermore, 
Basaria et al. (2002) also reported that the duration of ADT was inversely 
related to sexual desire showing a deleterious effect of prolonged hormonal 
therapy.
2.8.2 Vasomotor flushing
Vasomotor flushing, often described as hot flushes, is one of the most widely 
experienced side effects of ADT. Characterised by the temporary onset of 
body warmth, reddening skin and profuse sweating, often in tandem with 
feelings of intense nausea, vasomotor flushing is described by some as the 
most bothersome side effect of hormonal therapy (Holzbeierlain et al., 2003). 
Large variation can exist between individuals in the severity and frequency of 
these symptoms. While some men experience only occasional episodes 
lasting a few seconds, others will regularly experience hot flushes of up to an 
hour. Onset of symptoms can come as a result of changes in body position, 
ingestion of warm liquids, or changes in ambient temperature (Baum and 
Torti, 2007).
Prevalence rates of vasomotor flushing have been shown to be high in men 
treated with ADT. Studies have shown evidence of hot flushes to some 
degree in 60-80% of men within 3 months of initiating treatment (Schow et al., 
1998; Ulloa et al., 2009). Although symptoms can abate over time, Karling et
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al. (1994) reported that after 8 years of treatment more than 40% of men still 
experienced hot flushes. Furthermore, these researchers showed that in men 
discontinuing ADT hot flushes can persist, with 48% of men still experiencing 
symptoms 5 years after treatment cessation.
The underlying mechanisms behind vasomotor flushing are not fully 
understood. It is postulated that a disturbance of the hormonal feedback to 
the hypothalamus could be responsible. Decreased testosterone feedback is 
thought to diminish endogenous peptide secretion leading to an increase in 
catecholamine release. It is proposed that excess catecholamines stimulate 
the thermal neurons in the hypothalamus resulting in an unbalancing of the 
thermoregulatory capacity and subsequent sweating and vasodilator 
responses (Holzbeierlain etal., 2003; Frisk, 2010).
2.8.3 Gynaecomastia
Gynaecomastia can be a physically painful and embarrassing side effect of 
ADT characterised by proliferation of the glandular component of the male 
breast as an effect of the increase in the estrogen-to-androgen ratio (McLeod 
and Iverson, 2000; Thompson et al., 2003; Di Lorenzo et al., 2005; Suzuki et 
al., 2008). Generally starting within 12 months of androgen withdrawal, the 
effects are initially reversible; however, hyalinisation and fibrosis occurring 
after a year of gynaecomastia are irreversible (McLeod and Iverson, 2000). 
Reviewing the prevalence of gynaecomastia in men on ADT, McLeod and 
Iverson (2000) suggested that the form of ADT used can influence the rate of 
gynaecomastia onset. Gynaecomastia was reported in 7.6% of patients after 
orchiectomy, 28.6% of patients on LHRH-agonists, 43.7% of patients on non­
steroidal anti-androgens (bicalutamide or flutamide), and 17% of patients on 
combined androgen blockade therapy (flutamide with orchiectomy or 
flutamide with LHRH-agonists).
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2.8.4 Anaemia
ADT has been linked with anaemia in men with advanced prostate cancer 
(Nalesnik et al., 2004). Strum et al. (1997) reported large declines in 
haemoglobin 1 month after initiating complete hormonal blockade, with the 
nadir occurring after approximately 6 months of treatment. At nadir, 
haemoglobin concentrations had fallen >10% from baseline in 90% of 
patients, and >25% in 13% of patients. Anaemia has been linked to the 
effects of castration, with testosterone required for enhancement of 
erythropoietin formation in the kidneys and the action of erythropoiesis in 
bone marrow. Furthermore, in patients who suffer bony metastases the 
replacement of bone marrow with cancer cells will contribute to the degree of 
anaemia suffered (Nalesnik et al., 2004).
2.8.5 Bone health
The occurrence of bone loss with ADT has received increased attention since 
the link was initially described by Stepan et al. (1989). Testosterone is 
influential in regulation of bone resorption, and thus under hypogonadal 
conditions increased resorption occurs without concomitant increases in 
bone formation leading to a net loss in bone mineral density (Eastham, 2007). 
In a small prospective study, Morote et al. (2003) found that osteoporosis 
was detected in 41.5% of patients on ADT, compared with 28.1 % of men with 
prostate cancer but ADT naive. Of the patients on ADT, similar rates of 
osteoporosis were noted in men treated with LHRH-agonists alone (41.7%) 
to those in receipt of LHRH-agonists and anti-androgens for maximal 
androgen blockade (41.4%). Furthermore, Morote and colleagues provided 
evidence that osteoporosis risk increased with duration on treatment. 
Osteoporosis was reported in 36.4% of patients treated for 12-36 months, 
increasing to 42.1% and 50% of patients on ADT for 36-60 months and >60 
months, respectively. These results are supported by the work of others who 
have also reported ADT resulting in bone loss (Kiratli et al., 2001; Preston et 
al., 2002; Greenspan etal., 2005; Panju etal., 2009).
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2.8.6 Fatigue
Increased fatigue is a well-established side effect of treatment with ADT (Herr 
and O'Sullivan, 2000; Stone et al., 2000; Cherrier et al., 2009). Stone et al. 
(2000) reported increased fatigue after 3 months of hormonal therapy in as 
many as 66% of patients, although this was higher than the prevalence of 
fatigue reported by Storey et al. (2012) who found 43% of men treated with 
ADT for at least 6 months described cancer-related fatigue. Although the 
precise cause of fatigue in this patient group remains unclear, the effects of 
anaemia, pain, inadequate nutrition, depression, anxiety, endocrine 
abnormalities and lack of sleep have all been considered potential 
contributors (Stempkowski, 2006). In the study by Storey et al. (2012) 
depression and pain were reported to be the only factors independently 
associated with patient fatigue (OR = 4.7; 95% Cl, 1.6-14.0 and OR = 3.1; 95% 
Cl, 1.0-8.9, respectively). Increased fatigue is one of a spectrum of 
psychological traits thought to be affected through ADT. Fatigue, together 
with depression, anxiety, malaise and memory difficulties, form what has 
been collectively termed the 'androgen deprivation syndrome' (Shahinian et 
al., 2006).
2.8.7 Cardiovascular risk
Just as ADT has been associated with many of the symptomatic side effects 
found with hypogonadism, there is evidence that men treated with ADT might 
also be at increased risk of cardiovascular events similar to that shown with 
hypogonadism because of the reduction in testosterone concentrations. 
Khaw et al. (2007) reported that endogenous testosterone concentrations 
were inversely related to mortality from all-causes, cardiovascular disease or 
cancer. Khaw et al. suggested that a 6 nmolT1 (173 ng-dl'1) increase in total 
testosterone was associated with a 14% decrease in risk of all-cause 
mortality (OR = 0.86; 95% Cl, 0.79-0.94) and a 17% decrease in risk of 
cardiovascular mortality (OR = 0.83; 95% Cl, 0.74-0.94). Moreover, Hak et al. 
(2002) reported that higher testosterone concentrations could be protective
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against cardiovascular morbidity. Men with total testosterone in the highest 
tertile (>12.6 to <36.8 nmolT1) had a relative risk ratio of only 0.4 (95% Cl, 
0.1-1.0) for development of severe aortic atherosclerosis in comparison with 
men with testosterone in the lowest tertile (0 to <9.8 nmol-1'1).
There is evidence of similar findings in men on ADT with the incidence of 
cardiovascular morbidity and mortality reported to be increased within 6 
months of treatment initiation. D'Amico et al. (2007) pooled data from 3 
randomized trials (including a total of 1,372 men) to investigate the timing of 
fatal myocardial infarctions in men on ADT (LHRH-agonist alone or in 
combination with an anti-androgen). In men older than 65 years of age, 6 
months of hormone therapy increased the incidence of fatal myocardial 
infarctions compared to age-matched men not treated using ADT. These 
findings are supported by others who also report increased cardiovascular 
events in androgen deprived men. Keating et al. (2010) calculated that in 
men treated with LHRH-agonists the risk of suffering coronary heart disease, 
myocardial infarction, sudden cardiac death or stroke increased by 19%, 28%, 
35% and 21% respectively in comparison with a reference group of men not 
on ADT. Furthermore, Saigal et al. (2007) reported that men treated with 
ADT for at least 12 months had a 20% higher risk of serious cardiovascular 
morbidity in comparison with patients who were not treated with ADT.
It must be noted that others have reported no association between ADT and 
incidence of cardiovascular mortality (Efstathiou et al., 2008; Roach et al., 
2008; Efstathiou et al., 2009). Reviewing the association between treatment 
with ADT and cardiovascular mortality, Nguyen et al. (2011) reported no 
increase in risk in men on ADT. Incidence of cardiovascular mortality in men 
on ADT (n = 2200) was 11% (95% Cl, 8.3%-14.5%) while among controls not 
currently receiving ADT (n = 1941) it was 11.2% (95% Cl, 8.3%-15%). These 
data resulted in a risk ratio for cardiovascular mortality with ADT use of 0.93 
(95% Cl, 0.79-1.10) which did not achieve statistical significance (P = 0.41). 
However, more recently this data has been called into question by editorials 
highlighting methodological flaws which cast doubt over the conclusions 
(Blankfield, 2012; Froehner and Wirth, 2012). It has been shown that around
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50% of the men included in the review only received relatively short-term 
ADT (<3 years) and so they cannot be considered indicative of the effects 
experienced by men on long-term treatment. Furthermore, -25%  of men in 
the control group of one of the largest studies included in the review were 
treated with ADT within 3 years of study enrolment, providing a clear 
contamination of results. Finally, it has also been reported that studies 
included in the review of Nguyen and colleagues did not stratify their findings 
for the presence of pre-existing cardiovascular disease, and hence it cannot 
be ascertained whether cardiovascular end-points reported are truly the 
effects of ADT.
In-spite of contradictory findings for cardiovascular mortality in men treated 
with ADT there is growing evidence suggesting increased prevalence of 
cardiovascular risk factors in men treated in this manner. Cardiovascular risk 
factors similar to those reported in other hypogonadal groups have been 
shown in men on ADT with the reduction in testosterone concentration highly 
implicated in there development. These findings might be of little surprise 
considering studies calculating cardiovascular risk using the Framingham risk 
score have reported an inverse association between total testosterone 
concentrations and 10-year cardiovascular risk (Miner et al., 2011; Chock et 
al., 2012).
2.8.7.1 Body composition
Negative changes in body mass and body composition have been reported in 
men treated with ADT (Smith et al., 2002; Nishiyama et al., 2005; Smith et al., 
2008a; van Londen et al., 2008). In the review of body composition changes 
in men on ADT by Haseen et al. (2010) they included 16 studies with data on 
573 patients. Increases in body mass were reported in all studies, mean 
percentage increase of 2.1% (range 0.6-5.4%) over treatment durations from 
1 to 12 months. Seven studies used dual energy x-ray absorptiometry (DEXA) 
to investigate changes in fat mass with increases reported in all studies with
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a mean gain of 7.7%. Conversely, lean body mass was investigated in 6 
studies with a mean loss of 2.8%.
Rapid changes in body composition have been shown to occur on 
commencement on ADT. After 1 month of treatment using LHRH-agonists or 
orchiectomy losses in lean body mass and gains in total body mass and body 
fat mass were reported by Smith et al. (2001). These trends continued at 3 
months with further losses in lean body mass reported. The longitudinal study 
by van Londen et al. (2008) further confirmed the rapid changes in body 
composition after the initiation of ADT. Data collected 6 month after initiation 
of ADT showed gains in body fat mass, and percentage body fat, as well as 
losses in percentage lean body mass. Importantly, van Londen et al. (2008) 
also showed that duration of hormone therapy was correlated with the extent 
of adverse changes in body fat and lean body mass. After 24 months of 
hormone therapy, increases in body fat mass (2.2 kg) and percentage body 
fat (2.1%), and decreases in lean body mass (1.8 kg) and percentage lean 
body mass (2.3%) were reported in comparison with baseline data.
These alterations can lead to sarcopenic obesity, characterised by excess 
body fat in combination with reduced muscle mass or strength (Zamboni et 
al., 2008). In addition to exacerbating feelings of fatigue, decreasing physical 
function, contributing to emotional distress and further decreasing quality of 
life, the onset of obesity can increase the risk of cardiovascular events and 
mortality. Increased abdominal adiposity and BMI have been linked with 
increased risk of type II diabetes mellitus, ischaemic stroke, coronary heart 
disease and development of other cancers (Chan et al., 1994; Bianchini et al., 
2002; Suk et al., 2003; Canoy et al., 2007). Moreover, excess gains in fat 
mass and central adiposity leading to an increase in BMI has been 
associated with increases in all-cause and cardiovascular mortality (Stevens 
etal., 1998; Taylor et al., 2010).
The decrease in serum testosterone concentrations experienced with ADT is 
potentially responsible for changes in lean body mass. Supplementation of 
supra-physiological doses of testosterone have been shown to increase 
muscle mass without exercise in healthy adults (Bhasin et al., 1996).
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Similarly, testosterone replacement in hypogonadal men using physiological 
doses led to significant increases in muscle size and fat free mass (Bhasin et 
al., 1997). It has been elucidated that these effects are a result of 
testosterone acting on the hypothalamus to stimulate growth hormone 
release leading to increased protein synthesis and decreased protein 
degradation (Mudali and Dobs, 2004).
Testosterone concentrations have also been directly linked to changes in fat 
mass with low concentrations of total, free and bioavailable testosterone all 
associated with obesity. Testosterone stimulates lipolysis while concomitantly 
inhibiting lipid uptake, lipoprotein lipase activity and differentiation of 
adipocyte precursors cells (De Pergola, 2000). Accordingly, in men with low 
testosterone concentrations, the resultant non-lipolytic environment leads to 
accumulation of fat mass, as is evident through increases in visceral and 
subcutaneous fat found with the age-associated testosterone loss and in 
hypogonadal males (Katznelson et al., 1998; Vermeulen, 2000). It is noted 
that androgen deficiency has been most prominently associated with 
increases in visceral fat (Bhasin, 2003). In an investigation of the effect of 
testosterone concentrations on body fat distribution, Tsai et al. (2000) 
reported that lower total testosterone was an independent predictor of intra­
abdominal fat area but not significantly associated with subcutaneous fat 
area. These authors suggested that the inhibition of lipoprotein lipase activity 
by endogenous testosterone was greater in visceral fat than in subcutaneous 
fat resulting in greater accumulation of visceral fat under hypogonadal 
conditions. The increase in fat mass signals the start of a vicious cycle, as 
increased cytokine concentrations found with increased adiposity act as 
catabolic agents resulting in exacerbation of sarcopenia initiated through the 
decreased anabolism as previously described (Mudali and Dobs, 2004).
2.8.7.2 Metabolic changes
ADT has been linked to adverse metabolic alterations promoting increased 
cardiovascular risk (Shahani et al., 2008; Saylor and Smith, 2009; Choong
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and Basaria, 2010). Decreased insulin sensitivity has been widely reported in 
men on ADT (Dockery et al., 2003a; Basaria et al., 2006; Smith et al., 2006; 
Smith etal., 2008a). Negative changes in insulin sensitivity index and fasting 
plasma insulin concentrations have been noted within 3 months of 
commencing treatment (Smith et al., 2008a), with the continued decline in 
insulin sensitivity directly related to the duration of ADT (Basaria et al., 2006, 
as cited in Choong and Basaria, 2010).
Secreted from pancreatic p-cells in response to increases in circulating 
glucose and amino acids, insulin regulates glucose concentrations by 
reducing gluconeogenesis and glycogenolysis in the liver and increasing 
glucose uptake in skeletal muscle and adipose tissue (Sesti, 2006). 
Inadequate responses of these target tissues to circulating insulin are the 
primary impairment in the development of insulin resistance. Decreasing 
insulin sensitivity is characterised by depressed insulin-stimulated inhibition 
of hepatic glucose production, decreased stimulation of glucose uptake into 
skeletal muscle and an impaired effect of lipolysis inhibition in adipose tissue 
(Schenk etal., 2008).
Insulin resistance is a major precursor in the development of impaired 
glucose tolerance and type II diabetes mellitus, as well as featuring highly in 
other medical conditions such as obesity, dyslipidemia and hypertension. 
Moreover, insulin resistance has been linked to the development of 
atherosclerosis and coronary artery disease (Howard et al., 1996; Rewers et 
al., 2004). Insulin resistance at the level of the fat cell leads to a decrease in 
free fatty acid (FFA) uptake and/or an increase in the release of FFA from the 
fat cell. The response of the liver to the increased lipid synthesis is rapid 
incorporation of lipids into very low-density lipoprotein cholesterol (VLDL-C) 
which is subsequently secreted back into the blood stream. Increased 
circulating VLDL-C promotes atherosclerotic plaque formation both directly, 
by entering the vessel wall, and indirectly, by reducing high-density 
lipoprotein cholesterol (HDL-C) concentrations (Ginsberg, 2000).
Changes in glucose concentrations have been reported with ADT, but are 
slower to arise than the alterations in insulin described above. After 3 months
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of treatment, multiple studies have reported no changes in fasting glucose 
(Dockery et al., 2003a; Smith et al., 2006; Smith et al., 2008a), however, in 
the cross sectional study by Basaria et al. (2006) in which men treated with 
ADT for a minimum of 12 months were compared against men with prostate 
cancer not on ADT and healthy age-matched controls, ADT was associated 
with increased fasting glucose even after adjustment for age and BMI. These 
findings are suggestive of hyperglycaemia being a longer-term adaptation to 
hormone therapy. The authors speculated that the development of 
hyperinsulinaemia with the rapid onset of insulin resistance at the initiation of 
ADT temporarily maintains glucose concentrations, but the eventual (3-cell 
failure with prolonged hormone therapy leads to hyperglycaemia.
Increased lipoprotein concentrations have also been widely reported in men 
on hormone therapy (Smith et al., 2002; Braga-Basaria et al., 2006b; Smith 
et al., 2008b). Similar to the time-scale for the deterioration in insulin 
sensitivity, increases in low-density lipoprotein cholesterol (LDL-C) and HDL- 
C have been reported within 3 months of commencing ADT (Smith et al., 
2008b). After 48 weeks of LHRH-agonist therapy serum levels of total 
cholesterol, HDL-C and LDL-C were shown to be increased by 9.0%, 11.3% 
and 7.3%, respectively (Smith etal., 2002).
It should be noted that the relevance of the changes in lipid profile to 
cardiovascular risk is still somewhat unclear. It is accepted that elevated total 
cholesterol with reduced HDL-C is associated with increased cardiovascular 
risk (D'Agostino et al., 2008), however, elevated HDL-C has been shown to 
have anti-atherogenic qualities (Gordon et al., 1989). Furthermore, there is 
the question of LDL-C particle size, with some evidence suggesting the 
quantity of small, dense LDL-C particles is of greater relevance than total 
LDL-C content to increased cardiovascular risk (Rizzo and Berneis, 2006). 
With current data from men on ADT showing significant increases in HDL-C 
and no data on LDL-C particle size, the atherosclerotic nature of the 
described lipid profiles could be questionable. What might be of importance 
in interpreting these data however, is the ratio of total cholesterol/HDL-C 
which has been shown to be directly related to increased total risk of
53
mortality in older men (Chyou and Eaker, 2000). In a small cross-sectional 
study, total cholesterol/HDL-C ratios of 4.7, 4.4 and 3.8 were reported for 
men on ADT, men with prostate cancer not on ADT and age-matched healthy 
controls, respectively (Braga-Basaria et al., 2006b). Furthermore, analysis of 
data presented by Smith et al. (2002) shows a marginally increased total 
cholesterol/HDL-C ratio after 48 weeks of hormone therapy. The non­
significant nature of these figures means this link can only be speculated 
upon at this time with further work clearly warranted in this area.
The metabolic alterations reported above could all be associated with the 
decrease in male sex hormones found with ADT. Studies in healthy males 
and hypogonadal populations have reported total testosterone to be inversely 
associated with insulin, glucose, triglycerides, total cholesterol and LDL-C, 
but positively associated with HDL-C concentrations (Oppenheim et al., 1989; 
Haffner et al., 1993; Simon et al., 1997). Moreover, improvements in fasting 
glucose, insulin sensitivity, total cholesterol and LDL-C have been shown in 
hypogonadal males after testosterone replacement therapy (Zgliczynski et al., 
1996; Boyanov et al., 2003; Naharci et al., 2007).
The increase in body fat mass with reduced testosterone concentration could 
be the precursor to these metabolic alterations. Body fat accumulation is a 
common side effect of a reduction in male sex hormones (reviewed in 2.8.7.1 
Body composition) and it is widely acknowledged that increased adiposity 
can induce numerous adaptations to the metabolic profile (Bays et al., 2008; 
de Ferranti and Mozaffarian, 2008). Excess body fat is associated with an 
increase in the release of FFA and triglycerides into the circulation leading to 
lipid accumulation in tissues of the liver, heart, skeletal muscle and 
pancreatic (3-cells. Dysfunction of substrate storage in these targets tissues 
can bring about the development of insulin resistance as previously 
described. This can subsequently result in an attenuation of lipolysis of 
chylomicrons and triglycerides further increasing circulating FFA 
concentrations and thus adding to the dysfunctional cycle.
Increases in fat mass as a result of reduced testosterone concentrations 
might not be the single mediating factor resulting in metabolic alterations
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however, as testosterone could also have a direct effect on metabolic 
function. Acute sex steroid withdrawal in young men with idiopathic 
hypogonadotropic hypogonadism has been shown to reduce insulin 
sensitivity with no changes in body composition (Yialamis et al., 2007). 
Similarly, testosterone replacement therapy can lead to reductions in total 
cholesterol and LDL-C in hypogonadal men with no effect on BMI 
(Zgliczynski et al., 1996). Although the specific mechanisms underlying such 
an association remain unproven, there is evidence to suggest that androgen 
withdrawal might cause abnormalities in the hypothalamic-pituitary-gonadal 
axis at the level of Leydig cell function resulting in changes in insulin 
sensitivity (Traish et al., 2009a). Furthermore, studies in mice have shown 
early evidence that testosterone deficiency is associated with changes in 
expression of GLUT-4 and hexokinase 2, which could also influence insulin 
concentrations (McLaren et al., 2012).
2.8.7.3 Diabetes
Men treated with ADT are at increased risk of developing diabetes (Keating 
et al., 2006; Lage et al., 2007; Alibhai et al., 2009; Keating et al., 2010). In 
the observational study by Keating et al. (2006) including 73,196 men with 
local or regional prostate cancer, the risk of developing diabetes was 
increased by 44% and 34% for men treated with LHRH agonists or 
orchiectomy, respectively, in comparison with a control group of men with 
prostate cancer on no treatment. Similarly, in a more recent article by the 
same research group, diabetes prevalence was assessed in a cohort of 
37,443 men recruited from the Veterans Healthcare Administration (Keating 
et al., 2010). After a median of 2.6 years, diabetes risk was found to be 
higher in men on hormone therapy compared with men with prostate cancer 
not on ADT. Risk was increased by 28% with LHRH agonists, 16% with 
orchiectomy, 17% with combined androgen blockade and 2% with oral anti­
androgen therapy.
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The alterations in body composition and metabolic profile in patients on 
hormone therapy are considered highly influential in the development of overt 
diabetes. Characterised by peripheral insulin resistance, impaired regulation 
of hepatic glucose and loss of (3-cell function, overt diabetes is associated 
with loss of glycaemic control leading to macro- and microvascular 
complications (Mahler and Adler, 1999). In the presence of insulin resistance, 
compensatory insulin release from pancreatic (3-cells prevents the 
development of hyperglycaemia, however under the influence of adipokines, 
increased FFA and inflammatory cytokines often found with excess adipositiy, 
(3-cell dysfunction and apoptosis can develop. In the face of insulin resistance 
at the liver resulting in increased glucose production and decreased glucose 
utilisation, the loss of (3-cell insulin secretion leads to the development of a 
hypoinsulinaemic state and increased hyperglycaemia (Virally et al., 2007; 
Jones et al., 2010). Further compounding these events can be increased 
glucagon production by pancreatic a-cells. In healthy individuals glucagon 
acts to stimulate glycogenolysis and gluconeogenesis in the liver during 
periods of low blood glucose, and as a result glucose consumption inhibits 
glucagon release. However, loss of a-cell responsiveness with diabetes 
leads to an impairment of glucose inhibition of glucagon release, and thus 
further increases hepatic glucose production contributing to the 
hyperglycaemic state (Jones et al., 2010).
Patients with diabetes are at increased risk of suffering a multitude of 
complications that can include accelerated atheroma development, renal 
failure, retinopathy, neuropathy, susceptibility to infections, cataracts, diabetic 
ketoacidosis and diabetic coma (Underwood, 2007). Furthermore, individuals 
with diabetes are at increased cardiovascular risk with evidence of higher 
incidence of cardiovascular morbidity and mortality reported in diabetic 
patients (Casiglia et al., 2000).
In males, low testosterone concentrations have been associated with an 
increased incidence of type II diabetes mellitus (Ding et al., 2006). Body 
composition changes will contribute to this increased risk with excessive 
adiposity promoting insulin resistance, lipotoxicity and negative adipokine
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responses (Day and Bailey, 2011). It is of note however that in the Third 
National Health and Nutrition survey low testosterone was associated with an 
increased incidence of diabetes independently of adiposity (Selvin et al., 
2007). This evidence adds further credence to the data reviewed above 
(2.8.7.2 Metabolic changes) describing a direct link between testosterone 
withdrawal and the development of an insulin resistant state.
2.8.7.4 Arterial stiffness
The ability of the artery to expand and recoil in response to the cardiac cycle 
is related to the elastic properties of the artery. This is determined to a large 
extent by the elastin and collagen content within the arterial walls (Laurent et 
al., 2005; Zieman et al., 2005; Anderson, 2006). These elastic qualities allow 
the artery to stretch to accommodate blood flow during systole, with the 
subsequent recoil during diastole promoting forward flow (Arnett et al., 1994). 
When arterial compliance is reduced the cushioning of blood ejected during 
systole decreases and thus blood flow to the periphery occurs more rapidly 
under increased pressure, characterised by raised systolic pressure and 
decreased diastolic pressure (Noon, 2009).
Evidence has shown arterial stiffness can be increased by a multitude of 
factors including ageing (McEniery et al., 2005), diet (Kesse-Guyot et al., 
2010), physical inactivity (Vaitkevicius et al., 1993) smoking (Kim et al., 2005), 
type I and type II diabetes (Wilkinson et al., 2000; Schram et al., 2004), end 
stage renal disease (Pannier et al., 2007) and hypercholesterolaemia 
(Wilkinson et al., 2002). The implications of these effects can be severe, with 
increased risk of coronary artery disease (Gatzka et al., 1998; Mattace-Raso 
et al., 2006), hypertension (Franklin, 2005), myocardial infarction (Hirai et al., 
1989) and total cardiovascular risk (Haluska et al., 2010; Mitchell etal., 2010) 
all reported as a result of increased arterial stiffness. Moreover, arterial 
stiffness has been positively associated with cardiovascular and all-cause 
mortality (Blacher et al., 1998; Laurent et al., 2001; Shoji et al., 2001). An 
increase in carotid-femoral pulse wave velocity (PWV) (a measure of transit
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time directly related to arterial stiffness) of 1 standard deviation relates to a 
48% increase in the risk of a first major cardiovascular event (Mitchell et al., 
2010). Furthermore, an increase of 1 m s'1 in PWV has been shown to 
produce risk ratios of 1.69 (95% Cl, 1.35-2.11) for cardiovascular events and 
2.41 (95% Cl, 1.81-3.2) for all-cause mortality (Khoshdel et a!., 2007).
Structural changes are evident in the pathophysiology of arterial stiffness. 
Progressive stiffening of the arteries found with normal ageing is the result of 
degeneration of elastic fibres within the arterial wall with concomitant 
increases in collagenous material (Laurent et at., 2005; Anderson, 2006). 
Inflammation can also lead to dysregulation of the elastin-collagen balance 
promoting abnormal collagen deposition and diminished elastin content. The 
production of catabolic matrix metalloproteases (MMP) by inflammatory 
stimuli such as macrophages, oxidant radical formation, and vascular 
adhesion molecules is key in this process. MMP exert collagenolytic and 
elastinolytic effects resulting in this degradation of the extracellular matrix 
(Zieman et al., 2005).
The work by Dockery et al. (2000) was the first to report increased arterial 
stiffness in men on ADT. In a small cross-sectional study comparing 
androgen deprived men against healthy age-matched controls they reported 
higher central PWV in men on ADT. The same group confirmed these results 
in a further cross-sectional study in which systemic arterial compliance was 
also reported to be increased in men on ADT (Dockery et al., 2002). 
Stiffening of the arteries has been shown to be evident within as little as 3 
months of commencing hormone therapy (Smith et al., 2001; Dockery et al., 
2003a).
Further work by Dockery and colleagues highlights the impact of testosterone 
on arterial stiffness (Dockery et al., 2009). Investigating the effects of 
different forms of ADT on arterial compliance they randomised 43 men to 
receive LHRH-agonist or anti-androgen therapy for 24 weeks. Although 
central and peripheral PWV were increased after 12 weeks with both forms of 
ADT, after 24 weeks differences between groups were evident. Arterial 
stiffness continued to increase between weeks 12-24 in men treated with
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LHRH agonists, but in men on anti-androgens there was an improvement in 
arterial compliance resulting in no statistical difference in PWV between 
baseline and 24 weeks for patients in the anti-androgen group. Although it is 
unclear from these findings whether or not differences between groups for 
testosterone concentrations directly influenced arterial compliance, it is 
apparent that no other outcome measures demonstrated statistically 
significant changes at week 24.
This possible finding of a link between arterial stiffness and testosterone 
concentration would be in agreement with data previously presented 
demonstrating reduced arterial compliance in men with low testosterone 
(Dockery et al., 2003b; Hougaku et al., 2006; Yaron et al., 2009). Dockery et 
al. (2003b) and Hougaku et al. (2006) both reported the findings of 
observational studies in groups of elderly men showing negative correlation 
between testosterone concentrations and arterial stiffness. These data are 
further supported by the work of Yaron et al. (2009) who demonstrated 
increased PWV in hypogonadal males in comparison with age-matched 
eugonadal controls.
2.8.7.5 Endothelial function
Considering the evidence reviewed above describing the development of a 
pro-atherogenic environment, it could be hypothesised that treatment with 
ADT would lead to the development of endothelial dysfunction. Endothelial 
dysfunction incorporates an array of disruptions to normal endothelial 
function. However, this term is most commonly defined as an abnormality in 
the regulation of the vessel lumen (Grover-Paez and Zavalza-Gomez, 2009). 
This state is characterised by impaired vascular reactivity, in addition to being 
proinflammatory and prothrombotic. Endothelial dysfunction is now widely 
regarded as an important initial event in the development of atherosclerosis 
which can precede plaque and fatty streak formation (Celermajer, 1997), and 
as such, endothelial function is considered by some to be a barometer of 
cardiovascular risk (Vita and Keaney, 2002).
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The vascular endothelium is a single layer of cells located between the lumen 
and the vascular smooth muscle. Responding to changes in hemodynamic 
forces or blood-borne stimuli, the normal vascular endothelium regulates 
arterial tone, platelet and leukocyte interactions, coagulation, fibrinolysis and 
vascular growth through the synthesis and release of a plethora of vasoactive 
and thromboregulatory molecules and growth factors such as nitric oxide 
(NO), endothelins, prostacyclin and endothelial cell growth factors 
(Celermajer, 1997). Of these substances, one of the most important for 
maintenance of vascular homeostasis is NO. NO is a gaseous lipophilic free 
radical generated in the endothelium by endothelial NO synthase (Chatterjee 
and Catravas, 2008) and is the primary endothelium-derived relaxing factor 
responsible for maintaining vascular smooth muscle tone and opposing the 
actions of endothelial-derived contracting factors.
In the presence of risk factors including hypercholesterolaemia, hypertension, 
diabetes and smoking, decreased expression and loss of function of 
endothelial NO synthase causes a decline in NO synthesis, while elevated 
reactive oxygen species formation leads to accelerated NO degradation as 
superoxide anions inactivate available NO (Cai and Harrison, 2000; Hirata et 
al., 2010). With the development of this pro-atherogenic state NO 
suppression of endothelial-derived contracting factors is lost leading to 
increased expression of vasoconstrictors such as endothelin-1 and 
angiotensin-ll. Consequently, increases in vascular inflammation and 
oxidative stress further promote NO degradation, while increased expression 
of adhesion molecules on the surface of endothelial cells lead to binding of 
leukocytes and early atheroma formation (Grover-Paez and Zavalza-Gomez, 
2009).
These descriptions of mechanisms involved in endothelial dysfunction are 
supported by evidence from studies in different populations where endothelial 
function has been shown to be impaired. Patients presenting with insulin 
resistance (Shinozaki et al., 2001), hypercholesterolaemia (Perrault et al., 
2000; Vladimirova-Kitova et al., 2009) and obesity (Al Suwiadi et al., 2001) 
have all been shown to suffer endothelial impairment further strengthening
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the hypothesis of endothelial dysfunction in men on ADT in whom, as 
previously described, the risk of developing these cardiovascular risk factors 
is increased. Moreover, evidence of reduced arterial compliance in men on 
ADT also strengthens this hypothesis as arterial stiffness has been shown to 
correlate with endothelial function (Nigam et al., 2003; Wang, 2007). 
Endothelial-derived NO has a role in modulation of arterial compliance 
(Kinlay et al., 2001), with long-term NO deficiency thought to lead to 
increased arterial stiffness as a result of vascular remodelling (Wang, 2007).
2.8.7.5.1 Measurement o f endothelial function
Although there are several methods by which endothelial function can be 
both directly or indirectly measured (Al-Qaisi et al., 2008), use of high 
resolution ultrasound to detect flow-mediated dilatation (FMD) in the brachial 
artery has become increasingly popular. First described by Celermajer et al. 
(1992), FMD allows a non-invasive assessment of endothelial-dependent 
vasodilatation. The inflation and release of an occluding cuff results in 
changes in arterial diameter in response to the subsequent reactive 
hyperaemia. Increased blood flow into the previously occluded vascular bed 
distal to the cuff position induces an increase in shear stress at the level of 
the endothelial cells lining the artery. This stimulates the release of 
endothelial-derived relaxing factors that diffuse into the smooth muscle cells 
of the arterial wall leading to a signalling cascade which results in a lowering 
of calcium concentrations and vasorelaxation (Thijssen et al., 2011).
The relaxing factors responsible for arterial dilatation will differ depending 
upon the position of the occluding cuff. FMD measured using a cuff 
positioned in the traditional location distal to the position of arterial imaging 
will be primarily NO-dependent (Joannides et al., 1995; Mullen et al., 2001). 
However, use of a proximal cuff results in arterial dilatation only partially 
mediated by NO and more dependent upon other vasoactive substances 
(Doshi et al., 2001). Although these data clearly suggest that different 
markers are being measured using a proximal or distal cuff position, FMD
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measured both ways has been linked to the risk of cardiovascular events 
(Green et al., 2011). Reanalysing data originally presented by Inaba et al. 
(2010), Green and colleagues reported that with 1% increase in FMD with a 
distal cuff the relative risk for future cardiovascular events was 0.91 (95% Cl, 
0.87-0.96), but with a 1% increase in FMD with a proximal cuff relative risk 
was 0.83 (95% Cl, 0.78-0.88). Thus, for a 1% decrease in FMD measured 
with a distal cuff risk of future cardiovascular events increases by 9%, while a 
1% decrease in FMD using a proximal cuff increases the risk by 17%. 
Proximal cuff assessments remain less common as a result of greater 
difficulty in achieving data of sufficient quality as cuff inflation and deflation 
can collapse or distort the distal arterial segment being imaged (Charakida et 
al., 2010).
FMD provides a measure of cardiovascular health exceeding that given by 
traditional risk factors for cardiovascular disease. As previously described, 
there is evidence that cardiovascular risk factors such as insulin resistance 
and increase blood lipid profile can influence endothelial function (Shinozaki 
et al., 2001; Vladimirova-Kitova et al., 2009), however, it has also been 
shown that changes in such traditional risk factors (plasma lipids, blood 
pressure, blood glucose, waist-to-hip ratio, BMI) do not fully account for 
alterations in FMD (Green et al., 2003). Although no studies have 
conclusively described other factors influencing this measure of endothelial 
dilatation, there is evidence to suggest that changes in endothelial progenitor 
cells (Liao et al., 2010) and dietary antioxidant content (Franzini et al., 2012) 
could also be important.
2.8.7.5.2 Endothelial function and hypogonadism
Evidence from trials investigating the effects of hypogonadism on endothelial 
function further supports the hypothesis of endothelial impairment with ADT. 
Clinical studies in humans have provided evidence of dysfunctional 
endothelia in other hypogonadal populations with these data strongly 
supported by evidence from pre-clinical studies using animal models.
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Investigations by Yilmaz et al. (2011) and Akishita et al. (2007) reported on 
the effects of testosterone concentrations on endothelial function in patients 
with chronic kidney disease and men with coronary risk factors, respectively. 
Both studies described a positive association between total and free 
testosterone concentrations and endothelial function, with Akishita et al. 
reporting that endothelial-dependent arterial dilatation in men in the highest 
quartile of free testosterone was 170% of that found in men in the lowest 
quartile. These results are supported by the baseline data of Bernini et al. 
(2006) who describes reduced vascular reactivity in hypogonadal men in 
comparison with a eugonadal control group. Notably however, Bernini et al. 
(2006) also reported that 6 months of testosterone therapy in the 
hypogonadal group further reduced endothelial function. This finding is in 
agreement with data presented in other studies describing reduced arterial 
reactivity in hypogonadal men after treatment with testosterone replacement 
therapy (Zitzmann et al., 2002; Sader et al., 2003). Taken together the data 
above suggests that while low physiological testosterone concentrations can 
impair endothelial function, use of exogenous testosterone supplementation 
can have further deleterious effects.
Mechanisms underlying endothelial impairment with low testosterone 
concentrations are as yet incompletely understood with different opinions 
available in the current literature. While there is evidence supporting a direct 
effect of reduced testosterone concentrations on the endothelial cell (Foresta 
etal., 2006; Lu etal., 2007; Milardi etal., 2012), others consider the increase 
in metabolic risk factors with hypogonadism to be responsible for endothelial 
damage (Traish etal., 2009b).
Considering the wealth of evidence supporting a hypothesis of endothelial 
dysfunction in men treated with ADT it is interesting that this has only been 
investigated by a single study that, rather counter-intuitively, reported 
enhanced endothelial function in men on ADT (Herman etal., 1997). Herman 
and colleagues compared FMD results of 10 men with prostate cancer 
treated with ADT (orchiectomy or maximal anti-androgen therapy for >6 
months), to a control group of men in remission after non-prostate
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malignancies, and a group of healthy age-matched controls. FMD for men on 
ADT was 6.2%, while for men with non-prostate malignancies and healthy 
controls FMD was measured as 2% and 2.7%, respectively. No differences 
between groups were reported for arterial responses to glyceryl trinitrate 
(GTN).
The findings of Herman et al. (1997) could be considered to contradict the 
evidence reviewed above describing increased development of 
cardiovascular risk factors in men treated with ADT and the evidence of 
endothelial dysfunction in other hypogonadal populations. Accumulation of 
body fat, changes in blood lipid profile and increases in insulin resistance 
have all been associated with endothelial dysfunction in other patient groups 
(Grover-Paez and Zavalza-Gomez, 2009), and as such it seems intuitive that 
the development of these cardiovascular risk factors in men on ADT would 
be indicative of a reduction in endothelial function. Furthermore, the evidence 
of decreased arterial compliance in men on ADT could be considered to be 
symptomatic of endothelial dysfunction in consideration of the inverse 
relationship between arterial stiffness and endothelial function previously 
described (Wang, 2007). Hence, it must be questioned whether Herman and 
colleagues have reported data with a type I error. It is possible that 
insufficient sample size, recruitment of a sample unrealistic of men usually 
found in this patient group or errors in data collection during FMD 
assessments (Black et al., 2008) could have all influenced the results 
described. Further research is clearly warranted to investigate whether the 
findings of Herman etal. (1997) can be supported or challenged.
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2.9 Study 1. The effects of treatment of prostate cancer with androgen 
deprivation therapy on endothelial function
Study research question, aims and hypotheses
In consideration of the evidence reviewed above the following research 
question was developed along with study aims and hypotheses.
Research question
Is there a difference in endothelial function between men with prostate 
cancer treated with ADT and age-matched controls who have no history of 
prostate cancer or androgen treatment?
Study aims
To investigate if there is a difference in endothelial function between men 
treated with ADT for prostate cancer and age-matched controls who have no 
history of prostate cancer or androgen treatment.
Null hypothesis
There is no difference in endothelial function between men treated with ADT 
for prostate cancer and age-matched controls who have no history of 
prostate cancer or androgen treatment.
Experimental hypothesis
Endothelial function is different in men treated with ADT for prostate cancer 
compared with age-matched controls who have no history of prostate cancer 
or androgen treatment.
65
3.0 METHODS: Study 1
3.1 Study design
The study used a cross sectional design with two groups; men on ADT for 
prostate cancer and community dwelling, physically inactive, age-matched 
controls who had no history of prostate cancer or androgen treatment. Data 
for these independent groups were collected and compared for between 
group differences.
3.2 Ethics
Institutional ethics approval was granted for this study by the Research 
Ethics Committee of the Faculty of Health and Wellbeing, Sheffield Hallam 
University (appendix 1). This approval allowed the recruitment of a group of 
men to act as a control group. Ethics approval for recruitment of men with 
prostate cancer was granted by the NHS Yorkshire and Humber Research 
Ethics Committee as part of a larger lifestyle intervention study (appendix 2). 
All procedures conformed to the Declaration of Helsinki.
3.3 Sample size calculation
This study used a case-control design with 20 men recruited to both the ADT 
and control groups. This number of participants was calculated based upon a 
previous investigation of the effects of testosterone concentrations on FMD 
(Akishita et a/., 2007) assuming a similar absolute difference between groups 
of 2.3 ± 2.4% for arterial dilatation. Sample size was determined using the 
nQuery statistical software (nQuery Advisor 6.01, nQuery Statistical Solution, 
USA) using 80% power at an alpha level of 0.05.
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3.4 Participant recruitment
Data for men with prostate cancer treated with ADT was taken from the 
baseline assessments of men recruited for a lifestyle intervention study. The 
20 men included in this cross-sectional evaluation were the first twenty 
recruited for the lifestyle intervention study fitting all inclusion and exclusion 
criteria for this study. A consort diagram for recruitment of men for the 
intervention study is presented in the methods for study 2 in this thesis 
(Figure 7.2).
Controls were recruited from within the local community. Organisations 
considered likely to have men aged 60 years or older were approached either 
in person, over the phone or by email and asked to display a recruitment 
poster to their members (copy of poster provide in appendix 3). In total 34 
organisations were approached, of which 17 agreed to display the 
information. Men interested in participating were asked to contact the 
research team, at which time they were screened for inclusion/exclusion 
criteria (see 3.5 Inclusion and exclusion criteria). Those considered eligible 
were sent further information about the study (copy of participant information 
sheet in appendix 4) and given a minimum of 5 days to consider whether 
they chose to participate. Men still interested in taking part after the cooling 
off-period were invited to meet a study researcher at which time they 
completed a medical questionnaire and provided informed consent (appendix 
5 and 6, respectively). These men were also asked to quantify the volume 
and intensity of physical activity they completed in their leisure time using the 
Godin Leisure Score Index (Godin LSI; Godin and Shephard, 1985; appendix 
7). Participants were asked to report the number of times they performed 
more than 15 minutes of strenuous, moderate and mild exercise in an 
average week. The total leisure activity score was subsequently calculated 
using the equation:
Total leisure activity score = (9 x number of strenuous sessions) + (5 x 
number of moderate sessions) + (3 x number of mild sessions)
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A consort diagram for the recruitment of controls is provided in Figure 3.1. In 
total 47% of men requesting further information about the study maintained 
their interest and were willing to participate. The twenty men included in the 
study constituted 32% of those initially showing interest in participating.
Men responding to the advert interested in participating 62
Excluded
Medical reasons 
Exercise habits
18
15
3
Men meeting inclusion / exclusion criteria sent 44 
participant information sheet
Lost interest 15
Men still interested in participating 29
Not fitting group matching
Men included in the study 20
Figure 3.1. Consort diagram for the recruitment of controls
3.5 Inclusion and exclusion criteria
Criteria for prostate cancer patients being included in the study:
• Histologically confirmed advanced prostate cancer, at least stage T3 
NO MO
• Been in receipt of ADT for a minimum of 6 months and due to receive 
for at least the next 6 months
• Current stable disease; defined as PSA <5 ng.ml'1 or three 
consecutive decreasing PSA readings
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• Able to provide signed informed consent
Criteria for prostate cancer patients being excluded from the study:
• Unable or unwilling to complete assessments
• Current participation in regular physical activity meeting the minimum
guidelines for older adults described by the American College of
Sports Medicine (2009), defined as moderate-intensity physical activity 
for 30 minutes at least 3 times per week, or vigorous physical activity 
for 20 minutes at least 3 times per week for the last 6 months
• Painful bony metastases
• Less than 12 months since completion of radiotherapy
• Having ever received chemotherapy
• Less than 2 months post surgical treatment
• Unstable angina, uncontrolled hypertension, recent myocardial 
infarction or pacemaker
• History of sudden onset shortness of breath, blurred vision or fainting 
spells
• Any physical or mental impairment that would limit the ability to 
understand and complete the study and make consent unethical
Criteria for men being included in the control group:
• Aged 60 years or older
• Able to provide signed informed consent
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Criteria for men being excluded from the control group:
• Current participation in regular physical activity meeting the minimum 
guidelines for older adults described by the American College of 
Sports Medicine (2009), defined as moderate-intensity physical activity 
for 30 minutes at least 3 times per week, or vigorous physical activity 
for 20 minutes at least 3 times per week for the last 6 months
• Current infection or clinically significant illness in the 2 weeks prior to 
enrolment
• A previous diagnosis of prostate cancer
• Taking any medication that would affect androgen concentrations
• Any medical conditions that would affect androgen concentrations
• Having ever received chemotherapy
• Unstable angina, uncontrolled hypertension, recent myocardial 
infarction or pacemaker
• History of sudden-onset shortness of breath, blurred vision or fainting 
spells
• Any physical or mental impairment that would limit the ability to 
understand and complete the study and make consent unethical
3.6 Outcome measures
Assessments were completed in the exercise physiology laboratories of the 
Centre for Sport and Exercise Science, Sheffield Hallam University. 
Participants were asked to attend the assessment session in the fasted state, 
having refrained from the consumption of food or beverages (except water) 
for at least 8 hours, and having avoided tobacco products for at least 12 
hours. These sessions were undertaken in the morning to minimise the 
impact of fasting on participants daily routine. Participants were asked to
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refrain from taking part in any strenuous physical activity for at least 12 hours 
prior to attending the assessment. Where possible, participants were asked 
to refrain from taking any vasoactive medications for at least 12 hours prior to 
attending the assessment session.
3.6.1 Assessment of vascular function
Vascular function assessments were conducted in accordance with the 
guidelines described by Thijssen et al. (2011). All assessments took place in 
a quiet, dimly-lit and temperature-controlled room with the participant resting 
supine. Prior to commencing ultrasound assessments participants rested 
quietly for a minimum of 15 minutes with their right arm extended and 
supported in a position approximately 80° from the torso where it stayed for 
the duration of vascular function assessments. Resting blood pressure and 
heart rate were assessed in the contra-lateral arm with an automated 
sphygmomanometer (Dinamap, Dash 2500, GE Healthcare, Waukesha, Wl, 
USA). Ultrasound assessments of the right brachial artery were performed in 
the distal third of the upper arm using a 7-mHz linear array transducer 
attached to a high-frequency ultrasound system (Terason T3000, Teratech 
Corporation, Burlington, MA, USA). Once a suitable longitudinal B-mode view 
of the artery had been located the probe was held stable and image 
optimisation was performed by manipulation of depth and gain settings to 
allow clear visualisation of the near and far arterial walls and the lumen. 
Doppler assessment of blood velocity was performed throughout all 
assessments. The angle of insonation was set at £60° to the artery walls with 
greater angles of insonation previously shown to overestimate blood velocity 
(Harris et al., 2010). Where necessary 'heel-toe1 adjustments of the probe 
and manipulation of the doppler steering angle were performed to achieve an 
insonation of 60°.
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3.6.1.1 Endothelial-dependent dilatation
Endothelial-dependent dilatation was assessed using the FMD technique as 
originally described by Celermajer et al. (1992). A pneumatic rapid 
inflation/deflation cuff (Hokanson E20 rapid cuff inflator with Hokanson 
AG101 cuff inflator air source, D.E. Hokanson Inc, Bellevue, WA, USA) was 
placed distal to the olecranon process on the right arm prior to commencing 
the ultrasound assessment (set-up for FMD scan shown in Figure 3.2). The 
cuff was subsequently inflated to a pressure 50 mm Hg above systolic blood 
pressure, with occlusion maintained for 5 minutes. Baseline recordings of 
vessel diameter and blood velocity were performed for 1 minute prior to cuff 
inflation. Recordings were restarted 30 seconds prior to cuff release and 
continued for a further 3 minutes thereafter. Continuous recording throughout 
the duration of the 3-minute, post-deflation period was considered sufficient 
to ensure peak vessel diameter had been recorded (Black etal., 2008).
Figure 3.2. Position of ultrasound probe and rapid inflation cuff for assessments of 
endothelial-dependent dilatation of the brachial artery using a distal cuff placement.
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3.6.1.2 Endothelial-independent dilatation
Endothelial-independent arterial dilatation was assessed as the arterial 
response to a single dose (0.4 mg) of GTN. Participants rested quietly for 15 
minutes after completion of endothelial-dependent assessments to ensure 
recovery of baseline arterial diameter prior to commencing image acquisition. 
GTN was administered sublingually by an exercise physiologist external to 
the research team. Arterial imaging was performed for 1 minute prior to GTN 
administration and continued for a further 6 minutes thereafter with recording 
maintained throughout. Continual recording for 6 minutes post-GTN 
administration was considered sufficient to detect maximal arterial dilatation, 
which Corretti et al. (2002) suggested should occur within 3-4 minutes. 
Furthermore, 6 minutes exceeded the time for GTN-mediated dilatation 
during pilot testing in a group of 6 men of similar age to those to be involved 
in the study (age = 64 ± 6 years, time to peak dilatation 253 ± 36 seconds). 
An example of the pattern of arterial dilatation post-GTN is displayed in 
Figure 3.3. Participants' blood pressure was measured in the contra-lateral 
arm using an automated sphygmomanometer (Dinamap, Dash 2500, GE 
Healthcare, Waukesha, Wl, USA) prior to, and then every 2 minutes after, 
GTN administration. Blood pressure measures were repeated until blood 
pressure returned to baseline values.
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Figure 3.3. Arterial diameter during assessment of endothelial-independent 
dilatation. GTN delivered at 0 minutes (represented by dashed line). Arterial 
diameter before dashed line represents diameter during baseline minute. Peak 
arterial diameter represented by arrow (occurs 4 minutes 21 seconds after GTN 
delivery).
3.6.1.3 Ultrasound analysis
Throughout vascular assessments the ultrasound on-screen display was 
recorded at a rate of 15 frames per second using Camtasia Studio software 
(v5.0.0, TechSmith Corporation, Okemos, Ml, USA). Recorded files were 
subsequently converted to an audio video interleave (avi) format prior to 
analysis using the Brachial Analyser for Research software package (v5.6.19, 
Medical Imaging Applications, Iowa, USA). A screenshot of arterial analysis 
in this manner is provided in Figure 3.4. This software allows vessel diameter 
measurement by using automated electronic callipers to track movement of 
the vessel walls within a selected region of interest for each frame of the 
video file. Changes in blood velocity throughout FMD scans were assessed 
using the same software. A region of interest was drawn around the blood- 
flow waveform in which the peak of the blood velocity waveform was
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automatically detected. Calibration of the analyser software was performed 
prior to both arterial diameter and blood flow analyses using the in-built 
calibration tools.
Electronic callipers 
tracking arterial walls
Arterial diameter data 
and trace
Arterial image with 
Doppler gate
Doppler flow with analysis 
trace (purple line over top 
of blood flow waveform)
Figure 3.4. Screen shot of analysis of arterial scan using Brachial Analyser for 
Research. Annotated to highlight key aspects of analysis.
Arterial shear rate (SR) was calculated for endothelial-dependent scans to 
quantify the stimulus eliciting changes in vessel diameter following cuff 
release. Arterial shear was calculated using the equation:
SR = 4*V/D
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where V is Doppler velocity and D is vessel diameter (Parker et al., 2009). 
SR area under the curve (SR AUC) was calculated as the sum of arterial 
shear from cuff release through to peak vessel diameter.
Raw data for arterial diameter were smoothed prior to calculation of the 
magnitude of arterial dilatation. This smoothing technique calculates the 
median diameter of 50 consecutive frames (3.3 seconds of data) with each 
50 frame bracket sharing a 20% overlap with the preceding bracket. As there 
is no accepted consensus on the best method by which to smooth arterial 
diameter data, this method was selected being amongst the most widely 
used in current research (Black et al., 2008; Tinken et al., 2008). An example 
of smoothed and unsmoothed data is provided in Figure 3.5.
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Figure 3.5. Post-analysis smoothing of FMD scan. 3.5.A unsmoothed data, 3.5.B 
smoothed data.
Baseline arterial diameter was calculated as the mean of data acquired 
through the minute prior to cuff inflation or GTN administration. Peak 
diameter was considered the highest data point following cuff release or GTN 
administration. Absolute change in arterial diameter was calculated as:
Absolute arterial dilatation = Peak diameter - Baseline diameter
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Additionally, the relative change in arterial diameter was calculated as a 
percentage increase from baseline using the equation:
Percentage arterial dilatation = [(Peak diameter - Baseline diameter) /
Baseline diameter] * 100
Allometrically-scaled data were also presented for all arterial dilatation 
assessments in accordance with the guidelines presented by Atkinson et al. 
(2013) to account for differences between groups in baseline arterial 
diameter. Data for baseline and peak arterial diameter were transformed 
using a natural log (logn) prior to the difference in arterial diameter between 
time points being calculated using the equation:
Allometrically-scaled arterial diameter change = logn peak diameter - logn
baseline diameter
The difference between groups for the logn transformed diameter change 
was subsequently analysed with the logn of baseline diameter included as a 
covariate. Data presented in the results show the antilog of mean values of 
logn transformed data, which has subsequently been converted to a 
percentage using the equation:
Percentage allometrically scaled dilatation = (Antilog of scaled diameter
difference -1 )  * 100
Exponents for scaling of baseline data were calculated using linear 
regression, with logn peak diameter included as the dependent variable, while 
group and logn baseline diameter were included as independent variables. A 
variable of group*logn baseline diameter was also created and included as an 
independent variable in an initial regression analysis to examine whether 
there was an interaction between group and logn baseline diameter which 
would necessitate the need for separate exponents for the different groups. 
To show the spread in data 95% Cl of the exponent were also reported. The 
between group analysis for allometrically scaled arterial diameter change 
was re-run including body fat mass, cardiovascular disease drugs 
(antihypertensive medications, aspirin, nitrates and statins) and logn baseline
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diameter as covariants to estimate the additional confounding effects of fat 
mass and concomitant medications on arterial diameter change.
To avoid researcher bias, all video files were re-coded prior to analysis to 
ensure the researcher was blinded to the participant’s group.
3.6.2 Anthropometry
Participant's stature (Holtain Stadiometer, Holtain Ltd, Pembrokeshire, UK) 
and body mass (Weylux Beam Balance Scales, Weylux, UK) were measured 
using standard laboratory techniques. BMI was subsequently calculated 
using the equation:
BMI = body mass / stature2
Body composition was assessed via bioelectrical impedance using the 
Inbody 720 (Biospace, Seoul, South Korea). The Inbody 720 performs multi­
frequency bioelectrical impedance at 1, 5, 50, 250, 500 and 1000 KHz to 
calculate segmental muscle and fat mass through measurement of 
intracellular and extracellular water. The Inbody 720 uses eight contact 
electrodes positioned on the palm and thumb of both hands and anterior and 
posterior aspects on the sole of both feet. Skin surfaces to make contact with 
the electrodes were cleaned with disinfectant wipes prior to test 
commencement as per the manufacturer instructions. During the test 
participants were asked to stand as still as possible with arms fully extended 
and abducted laterally to approximately 20 degrees.
3.6.3 Blood markers
Capillary and venous bloods were taken from all participants. Capillary blood 
was collected from a finger-prick performed on the middle finger of the left 
hand for immediate assessment of haemoglobin concentrations. Blood 
samples (10 pL) were collected on microcuvettes (B-Hemoglobin 
microcuvettes, HemoCue, Angelholm, Sweden) prior to analysis using a
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Haemoglobin Photometer (HemoCue, Angelholm, Sweden). A check of 
photometer calibration was performed at each assessment using a known 
standard.
Venous blood (20 ml) was drawn from the antecubital vein using standard 
phlebotomy techniques. Serum and plasma were separated from whole 
blood samples prior to freezing at - 80°C (Sanyo VIP-series Ultra Low 
Temperature Freezer, Sanyo Biomedical, Wood Dale, IL, USA). Batch 
analysis of samples was carried out in the Department of Clinical Chemistry 
at the Royal Hallamshire Hospital, Sheffield, UK. Samples were analysed for 
male sex hormones (testosterone and SHBG) and lipid profile (total 
cholesterol, HDL-C, LDL-C and triglycerides) using the Cobas 8000 Modular 
Analyser (Roche Diagnostics, Basel, Switzerland).
3.7 Statistical analyses
Data are presented as mean ± standard deviation (SD) unless stated. 
Statistical analysis was performed using Statistical Package for the Social 
Sciences (SPSS) for Windows (v 19.0.0, IBM inc, NY, USA). Variation in 
frequency distribution for demographic data was examined using Pearson's 
Chi squared test. Outcome data was analysed for standard descriptive 
statistics, with normality of distribution assessed using the Shapiro-Wilk test. 
Differences between groups for outcome measures were assessed using 
independent f-tests or the non-parametric equivalent (Mann Whitney-U) with 
all tests performed two-sided. Statistical significance was set as P <0.05. 
Additionally, outcome measures were assessed for effect sizes using 
Cohens-cf, with thresholds set at 0.2 for a small effect, 0.5 for a medium 
effect and 0.8 for a large effect (Cohen, 1992). Effect sizes were calculated 
using the equation:
Effect size = (meangroup1 - meangroup2) / SDpooled
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Where meangroup1 is the mean of group 1, mean9roup2 is the mean of group 2, 
and SDpooled is the pooled standard deviation. Pooled standard deviation was 
calculated using the equation:
gQpooled _  ^  ^ n group1_i) *  ^gQgroup1j2 +  ^n group2_^ *  ^ Q g r o u p 2 ^  j  n group1 +  n group2j
Where ngroup1 is the number of participants in group 1, ngroup2 is the number of 
participants in group 2, SDgroup1 is the standard deviation of group 1 and 
SD9roup2 is the standard deviation of group 2.
Relationships between variables were examined using tests of correlation. 
Duration of ADT and testosterone concentrations were correlated against 
measures of body composition, blood pressure, baseline arterial diameter 
and arterial dilatation. Additionally, variables associated with magnitude of 
arterial dilatation were assessed with duration of ADT, PSA, body 
composition and blood pressure included in the analysis. In cases where 
both variables were normally distributed, Pearsons bivariate correlation 
coefficient was used; however, if one or more variables did not achieve 
normal distribution, Spearmans rank correlation was employed. Correlation 
coefficients <0.35 were considered weak, 0.36-0.67 moderate, 0.68-0.89 
high and >0.9 very high (Taylor, 1990). To examine covariates influencing the 
association between variables partial correlations were performed with 
covariates included as controlled variables.
3.8 Reliability of measures
Reliability of measurement techniques was assessed to allow quantification 
of the technological and biological variability inherent in all physiological 
techniques. Ten men (n = 6 ADT patients and n = 4 controls) aged 69 ± 6 
years completed a second assessment within 7 days of the initial 
assessment session, with the testing procedures standardised between the 
two trials. To limit the circadian variation in outcome measures, participants 
were asked to attend this additional session at the same time of day as they 
had completed the initial assessment. Furthermore, participants were asked
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to prepare for the assessments in the same manner in accordance with the 
guidelines for vascular function assessment (Thijssen et al., 2011).
Standard error of measurement (SEM), intraclass correlation coefficient (ICC), 
relative technical error of measurement (rTEM) and coefficient of variation 
(CV) were calculated in accordance with suggestions of reliability tests in 
sports medicine (Atkinson and Nevill, 1998; Hopkins et al., 2009). The ICC 
was selected based upon the work of Weir (2005). Results of reliability tests 
are presented in Table 3.1.
Table 3.1. Reliability statistics for main outcome measures.
Outcome measure Trial 1 Trial 2 SEM rTEM (%) CV (%) ICC
Body mass (kg) 87.1 (18.2) 87.0(18.5) 0.45 0.19 0.39 1.00
Skeletal muscle mass 37.6 (4.7) 37.8 (5.0) 0.45 0.69 0.94 0.99
(kg)
Body fat mass (kg) 20.6(14.9) 20.5(14.6) 0.72 1.60 2.37 1.00
Body fat percentage 22.0(11.6) 21.8(11.6) 0.70 1.29 2.23 1.00
(%)
Visceral fat area (cm2) 119.9 (71.6) 121.6 (69.6) 4.25 2.91 2.80 1.00
Systolic blood pressure 142(11) 146(15) 5.47 5.01 3.73 0.76
(mm Hg)
Diastolic blood 80 (8) 81 (8) 4.39 1.59 4.40 0.67
pressure (mm Hg)
MAP (mm Hg) 105 (6) 105 (8) 4.06 0.61 3.97 0.51
Resting heart rate 57 (5) 61 (7) 2.77 13.73 5.78 0.71
(beatsmin'1)
Baseline arterial 5.2 (0.6) 5.2 (0.6) 0.15 0.54 2.00 0.94
diameter (mm)
Peak arterial diameter 5.5 (0.4) 5.5 (0.4) 0.17 1.27 1.96 0.86
(mm)
FMD (mm) 0.32 (0.21) 0.29 (0.20) 0.04 15.48 12.48 0.96
FMD (%) 6.5 (5.2) 6.1 (5.0) 0.80 11.52 10.97 0.98
Abbreviations. CV: Coefficient of variation, FMD: Flow-mediated dilatation, ICC: Intraclass 
correlation coefficient, MAP: Mean arterial pressure, rTEM: Relative technical error of 
measurement, SEM: Standard error of measurement. Data for trials stated as mean (SD).
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Considering the reproducibility results presented above against the standards 
described by Cicchetti, (2000) for levels of ICC (<0.4 = poor, 0.4-0.59 = fair, 
0.6-0.74 = good, >0.75 = excellent) suggests our findings are excellent for 
body composition and ultrasound data, and good for blood pressure 
measurements. Our results demonstrate CV of body composition 
measurements is comparable to those reported in studies investigating the 
reliability of DEXA (Guo et al., 2004).
There is no conventionally accepted level of reproducibility for ultrasound 
assessments of FMD, and current available data from assessments of FMD 
reliability vary greatly in their findings, at least partly as a result of variations 
between centres for FMD techniques (Charakida et al., 2010). However, 
reliability of baseline arterial diameter and FMD response found in the current 
assessment are of similar magnitude to those previously reported by studies 
using the same method for FMD assessment (Welsch et al., 2002; Donald et 
al., 2008). Donald et al. (2008) found CV of 2.6% and 10.6% for the 
difference in baseline arterial diameter and FMD response, respectively. 
Similarly, Welsch et al. (2002) reported ICC and SEM of 0.92 and 1.53%, 
respectively, for the difference in FMD response between days.
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4.0 RESULTS: Study 1
4.1 Demographic details and patient characteristics
Groups were well-matched for age, current smoking status and history of 
cardiovascular disease (Table 4.1). More men in the control group were 
previous smokers, however the difference between groups did not achieve 
statistical significance (P = 0.053). There were no marked differences 
between groups for daily physical activity measured using the Godin LSI (18 
± 1 3  points and 19 ± 13 points for ADT and control groups, respectively; P = 
0.878).
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Table 4.1. Cohort demographic details, given as count within cohort (% of
group) unless otherwise stated
ADT patients 
n = 20
Controls 
n = 20
P
Age- yr: Mean (SD) 69 (7) 69 (5) 0.779
Lifestyle
Current smokers 1(5) 1(5) 1.000
Previous smoker 9(45) 15(75) 0.053
Currently employed 4(20) 1(5) 0.151
Health history
History of cardiovascular disease 12(60) 10(50) 0.525
Diagnosed hypertension 12(60) 8(40) 0.342
Diagnosed diabetes 1(5) 1(5) 1.000
Previous myocardial infarction 3(15) 2(10) 0.292
Medications
Any anti-hypertensive medication 13(65) 9(45) 0.110
Statin therapy 9(45) 11(55) 0.527
Beta-blockers 6(30) 1(5) 0.037
Aspirin 8(40) 5(25) 0.311
ACE-inhibitors 10(50) 2(10) 0.006
Diuretics 4(20) 3(15) 0.677
Angiotensin II receptor antagonists 0 3(15) 0.072
Calcium channel blockers 8(40) 5(25) 0.311
Anti-coagulants 1(5) 2(10) 0.548
Abbreviations. ADT: Androgen deprivation therapy, ACE: Angiotensin converting
enzyme
Median duration of ADT was 22 months (range 6-133 months). All ADT 
patients were treated with LHRH-analogue injections alone (n = 18) or in 
addition to the anti-androgen Bicalutamide (n = 2). PSA for men on ADT was 
1.74 ± 2.96 ng-ml'1. Five men in the ADT group had previously received 
radiotherapy (median duration since treatment completion 18 months, range 
12-58 months). Serum testosterone concentrations were lower in men on 
ADT (0.4 ± 0.2 nmol-L'1) than in controls (18.5 ± 7.1 nmol-L'1; P <0.001) but
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SHBG was similar between groups (48 ± 24 nmol-L-1 and 53.4 ± 17.2 nmol-L" 
1 for ADT and controls, respectively; P  = 0.3).
4.2 Vascular function assessments
Data for ultrasound assessments are given in Table 4.2. Baseline and peak 
arterial diameter for FMD assessments were similar between groups 
(P >0.05). The FMD response was lower in men on ADT than in controls for 
all three methods of data presentation (P <0.05; mean difference for relative 
FMD = 2.1%; 95% Cl, 0.1 to 4.0). After adjustment for body fat mass and 
concomitant-medications, the difference in FMD remained significant (P = 
0.029), with the magnitude of difference in mean FMD between groups 
altered marginally from 2.1% (95% Cl, 0.3 to 4.0) for FMD scaled to baseline 
arterial diameter, to 2.4% (95% Cl, 0.3 to 4.5). There were no substantial 
differences between groups for blood flow at baseline or at peak velocity after 
cuff release (P >0.05). SR AUC was similar between groups (P >0.05).
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Table 4.2. Ultrasound assessment data, mean (SD)
ADT patients Controls P d
Baseline diameter (mm) 4.90 (0.56) 5.10(0.73) 0.338 0.04
Peak diameter (mm) 5.09 (0.58) 5.39 (0.71) 0.150 0.06
FMD (mm) 0.19(0.10) 0.29 (0.18) 0.034 0.02
FMD (%) 3.9 (2.1) 5.9 (3.8) 0.047 0.33
Allometrically-scaled FMD (%) 3.7 (2.7) 6.0 (2.7) 0.023 0.39
Time to peak diameter (sec) 54.3 (29.2) 60.6 (29.7) 0.401 0.15
Resting flow (ml-min'1) 123 (51) 126 (81) 0.607 0.03
Peak flow (ml-min'1) 1510(484) 1808 (587) 0.094 0.40
SR AUC 38811 (18298) 38064(16537) 0.893 0.03
GTN baseline diameter (mm) 5.17(0.54) 5.06 (0.47) 0.497 0.02
GTN diameter peak (mm) 5.80 (0.60) 5.80 (0.53) 0.985 0.00
GTN-mediated dilatation (mm) 0.63 (0.21) 0.74 (0.27) 0.152 0.02
GTN-mediated dilatation (%) 12.2 (4.2) 14.8 (5.7) 0.113 0.31
Allometrically-scaled GTN (%) 12.3 (4.6) 14.4 (4.6) 0.163 0.28
Abbreviations. ADT: Androgen deprivation therapy, FMD: Flow-mediated dilatation, 
GTN: Glyceryl trinitrate, SR AUC: Shear rate area under the curve
Arterial diameter prior to GTN assessments and peak arterial diameter after 
GTN administration showed no substantial differences between groups 
(P >0.05). GTN-mediated change in arterial diameter was similar between 
groups for all methods of data presentation (P >0.05).
Linear regression lines for log-transformed baseline and peak diameter for 
FMD assessments for ADT and control men are shown in Figure 4.1. The 
exponent for allometric-scaling of FMD assessments were calculated as 0.93 
(95% Cl, 0.83-1.00). Similarly, for GTN-mediated dilatation an exponent of 
0.87 (95% Cl, 0.73-1.01) was found.
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Figure 4.1. Linear regression of log baseline diameter and log peak diameter for 
FMD assessments in men on ADT (•) and controls (•).
4.3 Secondary outcomes
Table 4.3 shows body composition and blood pressure data. Groups were 
well-matched for body mass and BMI (P >0.05), however differences 
between groups were evident with body composition. Body fat mass and 
body fat percentage were both higher in men on ADT than in controls (P 
<0.05). There were no substantial differences between groups for skeletal 
muscle mass or visceral fat area (P >0.05).
Groups did not differ for systolic blood pressure, diastolic blood pressure, 
mean arterial pressure or pulse pressure (P >0.05). Resting heart rate was 
higher in men treated with ADT than in controls (P = 0.032).
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Table 4.3. Blood pressure and body composition data, mean (SD)
ADT patients Controls P d
Systolic blood pressure (mm Hg) 145(16) 139(12) 0.167 0.31
Diastolic blood pressure (mm Hg) 79 (8) 79 (9) 0.843 0.04
Mean arterial pressure (mm Hg) 105(10) 103 (9) 0.390 0.19
Pulse pressure (mm Hg) 66(15) 59 (9) 0.940 0.38
Resting heart rate (beatsmin'1) 66(12) 58 (9) 0.032 0.49
Body composition
Body mass (kg) 90.5(12.1) 89.0(14.4) 0.718 0.08
BMI (kg-m'2) 29.6 (3.3) 28.4 (3.8) 0.273 0.19
Skeletal muscle mass (kg) 32 (5.1) 34.4 (5.2) 0.152 0.28
Body fat mass (kg) 32.5 (8.2) 27.4(7.6) 0.035t 0.43
Body fat (%) 35.8 (6.2) 30.5 (4.6) 0.004 0.60
Visceral fat area (cm2) 179 (30) 168 (25) 0.216 0.29
Abbreviation. BMI: Body mass index. (T) denotes assessed using Mann Whitney U 
test
Results of bloods analysis are displayed in Table 4.4. HDL-C, LDL-C, total 
cholesterol and total cholesterol / HDL-C ratio were all similar between 
groups (P >0.05). Triglycerides were higher in men on ADT than controls (P 
= 0.001). Haemoglobin concentrations were lower in men on ADT (P = 0.006).
Table 4.4. Blood analysis, mean (SD)
ADT patients Controls P d
HDL-C (mmolT1) 1.35 (0.39) 1.49 (0.39) 0.213t 0.03
LDL-C (mmolT1) 2.81 (1.14) 2.88(1.07) 0.841 0.01
Total cholesterol (mmol I'1) 5.08(1.22) 4.92(1.17) 0.766* 0.04
Total cholesterol/HDL-C ratio 3.97(1.18) 3.45 (0.99) 0.143 0.11
Triglycerides (mmolT1) 2.03 (0.9) 1.22 (0.52) 0.001 0.18
Haemoglobin (g I'1) 131 (15) 146(15) 0.006 0.65
Abbreviations. HDL-C: High-density lipoprotein cholesterol, LDL-C: Low-density 
lipoprotein cholesterol. (t ) denotes assessed using Mann Whitney U test
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4.4 Correlations
Relationships between outcome measures and duration of ADT were 
assessed using non-parametric tests as a result of data for ADT duration 
being non-normally distributed. ADT duration was positively correlated with 
body fat mass (rs = 0.416, P  = 0.068) and body fat percentage (rs = 0.386, P 
= 0.092), however, neither achieved statistical significance (both P >0.05). 
ADT duration demonstrated a statistically significant relationship with visceral 
fat area (rs = 0.519, P  = 0.019; Figure 4.2). Adjusting correlations for age 
resulted in strengthening of the association of ADT duration to body fat mass 
(r = 0.582, P = 0.009), body fat percentage (r = 0.486, P = 0.069) and 
visceral fat area (r = 0.661, P = 0.002).
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Figure 4.2. Relationship between duration of treatment with ADT and visceral fat 
area. Black line represents line of best fit for data.
Relationships between testosterone concentrations and other outcome 
measures were assessed for the two groups separately due to the wide 
variation between groups in testosterone caused by castration in men on 
ADT. Scatterplots for the relationship between testosterone and systolic
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blood pressure, body fat mass, BMI and baseline arterial diameter for men in 
the control group are presented in Figure 4.3. For men in the control group 
testosterone concentrations were negatively correlated with body fat mass (rs 
= -0.448, P = 0.048) and BMI (r = -0.421, P = 0.064). After controlling for age 
the association with both fat mass and BMI were strengthened (r = -0.467, P 
= 0.044 and r = -0.492, P = 0.032, respectively). Testosterone also showed a 
strong negative correlation with skeletal muscle mass (r = -0.710, P <0.001); 
however the significance of this finding was lost when skeletal muscle mass 
was assessed as a percentage of total body mass (r = -0.056, P = 0.813).
Serum testosterone concentrations showed a negative correlation with 
systolic blood pressure (r = -0.495, P = 0.026) and baseline arterial diameter 
(r = -0.441, P = 0.052). Controlling for body fat mass resulted in a loss of the 
significance of the association between testosterone and systolic blood 
pressure (r = -0.444, P = 0.057). Adjustment of the correlation between 
testosterone and baseline arterial diameter for systolic blood pressure 
resulted in a weakening of the association (r = -0.320, P = 0.182), but 
controlling for body fat mass made the correlation stronger (r = -0.509, P = 
0.026).
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Figure 4.3. Relationship between testosterone concentrations and systolic blood 
pressure (4.3.A), body fat mass (4.3.B), BMI (4.3.C) and baseline arterial diameter 
(4.3.D) for men in the control group. Black lines denote line of best fit for each data 
set.
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There was no relationship between serum testosterone concentrations and 
any measures in men treated with ADT (P >0.05).
In men on ADT percentage body fat was weakly correlated with change in 
arterial diameter when expressed as both relative diameter change (r = - 
0.365, P  = 0.113) or as the ratio of peak arterial diameter to allometrically- 
scaled baseline diameter (r = -0.369, P = 0.110). This relationship was not 
evident in men in the control group (r = 0.069, P = 0.773 for relationship with 
percent FMD and r = 0.032, P = 0.892 for relationship with scaled ratio).
FMD was not correlated to any other variables in either group (data not 
presented, all P >0.05). When data for both groups were combined, no 
associations were evident between arterial dilatation calculated using any 
method and any other variables.
4.5 ADT compared to eugonadal controls
Table 4.5 presents data for main outcomes after the exclusion of men in the 
control group with biochemical hypogonadism (n = 3). Differences between 
groups were evident for FMD for all methods of data presentation (P <0.05). 
In addition, differences between groups were observed for body fat mass, 
body fat percentage and triglyceride concentrations (P <0.05). Exclusion of 
hypogonadal controls also led to a trend for higher systolic blood pressure in 
men treated with ADT, although this did not achieve statistical significance (P 
= 0.071).
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Table 4.5. Comparison of ADT patients against eugonadal controls for main outcomes, mean 
(SD)
ADT patients 
(n = 20)
Eugonadal controls 
(n = 17)
P d
Body mass (kg) 90.5(12.1) 86.1 (13.4) 0.297 0.24
BMI (kgm2) 29.6 (3.3) 27.9 (3.9) 0.146 0.26
Skeletal muscle mass (kg) 32.0 (5.1) 33.1 (4.2) 0.494 0.14
Body fat mass (kg) 32.5 (8.2) 26.8 (8.1) 0.012 0.47
Body fat (%) 35.8 (6.2) 30.7 (4.9) 0.010 0.57
Visceral fat area (cm2) 179 (30) 166 (26) 0.157 0.35
Systolic blood pressure (mmHg) 145(16) 136(12) 0.071 0.44
Diastolic blood pressure (mmHg) 79 (8) 77 (8) 0.521 0.14
Mean arterial pressure (mmHg 105(10) 101 (8) 0.107 0.37
FMD (mm) 0.19(0.10) 0.29 (0.15) 0.022 0.02
FMD (%) 3.9 (2.1) 5.9 (3.2) 0.028 0.34
Allometrically-scaled FMD (%) 3.8 (2.7) 5.9 (2.5) 0.024 0.38
Serum testosterone (nmolT1) 0.4 (0.0) 20.4 (5.0) <0.001 3.02
HDL-C (mmoi r1) 1.35 (0.09) 1.47 (0.39) 0.314 0.03
LDL-C (mmolT1) 2.81 (0.25) 2.83(1.15) 0.843 0.01
Total cholesterol (mmolT1) 5.08 (0.27) 4.86(1.23) 0.593 0.05
Triglycerides (mmolT1) 2.03 (0.20) 1.22 (0.55) 0.002 0.18
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5.0 DISCUSSION: Study 1
The primary finding of this study is that of reduced FMD of the brachial artery 
in physically-inactive men treated with ADT for prostate cancer in comparison 
with a group of controls matched for age, activity levels and comorbidity. 
These findings suggest that the function of the vascular endothelium is 
impaired in men treated with ADT for prostate cancer (Deanfield et al., 2007). 
As endothelial function is linked to vascular health, the findings provide 
evidence in support of epidemiological data showing increased 
cardiovascular risk in men with prostate cancer treated in this manner 
(Keating et al., 2010; Levine et al., 2010; Bourke et al., 2012).
ADT has been associated with the development of cardiovascular risk factors 
(Smith et al., 2001; Mohamedali et al., 2011) and an increased incidence of 
adverse cardiovascular events and mortality (D'Amico etal., 2007; Keating et 
al., 2010): as such it is intuitive for ADT to also be associated with endothelial 
dysfunction. Disruption of normal endothelial function is an important event in 
the development of atherosclerosis (Celermajer, 1997). In the presence of 
cardiovascular risk factors, evidence of endothelial dysfunction can be 
detected before any angiographic evidence of disease or increased intima- 
media ratio (Werns et al., 1989). The effect of cardiovascular risk factors on 
the endothelium can lead to increased expression of the vasoconstrictor 
endothelin-1 and reduced expression of endothelial NO synthase, increasing 
vascular inflammation. Under these conditions increased expression of 
adhesion molecules (e.g. vascular cell adhesion molecule-1) on the surface 
of the endothelia increases binding of leukocytes found in early atheroma 
formation (monocytes and T-lymphocytes). Once adherent to the 
endothelium, leukocytes penetrate into the intima where they perpetuate a 
local inflammatory response which can result in macrophages displaying 
scavenging receptors for lipoproteins and ingesting lipids. This process leads 
to the development of foam cells and the earliest signs of fatty streak 
formation on the arterial wall (Grover-Paez and Zavalza-Gomez, 2009).
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The decreased expression of endothelial NO synthase is a key event in this 
process of atheroma formation as this results in reduced production of NO. In 
addition to being a potent vasodilator, NO also exerts a number of other 
vasoprotective and anti-atherosclerotic properties (Naseem, 2005). In a 
review of the role of NO in cardiovascular disease, Naseem (2005) describes 
how NO inhibits cell adhesion molecule expression, platelet-leukocyte 
interactions, LDL-C oxidation and vascular smooth muscle cell proliferation 
limiting atheroma development. These findings are of particular importance 
for the results of the current study due to the NO-dependence of FMD 
assessed using an occlusive cuff placed distal to the location of arterial 
imaging (Joannides et al., 1995). It is consistent with this evidence to assume 
that our findings suggest treatment of prostate cancer with ADT decreases 
NO availability and thus increases the risk of atheroma formation compared 
to a group of matched controls.
The finding of reduced endothelial function in this study is strengthened by 
the use of allometric-scaling in the calculation of FMD. Although FMD 
calculated as an absolute or relative measure has been shown to be related 
to endothelial function and cardiovascular risk (Yeboah et al., 2009; Inaba et 
al., 2010), the recent article by Atkinson et al. (2013) describes the 
importance of scaling FMD for baseline arterial diameter. FMD response has 
been shown to be greater in smaller diameter arteries (Celermajer et al., 
1992) and hence, allometric-scaling of the FMD response ensures that 
differences reported between groups can be attributed to variations in 
endothelial function instead of being the result of different magnitudes of 
response from different calibre arteries. In the current study the increased 
difference in FMD response between groups after allometric-scaling is 
therefore suggestive of endothelial dysfunction in men on ADT for prostate 
cancer. In addition, with the on-going development of this new technique for 
FMD analysis it can be noted that the exponent for allometric-scaling 
calculated for FMD results for our data (0.93) is similar to those previously 
reported for this technique (Atkinson et al., 2013; Atkinson and Batterham, 
2013).
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Although the mechanisms underlying a reduction in FMD in men treated with 
ADT for prostate cancer cannot be fully explained from this study, the 
reduction in serum testosterone with ADT could directly influence vascular 
function. Evidence from both animal and human studies suggests a direct 
vasodilatory effect of testosterone. In vivo studies in dogs and pigs have 
demonstrated dose-response increases in arterial dilatation with testosterone 
infusion (Chou et al., 1996; Molinari et al., 2002). This evidence is supported 
by the findings from studies in men with coronary artery disease where 
arterial infusion of testosterone has been shown to cause dilatation of the 
coronary artery and can reduce exercise-induced myocardial ischemia 
(Rosano et al., 1999; Webb et al., 1999). It has been reported that this direct 
vasodilatory action of testosterone is independent of the androgen receptor, 
aromatase and the vascular endothelium, but is associated with inactivation 
of L-type calcium channels and/or activation of potassium channels (Jones 
and Saad, 2009). In a review of the mechanisms behind the vasodilatory 
properties of testosterone, Jones et al. (2003) concluded that the majority of 
studies supported a calcium antagonistic action of testosterone leading to 
vasodilatation.
Testosterone withdrawal may also indirectly affect endothelial function 
through the development of cardiovascular risk factors. Negative changes in 
insulin sensitivity, blood lipid profile and body composition have all been 
shown in men treated with long-term ADT (Braga-Basaria et al., 2006b; 
Derweesh et al., 2007; van Londen et al., 2008) and these changes can be 
associated with the reduction in circulating testosterone (Jones & Saad, 
2009). In other populations the presence of such cardiovascular risk factors 
has been independently linked to endothelial dysfunction (Perrault et al., 
2000; Al Suwaidi et al., 2001; Kim et al., 2006), and as such, the evidence of 
increased fat mass and triglyceride concentrations in men on ADT in the 
current study could have an impact on the finding of endothelial dysfunction. 
Although there is evidence both supporting and contradicting an effect of 
triglycerides on endothelial function (Schnell et al., 1999; Capell et al., 2003) 
excess body fat has been strongly linked to increased endothelial dysfunction
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(Al Suwaidi et al., 2001; Perticone et al., 2001; Arkin et al., 2008). Increases 
in insulin concentrations, circulating fatty acids and vascular inflammation are 
all associated with excess adiposity and each of these outcomes has been 
linked to reductions in endothelial function (Barton et al., 2012; Campia et al., 
2012).
In addition, low testosterone concentrations have been associated with other 
changes that could affect vascular function. It must be noted however that 
whether or not these effects are a direct result of the reduction in 
testosterone or an outcome of the increase in cardiovascular risk factors with 
hypogonadism cannot be determined from these studies. Endothelial 
progenitor cells have been shown to be important for maintenance of 
vascular health (Shantsila et al., 2007) but are thought to be reduced in 
hypogonadal men (Foresta et al., 2006). Foresta et al. (2006) reported that 
endothelial progenitor cells were around 60% lower in a group of men with 
hypogonadotropic hypogonadism compared with a group of age-matched 
controls, however, after 6 months of treatment with testosterone replacement 
therapy endothelial progenitor cell concentrations increased in the 
hypogonadal men to exceed that found in the controls (nearly 70% greater). 
Similarly, testosterone concentrations have been inversely linked to levels of 
endothelin-1 which, as described above, is a potent vasoconstrictor that can 
increase vascular inflammation. Higher endothelin-1 concentrations have 
been reported in hypogonadal patients compared with age-matched, healthy 
controls (Kumanov et al., 2002; Kumanov et al., 2007), but this difference 
between groups was removed by 6 months of testosterone replacement 
therapy (Kumanov et al., 2007). Although it was beyond the scope of the 
current study to perform measurements of endothelial progenitor cells or 
endothelin-1, it would be of interest for future studies to further investigate if 
these biomarkers are altered in ADT patients and subsequently to examine 
whether or not endothelial function of men on ADT is influenced by their 
concentrations.
The findings of the current study are in agreement with evidence of 
endothelial dysfunction in other hypogonadal populations (Akishita et al.,
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2007; Yilmaz et al., 2011). Moreover, the magnitude of the FMD results in our 
study are comparable with those reported in these previous investigations. 
Yilmaz et al., (2011) reported slightly higher FMD values (median (range) 
FMD responses for the lowest and highest groups 5.2% (4.0 - 7.2) and 8.4% 
(7.2 - 9.7), respectively) than were found in the current study, however their 
groups were younger, had lower BMI and less history of cardiovascular 
disease. In comparison, the study by Akishita et al., (2007) reported FMD 
responses very similar to those found in our study (mean FMD in lowest and 
highest quartiles of testosterone approximately 3.4% and 5.7%, respectively).
Although as suggested above the results of the current study are in 
agreement with evidence of endothelial dysfunction in other hypogonadal 
groups, they are in contrast to the results published in the only other study 
investigating endothelial function in men treated with ADT (Herman et al., 
1997). Herman and colleagues reported superior endothelial function in 10 
men treated with ADT for prostate cancer compared with a group of 10 
healthy controls and a group of 10 men in remission from a non-prostatic 
malignancy (arterial dilatation of 6.2 ± 3%, 2.7 ± 2% and 2.0 ± 1.9% for each 
group, respectively). There are a number of potential reasons for these 
apparently conflicting findings.
Firstly, differences in the samples recruited might be an important factor. Men 
in the study by Herman and colleagues were all free from any history of 
cardiovascular disease. This contrasts with the current study in which at least 
50% of men in both groups had some form of pre-existing cardiovascular 
comorbidity, which could be considered more representative of the health of 
an elderly population in a developed country where >60% of men aged 60-79 
years have been reported to have a history of cardiovascular disease 
(American Heart Association, 2013). Our findings therefore suggest ADT has 
deleterious effects on endothelial function in men with pre-existing 
cardiovascular disease, and hence ADT could represent an independent risk 
factor in this high risk group. This is in agreement with the findings of 
increased risk of myocardial infarction or diabetes in men on ADT with 
cardiovascular comorbidities (Keating et al., 2012).
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Secondly, technical factors in the assessment of FMD may also be involved 
in the variation between the two studies. In the study by Herman and 
colleagues arterial diameter measured 50-60 seconds post-deflation was 
reported as peak diameter, yet more recently this duration has been shown 
to be insufficient to detect the full dilatory response in some people (Black et 
al., 2008). In an investigation of the time to peak arterial diameter following 5 
minutes of forearm ischaemia, 25% of elderly inactive participants achieved 
their full dilatory response within a time frame of 50-70 seconds following cuff 
release, and only 58% achieved maximal dilatation in the first 90 seconds. 
Consequently Herman and colleagues might have missed the true peak 
arterial diameter in participants in each of their three groups. It is of interest in 
this context that, in the current study, 85% of participants had a peak 
diameter response occurring outside the 50-60 second window. Furthermore, 
in the study by Herman et al. changes in arterial diameter were not scaled for 
differences in baseline arterial diameter in accordance with the suggestions 
of Atkinson et al. (2013). Thus, differences reported between groups in FMD 
could be mediated by differences in arterial size instead of endothelial 
function. Although data presented by Herman and colleagues suggests 
baseline diameter was similar between groups, this does not eradicate the 
influence of baseline diameter on estimates of endothelial function reported 
using the traditional approach to FMD (Senn et al., 1994).
Thirdly, duration of treatment with ADT may also be an important variation 
between studies. Men on ADT in the work of Herman et al. had been 
medically castrated for a mean of 18 ± 4 months (range 6-33 months), in 
comparison with mean treatment duration of 37 ± 35 months (range 6-133 
months) in our study. Although increases in body fat percentage and insulin 
resistance have been demonstrated within the first 3 months following 
initiation of ADT (Smith et al., 2006), hyperglycaemia has only been reported 
in patients treated with ADT for a minimum of 12 months (Basaria et al., 2006; 
Mohamedali et al., 2011) suggesting an on-going effect of prolonged 
androgen deprivation. Thus, it could be speculated that long-term 
hypogonadism may lead to the development of endothelial dysfunction.
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Although there was no correlation between duration of ADT exposure and 
magnitude of FMD in the current study, this would warrant further 
investigation in a larger sample.
Analysis of correlations between variables demonstrates that the samples 
included in the current study are representative of the wider population. The 
positive correlation between duration of ADT and measures of body fat are in 
agreement with data presented by Haseen et al. (2010) who reported that 
duration of ADT was an independent predictor of increasing fat mass. 
Similarly, van Londen et al. (2008) reported increasing fat mass over a 2-year 
prospective study in groups of patients on acute ADT (treated for <6 months 
at study enrolment) and those on chronic ADT (treated for >6 months at 
study enrolment). Although rapid increases in body fat seen over the first 12 
months of treatment were not maintained, statistically significant increases in 
body fat mass and body fat percentage were still evident over the course of 
the study in patients established on ADT suggesting an on-going effect of 
treatment on fat mass accumulation.
In addition, correlation between serum testosterone and body fat mass in the 
control group agrees with previous evidence (Mudali and Dobs, 2004; 
Matsumoto, 2005; Dandona and Rosenberg, 2010; Mammi et al., 2012). 
Testosterone has been shown to impact adipose tissue accumulation by 
regulating lipolysis and adipogenesis (Mudali and Dobs, 2004) and hence 
increased body fat is an established side effect of low testosterone 
concentrations (Mammi et al., 2012) and is widely reported in male 
hypogonadism (Matsumoto, 2005; Dandona and Rosenberg, 2010). It is of 
interest that in our sample skeletal muscle mass did not show a positive 
correlation with serum testosterone concentrations in the control group as 
previous research has demonstrated the anabolic actions of testosterone 
(Bhasin et al., 2001) and there is evidence of a positive relationship between 
testosterone concentrations and muscle mass in elderly men (LeBlanc et al., 
2011). Although our finding may be a sampling issue, the strong inverse 
nature of this relationship was lost when skeletal muscle mass was assessed 
as a percentage of total body mass suggesting that this finding may also be
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explained, at least in part, by participants with higher levels of body fat 
developing increased skeletal muscle as a result.
Serum testosterone concentrations were also found to be negatively 
correlated to systolic blood pressure in men in the control group, which again 
is in agreement with previous data showing low testosterone concentrations 
are associated with hypertension (Khaw and Barrett-Connor, 1988; Svartberg 
et al., 2004). Khaw and Barrett-Connor (1988) described a decrease in both 
systolic and diastolic blood pressure for each quartile increase in 
testosterone in a sample of 1132 men aged 30-79 years. Moreover, Zitzmann 
and Nieschlag (2007) reported that treating hypogonadal men with long-term 
intramuscular testosterone injections resulted in statistically significant 
reductions in both systolic and diastolic blood pressure. It is noted however 
that these previous studies suggest this association between testosterone 
and blood pressure is at least partially mediated by the effects of 
testosterone on body composition. Adjustment of findings for BMI or body fat 
mass has been shown to weaken the association between testosterone and 
blood pressure (Khaw and Barrett-Connor, 1988; Svartberg et al., 2004; 
Zitzmann and Nieschlag, 2007). These findings are in agreement with our 
data where adjustment for body fat mass removed the statistical significance 
of the association between testosterone and systolic blood pressure.
It is of interest that our findings also demonstrate a trend for an inverse 
correlation between serum testosterone concentrations and baseline brachial 
arterial diameter, because to the best of our knowledge such an association 
has not been previously reported. It is postulated that the increase in blood 
pressure with reduced testosterone concentrations might mediate this effect 
on arterial diameter. Previous studies have provided data demonstrating that 
higher blood pressure is linked to increased internal artery diameter for the 
carotid and radial arteries, which is thought to be the result of arterial 
distension and remodelling under increased pressure (Khder et al., 1997; 
Boutouyrie et al., 1999). These findings would support our data showing a 
weakened correlation between testosterone and arterial diameter after 
controlling for systolic blood pressure. In addition, body size could also
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influence baseline arterial diameter. There is evidence of a positive 
association between arterial diameter and body size (Sandgren et al., 1999), 
and hence, it could have been expected that the negative correlation 
between testosterone and body fat mass could also influence the association 
between testosterone and arterial diameter in the current study as it would be 
expected that increased fat mass would be found in individuals with larger 
overall body size. However, including body fat mass as a control variable in 
the association between testosterone and arterial diameter in the current 
study only served to strengthen the association.
Although the current study examines the differences between a drastically 
hypogonadal population and a control group, the results cannot be 
generalised to a comparison of hypogonadal against eugonadal individuals 
because of the presence of men with biochemical hypogonadism in the 
control group. Three men in the control group (15% of the group) were found 
to have serum testosterone concentrations below the lower limit of normal 
measures suggested by the Endocrine Society (total testosterone 300 ng-dl'1 
or 10.4 nmolT1; Bhasin et al., 2010). Although retrospective exclusion of 
these men would have allowed greater generalisation of results, their 
inclusion makes our control group more representative of the wider 
population of elderly men (Harman et al., 2001). Harman et al. (2001) 
reported the incidence of hypogonadism (defined as total testosterone <325 
ng-dl'1 or 11.3 nmolT1) among men aged 60-69 years was 19%, which 
compares very closely to our finding from a group with a mean age of 69 
years. It should be noted that reanalysis of data after the exclusion of these 
men increased the statistical significance of the difference between groups 
for absolute and relative FMD, but had little effect on FMD allometrically 
scaled for baseline diameter. Furthermore, removal of hypogonadal men 
from the control group increased the differences between groups for 
measures of body fat mass, visceral fat area and systolic blood pressure. 
These changes from the original analysis are all congruent with the expected 
effects of hypogonadism on these markers (Svartberg et al., 2004; Dandona 
and Rosenberg, 2010).
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The finding of increased use of anti-hypertensive medication, specifically 
ACE-inhibitors and beta-blockers, in men on ADT could be considered 
indicative of the increased endothelial dysfunction with ADT use. Such 
treatments have been shown to improve endothelial function (Rajagopalan 
and Harrison, 1996), and as such, the difference between groups for use of 
these medications could be expected to have resulted in no difference, or 
improved endothelial function in men on ADT. The fact that endothelial 
function was still found to be impaired in men on ADT could therefore be 
suggestive of good compliance with the pre-assessment instructions to, 
where possible, avoid medication use on the morning of the assessment, 
thus allowing the activity of the treatment to be minimised (Brown and 
Vaughan, 1998). Conversely, if participants did not truthfully report 
compliance with pre-assessment preparations and had taken their 
medication, the difference between groups could be expected to be greater 
than was observed in the current findings should the effects of treatment be 
removed from the observed results for vascular function.
In conclusion, NO-mediated endothelial function measured using FMD is 
reduced in men treated with ADT for prostate cancer in comparison with 
community-dwelling, physically-inactive men matched for age and history of 
cardiovascular disease. These data support previous research on endothelial 
function in other hypogonadal populations, but contradict the findings of the 
single previous investigation of endothelial function measured in this manner 
in men on ADT (Herman et al., 1997). These results show that the effect of 
ADT on endothelial function in men with prostate cancer is concordant with 
data on other markers of cardiovascular risk in this population. Measures of 
endothelial function with FMD therefore provide a quantitative means by 
which changes in cardiovascular health could be assessed in men on ADT 
for prostate cancer, and thus would be a suitable method to examine 
longitudinal changes in cardiovascular risk in such men.
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6.0 REVIEW OF LITERATURE: Study 2
6.1 Lifestyle interventions
In an editorial on the on-going needs of cancer survivors and the remit of the 
NCSI, Richards et al. (2011) describe the importance of strategies to improve 
patients' health and wellbeing after cancer treatment. The authors consider 
the physical and mental consequences of living beyond a cancer diagnosis 
and highlight the need for interventions to enhance health outcomes.
Lifestyle interventions encouraging patients to increase physical activity and 
undertake dietary modifications provide one possible method that could lead 
to such benefits. While convincing evidence has been presented showing 
wide-spread benefits of this form of intervention among disease-free 
individuals and individuals with other morbidities (Lichtenstein et al., 2006; 
Blair and Morris, 2009; O'Donovan et al., 2010), the role of nutrition and 
exercise in the aftercare of cancer survivors is still being defined (Davies et 
al., 2011). This is the case for men with prostate cancer being treated with 
ADT. Such lifestyle interventions have been shown to be feasible and can 
lead to benefits in overall well-being in this patient group (Segal et al., 2003; 
Galvao et al., 2010; Bourke et al., 2011), however, many of the physical 
effects of diet and exercise remain largely unstudied in this population. In 
consideration of the plethora of evidence describing the physical burden of 
treatment in this manner (reviewed in Study 1), further investigations into the 
benefits that can be accrued through diet and exercise in men on ADT are 
clearly warranted.
6.1.1 Physical activity
Caspersen et al. (1985) provide definitions of physical activity and exercise. It 
is important to define these terms as although they are often used 
interchangeably they refer to different concepts. Physical activity is defined
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as any bodily movement produced by skeletal muscles that results in energy 
expenditure. This differs from exercise which is defined as planned, 
structured, and repetitive bodily movement done to improve or maintain one 
or more components of physical fitness. As an addition, it must also be noted 
that exercise can also include isometric muscular activity (Winter and Fowler,
2009), although this is not included in this definition.
Increasing physical activity has been shown to result in benefits to both 
physical and mental well-being. Studies in healthy individuals and various 
patient groups have shown that exercise can help to prevent and manage a 
wide range of pathologies and can lower the risk of mortality from all causes 
(Warburton et al., 2006).
6.1.1.1 Physical activity and the risk of disease and mortality
An inverse, dose-response relationship has been reported between the 
volume of physical activity performed and the risk of mortality from all causes 
(Lee and Skerrett, 2001). This conclusion is in agreement with data 
presented by Myers et al. (2004) showing a reduction in mortality risk with 
increasing amounts of physical activity (HR = 0.38; 95% Cl, 0.19-0.73 for risk 
of all-cause mortality for individuals in highest quartile of physical activity 
compared to those in lowest quartile).
Similarly, volume of physical activity has also been associated with 
cardiovascular mortality risk; Hamer etal. (2012) reported that participation in 
three sessions per week of moderate to vigorous activity led to a reduction in 
cardiovascular mortality risk of nearly 40% (HR = 0.61; 95% Cl, 0.38-0.98). In 
addition, there is evidence of a reduction in the incidence of cardiovascular 
events with increasing physical activity. Studies have shown decreased 
incidence of myocardial infarction (Lakka et al., 1994), ischemic stroke 
(Sacco et al., 1998), coronary heart disease (Tanasescu et al., 2002) and 
diabetes (Manson et al., 1992) with greater volumes of physical activity.
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Moreover, physical fitness has also been associated with cardiovascular risk, 
with Lee et al. (1999b) showing that men who were lean and unfit had more 
than three times the risk of cardiovascular mortality of men who were lean 
but fit (HR = 3.16; 95% Cl, 1.12-8.92). In fact, Blair et al. (1996) reported that 
the increase in cardiovascular risk incurred by low fitness can exceed that of 
established cardiovascular disease risk factors. Men with a fitness score in 
the lowest 20% had a relative risk (RR) of 1.70 (95% Cl, 1.28-2.25) for 
cardiovascular disease, which is higher than the risk accrued by cigarette 
smoking (RR = 1.57; 95% Cl, 1.18-2.10), hypercholesterolaemia (RR = 1.65; 
95% Cl, 1.26-2.15), high systolic blood pressure (RR = 1.34; 95% Cl, 1.00- 
1.80), family history of mortality due to coronary heart disease (RR = 1.18; 95% 
Cl, 0.89-1.57) or BMI >27 kg-rrV2 (RR = 1.20; 95% Cl, 0.91-1.58).
6.1.1.2 Mechanisms for exercise decreasing cardiovascular disease risk
It has been established that regular exercise training can decrease 
cardiovascular risk because of its effects on traditional markers of 
cardiovascular health such as lipid profile, blood pressure, insulin sensitivity 
and body composition (Paffenbarger et al., 1983; Myers, 2003; Kokkinos and 
Myers, 2010). Exercise has been shown to have comparable benefits in 
treating hypercholesterolaemia, hypertension and diabetes to drug therapies 
often used for management of these conditions (Joyner and Green, 2009).
The benefit of increased physical activity on these traditional markers does 
not fully account for the reduction in cardiovascular risk shown with exercise 
training, suggesting that exercise might also exert independent effects to 
lower cardiovascular risk. Mora et al. (2007) described that the effects of 
exercise training on markers of cardiovascular risk (blood lipids, inflammatory 
and hemostatic biomarkers, BMI, blood pressure and diabetes) only 
accounted for 59% of the reduction in cardiovascular disease risk, suggesting 
that 41% of risk reduction is mediated through other changes.
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6.1.1.2.1 Exercise and body composition
Exercise has been comprehensively shown to promote positive changes in 
body composition. Increased lean body mass and decreased fat mass are 
both widely reported outcomes associated with increasing physical activity in 
previously sedentary individuals (Fentem, 1994; Pollock et al., 2000; 
Warburton etal., 2006).
Skeletal muscle hypertrophy is a commonly recognised effect of exercise 
training. Increased protein synthesis in response to an overload stimulus 
results in the growth of new muscle tissue (Schoenfeld, 2010). Stimulation of 
satellite cells located between the lamina and sarcolemma play a key role in 
this process providing a pool from which myonuclei and myogenic regulatory 
factors are drawn. The donation of additional nuclei from the satellite cells 
into the exercised muscle fibre allows increased protein synthesis and the 
subsequent formation of further myofibrils. Furthermore, the stimulation of 
gene expression leads to the binding of DNA responsible for the generation 
of muscular repair, regeneration and growth leading to further myogenesis 
(Cornelison and Wold, 1997). Although satellite cell number and myogenic 
capacity is reduced with normal aging potentially inhibiting this process of 
muscle development, exercise has been shown to prevent and reverse this 
satellite cell decline maintaining the myogenic capacity (Shefer et al., 2010). 
Increases in satellite cells have been reported for up to 48-72 hours after 
acute bouts of exercise performed at an intensity sufficient to induce muscle 
damage. Long-term increases in satellite cell numbers have been reported 
with chronic exercise training (Martin and Lewis, 2012).
Changes in the rate of lipid breakdown and utilization occurring during 
exercise promote increased fat oxidation for several hours after acute bouts 
of exercise or chronically following prolonged exercise training (Thompson et 
al., 2012). Concomitant decreases in antilipolytic activity and increases in 
lipid oxidation rates have been shown to occur in subcutaneous adipose 
tissue following participation in aerobic exercise (de Glisezinski et al., 2003). 
Catecholamines binding to (3-adrenergic receptors on the surface of the fat 
cell stimulate increases in lipolytic rate through activation of hormone
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sensitive lipase which initiates lipolysis within the fat cell. Moreover, the 
exercise-induced increase in mitochondrial density in the trained muscle 
allows greater capacity for fat oxidation at the level of the muscle preventing 
FFA being reesterified in tissues such as skeletal muscle or the liver 
(Horowitz, 2001).
Improvements in body composition have been shown in exercise studies 
across a wide-range of age groups. Although a reduction in muscle mass and 
an increase in adiposity are accepted outcomes of normal aging, elderly 
people can still achieve gains in lean body mass and loss of fat mass by 
increasing daily physical activity (Evans and Campbell, 1993). Raguso et al. 
(2006) demonstrated that men and women above the age of 65 years 
performing greater amounts of daily moderate or intense physical activity 
(defined as activity above 4-6 metabolic equivalents (METs)) benefited from 
greater fat-free soft tissue in comparison with their less active peers. 
Furthermore, the amount of physical activity an individual performed was 
positively correlated with muscle mass and negatively correlated with whole 
body and abdominal fat accumulation. These results are in agreement with 
the results of training studies showing body composition changes after 
exercise training regimes. Stewart et al. (2005) reported a 3.5% decrease in 
body fat mass and a 3.5% increase in lean mass after 6 months of training 
with a mixture of aerobic and resistance exercises in men and women aged 
55-75 years. Similarly, Campbell et al. (1994) reported that 12 weeks of 
resistance training resulted in a 1.8 kg decrease in fat mass and 1.4 kg 
increase in fat-free mass in previously sedentary men and women aged 56- 
80 years.
6.1.1.2.2 Exercise and blood pressure
Physical activity is recommended in both the prevention and treatment of 
hypertension by the World Health Organisation (World Health Organization, 
2003), the European Society of Hypertension (European Society of 
Hypertension, 2003), and the Joint National Committee on Prevention,
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Detection, Evaluation and Treatment of High Blood Pressure (Chobanian et 
al., 2003). Meta-analyses of the training-mediated changes in blood pressure 
have consistently reported hypotensive effects of exercise. Examining the 
results of 54 randomized controlled trials (RCT's) investigating the effects of 
aerobic exercise training on blood pressure (range of intervention duration 3 
weeks to 2 years), Whelton et al. (2002) reported decreased systolic blood 
pressure in 44 trials (mean reduction 4 mm Hg) and diastolic pressure in 42 
trials (mean reduction 3 mm Hg). These findings were in agreement with 
Halbert et al. (1997) who analysed 29 RCT's using exercise interventions of 4 
weeks or longer (range of intervention duration 6-52 weeks) including a total 
of 1533 normotensive and hypertensive participants. They found a mean 
reduction in systolic and diastolic pressure of 5 mm Hg and 3 mm Hg, 
respectively, after training in the 26 studies using aerobic exercises.
It should be noted that although both of these meta-analyses only reported 
beneficial changes from aerobic exercise more recent studies have 
demonstrated improvements in blood pressure with resistance training. In the 
meta-analysis by Cornelisson and Fagard, (2005) it was reported that 
moderate intensity resistance exercise resulted in reductions in blood 
pressure comparable to those achieved with aerobic training.
Structural adaptations and changes in vascular responsiveness to vasoactive 
substances occurring with increasing physical activity have been identified as 
possible mechanisms behind exercise induced improvements in blood 
pressure (Pescatello et al., 2004). Decreases in endothelin-1 have been 
reported after exercise training (Maeda et al., 2001) while there is speculation 
that sympathetic nervous system activity may also be reduced with exercise 
training leading to a decrease in norepinephrine concentrations (Mueller, 
2007), although clinical evidence of this effect is limited. Both substances act 
as potent vasoconstrictors, and thus, such exercise-induced decreases 
promote reductions in vascular resistance. Similarly, improvements in 
vasodilatory function occur as an outcome of increased NO expression 
promoting reductions in vascular tone and improvements in arterial 
compliance (Green et al., 2004). In addition, exercise training induces
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structural changes of the arterial system resulting in a reduction in vascular 
resistance. Evidence from training studies show structural adaptations 
occurring in response to repeated bouts of exercise (Dinenno et al., 2001; 
Tinken et al., 2008), while conversely, decreases in arterial diameter and 
functional capacity have been shown with physical inactivity (Thijssen et al., 
2010).
6.1.1.2.3 Exercise and metabolic changes
Acute bouts of exercise increase glucose uptake and metabolism in skeletal 
muscle. Activation of intramyocellular signalling events within the skeletal 
muscle cell lead to translocation of the glucose transporter GLUT-4 to the 
plasma membrane, mediating an insulin-independent increase in glucose 
uptake (Kennedy et al., 1999). Furthermore, exercise promotes an increase 
in insulin-mediated uptake of glucose into the skeletal muscle with this 
insulin-sensitizing action reported to last up to 48 hours after exercise 
completion (Hawley and Lessard, 2008). This response has been reported in 
both healthy humans and individuals with type 2 diabetes (Kennedy et al., 
1999). Increases in glucose uptake after an acute bout of activity have been 
shown with both aerobic and resistance exercise (Kraniou et al., 2005; Black 
et al., 2010). Activities combining aerobic and resistance exercises might 
have the greatest benefit on blood glucose uptake by maximising the ability 
of the muscle to take on glucose through both insulin-dependent and 
independent pathways (Colberg et al., 2010).
Exercise induced improvements in glucose tolerance and insulin action are 
mediated by several mechanisms. Increases in GLUT-4 mRNA and protein 
expression have been associated with improved glucose uptake and 
metabolism while adaptations in the expression and activity of proteins for 
insulin signal transduction, including insulin receptor substrate isoforms (IRS- 
1 and IRS-2) and phosphatidylinositol 3-kinase (PI3K), lead to an increased 
rate and efficiency in insulin-mediated glucose clearance (Zeirath, 2002; 
Hawley and Lessard, 2008). Enhanced PI3K activity has been considered
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especially important in achieving improvements in glucose transport with 
chronic exercise. PI3K activity is higher in fitter individuals and has been 
positively correlated with glucose disposal rate and aerobic capacity (Kirwan 
et al., 2000).
Exercise induced changes in FFA uptake and oxidation in the skeletal muscle 
can be important factors determining these changes in insulin sensitivity. In 
insulin resistant individuals FFA uptake by skeletal muscle cells will be 
increased yet FFA oxidation will be reduced leading to higher fat 
concentrations within the muscle cell which can inhibit activation of IRS-1 and 
PI3K, thus decreasing insulin-stimulated glucose transport (Yu et al., 2002).. 
Exercise training results in an increase in oxidation of FFA in the muscle cell 
which has been shown to lead to improvements in insulin action (Solomon et 
al., 2008).
Because body fat mass will influence plasma FFA concentrations and thus 
FFA uptake by the skeletal muscle, it was concluded in early studies 
investigating changes in insulin sensitivity with exercise that improvements in 
insulin action must be mediated by exercise-induced reductions in body fat 
mass (Segal et al., 1991). These findings have been contradicted by more 
recent studies that have shown that periods of prolonged training of 
moderate intensity can improve insulin sensitivity independently of changes 
in BMI, waist circumference or fasting lipids (Duncan et al., 2003) providing 
evidence that exercise training can directing influence substrate metabolism 
within the muscle cell.
Aerobic exercise has been the most widely studied form of activity for 
benefits to insulin action. Improvements in whole-body insulin sensitivity have 
been reported after only 1 week of aerobic training in obese adults with type 
2 diabetes (Winnick et al., 2008). Resistance training can also lead to 
benefits in insulin response (Dunstan et al., 2002). It has been shown that 
training with combined aerobic and resistance exercise can result in greater 
improvements in glucose disposal than would be found with either exercise 
form individually (Cuff et al., 2003).
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Tambalis et al. (2009) reviewed the benefits of training using different forms 
of exercise on cholesterol and triglyceride concentrations in 84 studies 
(duration range 8 weeks to 1 year). In the 28 studies using moderate intensity 
aerobic exercise (defined as activity <60% maximal oxygen consumption or 
<60% maximal heart rate) the most marked benefits were found in HDL-C 
(statistically significant increase in 21.4% of studies) while only 7% of studies 
showed improvements in LDL-C, total cholesterol and triglycerides. High- 
intensity aerobic exercise (defined as activity >60% maximal oxygen 
consumption or >60% maximal heart rate) was used in 37 of the studies 
reviewed and resulted in more consistent benefits to HDL-C (improved in 60% 
of studies) although the magnitude of change was similar to those found with 
moderate intensity exercise (HDL-C increase of 3-20%). Similarly, reductions 
in LDL-C, total cholesterol and triglycerides were reported more consistently 
in high intensity aerobic training studies (20%, 34% and 22% of studies, 
respectively) but the magnitude of improvement was again no different from 
that reported with moderate intensity aerobic exercise. Data was also 
presented for 23 studies using resistance exercise alone or in combination 
with aerobic training. The most notable effect of including resistance training 
was marked reductions in LDL-C, with 39% of trials reporting statistically 
significant improvements although the magnitude of change was similar 
between exercise forms (6-21% reduction in LDL-C with aerobic training 
alone, 5-23% reduction with resistance exercise alone). Reductions in total 
cholesterol and triglycerides were reported in 23% and 13% of studies 
including resistance exercise, respectively. Resistance exercise was less 
effective in increasing HDL-C than training with aerobic exercise as 
improvements were only reported in 17% of studies (range from 6-14% 
increase in HDL-C).
Although the joint position stand from the American College of Sports 
Medicine and the American Diabetes Association suggests that changes in 
lipid profiles are mainly affected by weight loss (Colberg et al., 2010), 
changes in plasma lipase activity with training can also result in 
improvements in blood lipid profile. Increases in lipase activity with training
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can influence cholesterol concentrations without any changes in total body 
mass or fat mass (Duncan et al., 2003).
6.1.1.2.4 Exercise and the vascular endothelium
The ability of exercise to influence changes in the vascular endothelium 
provides a potential target whereby cardiovascular risk could be reduced, 
with or without concomitant alterations of traditional cardiovascular risk 
factors (Di Francescomarino et al., 2009). Although exercise-induced 
changes in traditional cardiovascular risk factors have a profound effect on 
endothelial function, it has been proposed that exercise also mediates 
functional improvements through independent mechanisms (Green et al., 
2003). Higashi and Yoshizumi (2004) suggested that in response to the 
stimulus of increased arterial shear stress brought about during bouts of 
exercise, NO bioavailability is increased by up-regulation of endothelial NO 
synthase gene expression and a reduction in oxidative stress. This leads to a 
decline in NO inactivation. This evidence is supported by Tuttle et al. (2001) 
who describe the functional and structural changes occurring in the arterial 
wall in response to increased shear stress. Using mesenteric arteries in rats, 
Tuttle et al. (2001) performed arterial ligation to manipulate the rate of 
perfusion to 50%, 200% or 400% of that found in control animals. After 2 
days lumen diameter decreased in arteries with 50% perfusion, but increased 
by 17% and 33% in arteries with 200% and 400% of normal perfusion rates, 
respectively. Increases in arterial shear stress experienced with higher 
perfusion rates were considered to be highly involved in this arterial 
remodelling with expression of endothelial NO synthase found to be 
positively correlated to the level of shear stress. The lack of further changes 
in lumen diameter found 7 days following the intervention led the authors to 
suggest that structural changes take place rapidly following initiation of 
periods of prolonged arterial shear stress, but diminish as shear rate 
decreases with lumen expansion.
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6.1.1.3 Physical activity after cancer diagnosis
Physical activity provides a non-pharmacological means of treating some of 
the physical and psychological challenges experienced by cancer survivors. 
In addition to reducing some of the negative side-effects associated with the 
disease and its treatments, there is also evidence of improvements in 
recurrence-free survival and disease-specific mortality in individuals taking 
part in greater volumes of physical activity (Schmitz et al., 2010; Sabiston 
and Brunet, 2012).
6.1.1.3.1 Cancer-related fatigue
Exercise has been shown to reduce cancer-related fatigue (McMillan and 
Newhouse, 2011; Cramp and Byron-Daniel, 2012). In the recent Cochrane 
review of exercise for the management of cancer-related fatigue, Cramp and 
Byron-Daniels (2012) reported on the findings of 56 studies including 4068 
participants, with the majority (28 studies) carried out in breast cancer 
patients. They describe how exercise can reduce fatigue, with greater 
benefits accrued through aerobic exercise training compared to resistance 
exercise or low-intensity mind-body exercise (e.g. yoga, qigong). It has been 
suggested that exercise induced improvements in fitness and muscular 
development can directly reduce fatigue, while in addition, the benefits of 
exercise on symptom clusters such as depression and anxiety can also have 
beneficial effects (McMillan and Newhouse, 2011).
6.1.1.3.2 Body size and body composition
Physical activity can help to manage the changes in body size and body 
composition that can occur with treatments for numerous cancers. Increasing 
body mass as a result of body fat accumulation is a widely reported outcome 
of certain cancer treatments such as ADT for prostate cancer (2.8.7.1 Body 
composition) and adjuvant chemotherapy for breast cancer (Sheean et al., 
2012), and can promote the development of further comorbidities in addition
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to increasing the risk of development of secondary cancers. While structured 
physical activity can help decrease or prevent the gain in fat mass it can also 
reduce the loss of lean muscle mass that is also associated with these forms 
of treatment (McDonald et al., 2011).
In contrast, patients with cancers of the head and neck, oesophagus and 
stomach can often be underweight or lose weight as a result of their 
treatment and again increasing physical activity can be beneficial. Activity 
regimes improving aerobic fitness and muscular strength can promote 
maintenance of a healthy body composition.
6.1.1.3.3 Immune function
There is early evidence that immune function could be improved in cancer 
survivors who take part in physical activity. Increases in natural killer cell 
activity were shown in post-menopausal breast cancer survivors randomised 
to receive 15 weeks of supervised exercise training (n = 25) compared to 
those in a non-exercise control group (n = 28, Fairey et al., 2005). Similarly, 2 
weeks of cycling exercise following curative resection of a stomach cancer 
resulted in higher natural killer cell activity than was found over the same 
duration in controls (Na et al., 2000).
These findings are contradicted by Nieman et al. (1995) who reported no 
difference in natural killer cell activity in breast cancer survivors after an 8 
week exercise training programme. However, only 12 of the 16 patients 
enrolled in this study were available for follow-up assessment and differences 
in age, BMI and natural killer cell activity were reported between groups at 
baseline.
6.1.1.3.4 Disease recurrence and mortality
Physical activity after a diagnosis of breast or colon-rectal cancer can 
decrease the risk of disease recurrence, cancer-specific or all-cause mortality.
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Studies have shown benefits can be accrued in a dose-response fashion with 
individuals participating in greater volumes and intensities of activity having 
the greatest reduction in risk. Furthermore, there is some evidence that 
disease progression in prostate cancer survivors can be influenced by the 
volume of vigorous activity after diagnosis and the patients history of physical 
activity.
The benefits of physical activity after a cancer diagnosis have been most 
extensively examined in women with breast cancer, with improvements in 
disease-specific and all-cause mortality reported in several studies (Holmes 
et al., 2005; Holick et al., 2008; Irwin et al., 2008; Sternfeld et al., 2009) 
although others have reported no effect (Enger and Bernstein, 2004). In one 
of the largest studies of physical activity and survival after breast cancer 
diagnosis, Holick et al. (2008) reported that compared to women expending 
<2.8 M E Tshw k'1 in physical activity, women engaging in 2.8-7.9 M ETshw k' 
1 had a HR for dying from breast cancer of 0.65 (95% Cl, 0.39-1.08) while 
women expending 8.0-20.9 METs h wk'1 had a HR of 0.59 (95% Cl, 0.35- 
1.01) and women expending >21.0 METs h wk'1 had a HR of 0.51 (95% Cl, 
0.29-0.89). Moreover, Irwin et al. (2008) described how changing physical 
activity habits at diagnosis could influence mortality risk. They found that 
women who decreased activity at diagnosis had an almost four-fold increase 
in risk compared to women who were inactive before and after diagnosis (HR 
= 3.95; 95% Cl, 1.45-10.50). Conversely, women who increased activity 
almost halved the risk of mortality compared to the continually inactive group 
(HR = 0.55; 95% Cl, 0.22-1.38).
Similarly, physical activity has been shown to reduce the risk of disease 
recurrence and total and disease-specific mortality in patients with colorectal 
cancer (Meyerhardt et al., 2006a; Meyerhardt et al., 2006b; Wolin et al.,
2010). Meyerhardt et al. (2006a) reported that patients completing >18 
METs h wk'1 of physical activity had a 61% reduction in risk of disease- 
specific mortality (HR = 0.39; 95% Cl, 0.18-0.82) and a 57% decrease in risk 
of all-cause mortality (HR = 0.43; 95% Cl, 0.25-0.74) compared to patients 
participating in <3 METs h wk'1. They also showed the importance of
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increasing physical activity upon cancer diagnosis with those who made the 
greatest increase in activity having the greatest reduction in mortality risk.
The evidence of benefits of physical activity after a prostate cancer diagnosis 
are limited to the findings of Richman et al. (2011) which reported that the 
risk of disease progression was inversely associated with walking pace. In a 
prospective study of physical activity after diagnosis in 1,455 men with 
localised prostate cancer, men who walked >3 hours per week at a brisk 
pace (>3 mph) had their risk of disease progression reduced by 57% in 
comparison with men walking <3 hours per week at a less than brisk pace 
(<2 mph) independent of age, BMI and PSA at diagnosis (HR = 0.43; 95% Cl, 
0.21-0.91). No association was found between total walking duration or 
volume of non-vigorous activity and disease progression.
Furthermore, an individual's history of physical activity has been reported to 
influence prostate cancer mortality, although evidence supporting this 
association remains sparse. Reporting on data from 2,705 men in the Health 
Professional Follow-Up Study diagnosed with non-metastatic prostate cancer, 
Kenfield et al. (2011) showed that total physical activity was inversely 
associated with all-cause mortality in a dose-response fashion. Compared to 
men engaging in <3 METs h wk'1 of activity, they found HR of 0.8 (95% Cl, 
0.61-1.06) for 3 - <9 METs h wk'1, 0.69 (95% Cl, 0.53-0.90) for 9 - <24 
METs h wk'1, 0.65 (95% Cl, 0.49-0.86) for 24 - <48 METs h wk'1 and 0.38 (95% 
Cl, 0.27-0.53) for >48 METs h wk'1. Furthermore, Kenfield (2011)
reported that prostate cancer specific mortality was associated with total 
physical activity. Durations of both non-vigorous and vigorous intensity 
activity were inversely linked to all-cause mortality, but only the amount of 
vigorous activity showed a statistically significant association with prostate 
cancer mortality (HR = 0.39; 95% Cl, 0.18-0.84 for >3 h w k '1 of vigorous 
activity compared to <1 h wk'1).
The findings of Kenfield et al. (2011) are supported by evidence from other 
studies which also reported a positive association between history of activity 
and prostate cancer progression or mortality (Giovannucci et al., 2005; 
Giovannucci et al., 2007), however, these authors were also drawing data
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from men in the Health Professional Follow-Up Study and hence, these 
findings add little to the data presented by Kenfield and colleagues. Studies 
in other samples have reported no effect of physical activity on prostate 
cancer mortality (Crespo et al., 2008).
6.1.1.4 Exercise studies in men on ADT
The evidence reviewed above shows the benefits that can be accrued 
through participation in regular physical activity. These data describe how 
increased physical activity can promote physical and mental benefits in 
disease-free populations and those with cardiovascular morbidities, in 
addition to leading to symptomatic benefits in cancer survivors. Furthermore, 
regular exercise has been shown to have an inverse, dose-response 
relationship to the risk of cardiovascular events or mortality for cancer-free 
individuals, while in cancer survivors, there is early evidence for benefits to 
disease recurrence or disease-specific mortality.
Considering the evidence reviewed above in the context of exercise training 
for men with prostate cancer on ADT has led to authors hypothesizing that in 
addition to providing the symptomatic relief for cancer survivors, exercise 
might also be able to reduce the burden of cardiovascular risk associated 
with treatment (Galvao et al., 2009). This hypothesis currently remains 
largely unstudied however, with exercise studies completed in this population 
to-date (shown in Table 6.1) not using cardiovascular outcomes as primary 
end-points. Accordingly, this remains an area where further research is 
warranted.
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6.1.1.4.1 Effects o f exercise on fatigue and quality o f life in men on ADT
Reductions in fatigue have been reported after interventions using resistance 
training alone (Segal et al., 2003), or in combination with aerobic training 
(Galvao et al., 2010; Bourke et al., 2011). In a randomized-controlled trial in 
which 155 men were assigned to receive 12 weeks of resistance exercise 
training three times per week (n = 82), or 12 weeks of usual care (n = 73), 
Segal et al. (2003) reported statistically significant improvements in fatigue in 
the exercise group. Similarly, Bourke et al. (2011) also reported 
improvements in fatigue over a 12 week intervention, with the magnitude of 
change exceeding that shown by Segal et al. (2003); studies can be 
compared due to use of the same measurement tool for fatigue. Using an 
exercise intervention including a mixture of aerobic and resistance exercises, 
in addition to providing dietary advice, Bourke et al. (2011) reported 
improvements in fatigue for the exercise group in comparison to little change 
for the men in the control group, with the difference between groups at the 
end of the intervention exceeding that required to be considered of clinical 
importance (Celia eta!., 2002).
Both Segal etal. (2003) and Bourke et al. (2011) also reported improvements 
in health related quality of life. Segal and colleagues reported a statistically 
significant difference between groups for quality of life measures with 
improvements in quality of life seen in men in the intervention group, while in 
the controls quality of life decreased. This pattern of change was similar to 
that shown by Bourke et al. (2011), who found small improvements in quality 
of life in the intervention group compared to a marked reduction in the 
controls, although in this study the difference between groups after the 
intervention was not found to be statistically significant.
It is worth noting that the study by Bourke et al. (2011) included a follow-up 
assessment 3 months after completion of the exercise intervention. Data for 
this assessment demonstrates that perceptions of both quality of life and 
fatigue got worse after cessation of the supervision, with follow-up values 
similar to those observed at baseline. Although the continued increase in 
perceptions of fatigue in the control group meant that the statistical
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significance for the difference between groups was still observed, the mean 
difference in change between groups was markedly reduced.
6.1.1.4.2 Effects o f exercise on physical performance and functional capacity 
in men on ADT
Measures of physical performance and functional capacity have consistently 
been shown to improve in men on ADT taking part in exercise training. 
Although comparison between studies is difficult because of the different 
measurement techniques employed to assess performance, improvements in 
walking test duration were shown in studies using predominantly gym based 
exercise (Galvao et al., 2006; Galvao et al., 2010; Bourke et al., 2011) and 
those using mainly home-based exercise (Culos-Reed et al., 2007). 
Moreover, there is evidence of improvements in muscular strength and 
muscular endurance in studies using resistance exercise alone (Segal et al., 
2003; Galvao et al., 2006), or in combination with aerobic exercise training 
(Galvao et al., 2010).
6.1.1.4.3 Effects o f exercise on body composition in men on ADT
Positive changes in body composition (reduction in body fat mass and 
increased skeletal muscle mass) are a widely acknowledged effect of 
increasing exercise in healthy humans, however, there is little evidence of 
such changes in exercise studies with men on ADT. Segmental body 
composition analysis and girth measurements have identified small increases 
in upper and lower limb lean mass with exercise training using combined 
aerobic and resistance exercise (Galvao et al., 2010) or resistance exercise 
alone (Galvao et al., 2006), although no positive changes in body mass or 
BMI were reported. Benefits to both body mass and BMI were reported in the 
work of Nobes et al. (2012), however this study combined exercise training 
with Metformin and thus the benefits of increased activity cannot be 
distinguished from those resulting from Metformin therapy.
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This evidence suggests that the negative effects of ADT on body composition 
cannot be easily overcome by increasing physical activity, however, regular 
exercise might reduce the increase in fat mass and reduction in muscle mass 
patients would have otherwise experienced. This is evident in the data 
presented by Culos-Reed et al. (2010), in which statistically significant 
changes in neck and waist girth were reported after 16 weeks of home and 
gym based exercises despite minimal improvement in these measures in the 
exercising group (intervention group change in neck girth = -0.36 ± 1.81 cm, 
change in waist girth = -0.53 ± 4.68 cm). Continued weight gain in the control 
group over the duration of the study was the primary factor accounting for the 
greater difference between groups at follow-up assessment (control group 
change in neck girth = 0.71 ± 1.77 cm, change in waist girth = 2.06 ± 4.84 
cm).
6.1.1.4.4 Exercise and cardiovascular health in men on ADT
In addition to the data reviewed above there is little further evidence for a 
beneficial effect of exercise on cardiovascular health or markers of 
cardiovascular disease from exercise studies in men on ADT. The effects of 
exercise on blood pressure in this population have been under-reported, with 
only 2 study reporting pre and post intervention values (Culos-Reed et al., 
2010; Nobes et al., 2012). Culos-Reed et al. (2010) did find a reduction in 
blood pressure in men taking part in the intervention, however this was of 
similar magnitude to the reduction in blood pressure observed in the control 
group, and hence no statistically significant difference between groups was 
found. Conversely, Nobes et al. (2012) found differences between groups 
from systolic blood pressure, but because participants were given Metformin 
with exercise the benefits of activity cannot be deduced.
Investigations of the effects of exercise on biomarkers for cardiovascular 
disease have shown little further benefit. No changes in insulin, glucose, 
HDL-C, LDL-C or triglycerides have been reported in exercise studies in men 
on ADT (Galvao et al., 2010; Bourke et al., 2011). It is noted however that the
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finding of a statistically significant change in C-reactive protein (CRP) over 
the 12 week intervention of Galvao et al. (2010) provides encouraging 
evidence of improvements in cardiovascular health with exercise in this 
population. For men in the exercise group CRP decreased from 2.7 mg I'1 at 
baseline to 1.8 mg I'1 after 12 weeks, while the control group showed an 
increase from 2.3 mg-1-1 to 4.5 mg I"1. As a marker of systemic inflammation, 
CRP concentrations have been regarded as a novel marker of cardiovascular 
health (Ridker, 2007), and as such, this finding is encouraging evidence of a 
beneficial effect of exercise training on cardiovascular health in men treated 
with ADT.
6.1.1.4.5 Summary o f exercise studies in men on ADT
The evidence reviewed above describes how exercise studies in men on 
ADT have found improvements in physical performance and patient well­
being, but little meaningful change in primary markers of cardiovascular risk. 
To-date cardiovascular health outcomes have not been primary outcome 
measures of any studies in this patient group however, and limited attention 
has been paid to the lack of change found in these measures. Currently, only 
one study has stated that participants were sedentary at baseline (Bourke et 
al., 2011) meaning that the possible changes in cardiovascular health 
outcomes in other studies could have been diluted by the effects of the 
participants exercise history. Furthermore, although current evidence has not 
shown changes in traditional markers of cardiovascular risk, the effects of 
exercise training on novel markers, such as endothelial function, remain 
unstudied.
6.1.1.5 Exercise monitoring and prescription
For studies investigating the effects of physical activity, or those encouraging 
participants to increase their activity, being able to effectively monitor current
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activity levels and prescribe safe and effective training regimes is very 
important.
6.1.1.5.1 Exercise monitoring
Assessment of the volume of activity individuals are participating in outside of 
a structured, supervised environment (e.g. home-based exercise) can 
provide a challenge for studies of current activity habits. Although there are a 
number of methods of measuring physical activity and energy expenditure, 
many of these can be limited by the need for technical or expensive 
equipment (Vanhees et al., 2005). Vanhees et al. (2005) suggest that 
methods for assessment of physical activity can be grouped into three 
categories; criterion methods, objective methods and subjective methods. 
Criterion methods include doubly labelled water, indirect calorimetry and 
direct observations. These are considered the most accurate methods of 
activity measurement; however, they are limited by being inpractical, 
expensive and are demanding of the participant. Objective methods for 
physical activity assessment include activity monitors (e.g. pedometers, 
accelereometers) or heart rate monitoring. The data collected from such 
assessments can permit subsequent calculation of daily activity and energy 
expenditure with the measurements having the benefit of not being unduely 
obstrusive to the participant. Limitations of these methods can include the 
wide variation in heart rate due to confounding factors and the fact that basic 
accelerometers will not be able to distinguish between exercise intensities. 
Subjective techniques use physical activity activity questionnaires for activity 
assessment. These methods are quick and inexpensive to use, and tend to 
be the most popular method in large-scale studies (LaPorte et al., 1985), 
however they can be limited by the participants interpretations of the 
questions and their perceptions of their activity.
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6.1.1.5.2 Exercise prescription
In all exercise training studies the volume of activity participants undertake 
should be tailored to the individual, with consideration given to the aim of the 
training, the health status and phsyical abilities of the participant and the 
available equipment or facilities. The outcomes of such considerations can 
then be included in the use of the FITT principle for exercise training, which 
considers the frequency, intensity, time (or duration) and type (or mode) of 
exercise being prescribed. Guidelines have now been developed by different 
international bodies (e.g. American College of Sports Medicine (ACSM), 
British Association of Sports and Exercise Science, etc) to cater for 
manipulating these training principles to the needs of different populations 
(e.g. children, healthy adults, older adults, different diseased populations) 
(American College of Sports Medicine, 2013; British Association of Sport and 
Exercise Science, 2013; Exercise and Sports Science Australia, 2013), 
however the applications of such guidelines will still be dependent upon the 
individual needs and abilities of the participant.
The type, or mode, of exercise being prescribed will be dependent upon the 
aims of the training, the abilities of individual and the equipment available. 
For elderly populations, aerobic activities that do not impose undue 
orthopaedic stress are recommended in addition to resistance activities using 
weight training or weight bearing activities that will strengthen the major 
muscle groups (American College of Sports Medicine, 2009).
The American College of Sports Medicine (2009) suggest that the frequency 
and time (or duration) of aerobic activities prescribed will both be dependent 
upon the intensity of the activity, with lower frequency and duration 
recommended with higher intensity activity. When moderate intensity activity 
(defined as 3-6 METs) is being performed a minimum of 5 sessions per week 
are recommended, with activity performed for 30-60 minutes per day in bouts 
of at least 10 minutes to accumlate 150-300 minutes per week. For vigorous 
activity (>6 METs), a minimum of 3 sessions per week are suggested with 
exercise performed for 20-30 minutes per day to accumulate 75-100 minutes
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per week. In addition, the same ACSM guidelines recommend resistance 
exercise should be performed on at least 2 days per week.
The American College of Sports Medicine (2009) define the intensity of 
activity prescribed for older adults on a 0-10 scale for rating of perceived 
exertion (RPE), stating that moderate activity would be considered an RPE of 
5-6 while vigorous activity would be an RPE of 7-8. It must be noted however 
that RPE is only one of a number of metrics of intensity, with alternatives 
including percentages of maximal heart rate or heart rate reserve, 
percentages of maximal oxygen consumption or metabolic equivalent 
workloads (METs). Selection of the correct intensity metric is important as not 
all of these measures are suitable for all patient groups. In the case of a 
population of elderly men with established cardiovascular risk factors, such 
as men on ADT, limitations exist in some of these measures. Use of maximal 
testing is limited by the high physiological strain placed upon the participant 
increasing the risk of adverse events, and hence, measurement of maximal 
outcomes is unsuitable in such a population outside of a clinical setting 
(Gibbons et al., 1997). Furthermore, the use of predicted maximal heart rates 
or heart rate zones can be limited by the widespread use of medications that 
will influence heart rate (e.g. Beta-blockers) (Herman et al., 2009). Moreover, 
use of of METs to prescibe or predict exercise intensity has been shown to 
be limited by the assumption that resting metabolic rate will be the same for 
all individuals at a rate of oxygen consumption of 3.5 m lkg '1 min'1. This figure, 
derived from the measurement of 1 man aged 40 years and weighing 70 kg, 
has been shown to not apply to all individuals (Byrne et al., 2005), and thus 
predicting exercise intensity based upon this assumption is flawed. RPE can 
therefore provide a suitable measure for monitoring exercise intensity in this 
population which can avoid such physiological limitations and can be used 
during home-based activity when other methods for monitoring intensity 
maybe unavailable (Herman et al., 2006).
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6.1.2 Diet
As an adjunct to increasing physical activity, men on ADT should be 
encouraged to make modifications to their diet to achieve greater health 
benefits. While there is suggestion that diet might influence prostate cancer 
progression there is stronger evidence supporting the role for dietary 
manipulation in promoting improvements in cardiovascular health.
6.1.2.1 Diet and prostate cancer
Just as diet is thought to have a role in the development of prostate cancer 
(reviewed in 2.3.1 Prostate cancer risk factors), there is evidence that 
nutrients consumed post-diagnosis can affect the rate of disease progression. 
Lycopene has been possibly the most widely researched nutrient for its 
effects on prostate cancer. An antioxidant found most abundantly in tomatoes, 
lycopene consumption has been shown to be inversely related to disease 
progression with studies reporting lower PSA, reduced prostatic DNA 
damage and improved surgical outcomes in men consuming higher 
quantities of lycopene after diagnosis (Chen et al., 2001; Kucuk et al., 2002; 
Chan et al., 2006). Evidence of similar effects with other nutrients is still 
sparse however. Although there are reports of lower rates of progression with 
low fat diets or diets high in fish or soy (Hussain et al., 2003; Demark- 
Wahnefried et al., 2004; Chan et al., 2006) these studies have all been 
contradicted by others who describe no benefit from these diets (Lloyd et al., 
2010; Bosland etal., 2013).
Similarly, evidence of nutrients increasing the risk of disease progression is 
equally limited. Prospective studies investigating diet post-diagnosis have 
reported negative effects of milk eggs and poultry with skin (Chan et al., 2006; 
Richman et al., 2010), however these findings are as yet unconfirmed. It is 
clear that further research is warranted in this area.
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6.1.2.2 Diet and cardiovascular risk
Diet is an important modifiable risk factor for the development of 
cardiovascular disease. The nutrients contained within foods consumed can 
strongly influence glucose and cholesterol concentrations, blood pressure 
and obesity, and as such can be critical in the development of atherosclerotic 
lesions and the incidence of cardiovascular events.
Considering the important role of diet in the reduction of cardiovascular 
disease the latest American Heart Association guidelines on diet and lifestyle 
recommend a diet high in fruits and vegetables, whole-grains and high-fibre 
foods but with limited consumption of saturated fats and high sugar products 
(Table 6.2, Lichtenstein et al., 2006). These recommendations of a healthy, 
well balanced diet still cover the main dietary components required for the 
maintenance of general health and the reduction of cardiovascular disease, 
and as such are in agreement with the dietary guidelines of the British 
Dietetic Association (Mead et al., 2006).
Importantly, dietary guidelines recommend increased consumption of fruit 
and vegetables providing vital sources of antioxidants that are thought to be 
beneficial for reducing vascular inflammation. Acutely, consumption of foods 
high in antioxidants as part of a meal has been shown to prevent the 
negative effect dietary fats would have on the vascular endothelia (Esposito 
et al., 2003). Chronic consumption of a diet high in antioxidants is considered 
to have further benefits as has been shown by positive health outcome 
achieved using a Mediterranean-style diet high in antioxidants, 
polyunsaturated fatty-acids and fibre. Benefits including improvements in 
body composition, vascular inflammation, insulin resistance and endothelial 
function have all been shown in patients following a Mediterranean style diet 
(Esposito et al., 2010). Moreover, there is evidence of reduced risk of 
cardiovascular events and all-cause mortality in individuals maintaining a 
Mediterranean style diet (de Lorgeril et al., 1999; Trichopoulou et al., 2003). 
Although the exact mechanisms underlying these benefits remain 
incompletely understood it is thought the cumulative effect of improved body
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composition, reduced cholesterol consumption and increased antioxidants 
are all involved.
Table 6.2. American Heart Association dietary recommendations for cardiovascular 
disease risk reduction. Taken from Lichtenstein et al. (2006).
• Balance calorie intake and physical activity to achieve or maintain healthy 
body weight
• Consume a diet rich in vegetables and fruits
• Chose whole-grain, high-fibre foods
• Consume fish, especially oily fish, at least twice a week
• Limit your intake of saturated fat to <7% of energy, trans fat to <1% of 
energy, and cholesterol to <300 mg per day by
• choosing lean meats and vegetable alternatives
• selecting fat-free, 1% fat and low-fat dairy products
• minimizing intake of partially hydrogenated fats
• Minimize your intake of beverages and foods with added sugars
• Choose and prepare foods with little or no salt
• If you consume alcohol, do so with moderation
6.1.2.3 Dietary monitoring
Although it is widely accepted that dietary content is an important aspect of a 
healthy lifestyle (Lichtenstein et al., 2006), there is little consensus opinion on the 
most appropriate methods for monitoring an individual's current diet. Available 
methods include food records (diet diaries), 24 hour or multiple pass recalls, food 
frequency questionnaires and household food surveys. Inherent in these techniques 
are weaknesses however, as bias in recording good and bad foods, detail on portion 
size and detail on food composition can be limitations to all methods.
The most appropriate method for use in a study can be dependent on the participant 
group being researched and the desired information required from the analysis (e.g. 
level of accuracy needed, food consumption of an individual or a household, time 
period of interest). In the case of working with an elderly population living in the 
community such issues are of importance and must be considered to ensure the 
most appropriate measures are used. In such a situation, the recall methods and
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food frequency questionnaires are limited by the reliance on memory of foods 
previously consumed. Additionally, in an analysis of an individual participant's diet, 
the household food surveys are inappropriate due to not easily distinguishing the 
foods consumed by a specific individual in a household of multiple people 
(Thompson and Subar, 2013).
Accordingly, use of diet diaries can be considered one of the most appropriate 
methods for working with this population. Food diaries can provide detailed and 
relatively accurate data. Moreover, diet diaries can provide information on food 
consumption frequency which can be beneficial in intervention studies when 
assessment of eating habits is required (Thompson and Subar, 2013). This 
information can exceed that gained through food frequency questionnaires which 
can be limited by the number of foods listed and the lack of detail on the methods of 
food preparation or the timing of food consumption. Furthermore, dietary records 
can be more appropriate for monitoring diets over a longer period than can be 
achieved through recall. Previous studies have demonstrated that the results of food 
diaries are comparable to those achieved with other diet analysis techniques (Block, 
1982; Brunner et al., 2001).
6.2 Summary of data on lifestyle interventions
These data highlight the effects that physical activity and diet can have on 
cardiovascular health in the general population and on disease-specific end­
points in men with prostate cancer. Although the evidence supporting a 
positive effect of exercise and diet on the general well-being of men treated 
with ADT continues to grow, as yet the consequences of such changes in 
lifestyle on cardiovascular health remain largely unstudied. Hence, further 
research investigating the effects of structured exercise training and dietary 
improvements on markers of cardiovascular health in men treated with ADT 
is clearly warranted. With the treatment of cardiovascular comorbidities of 
ADT estimated to have cost the NHS between £700 million and £2 billion 
from 2004-2007 (Bourke et al., 2012), such lifestyle interventions could 
provide a cost-effective means of decreasing the financial burden that can 
only be expected to grow as the number of men living with prostate cancer 
continues to increase.
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6.3 Study 2. The effects of supervised exercise training and dietary 
advice on markers of cardiovascular risk in men treated with androgen 
deprivation therapy for prostate cancer
Study research question, aims and hypotheses
In consideration of the evidence reviewed above the following research 
question was developed, along with the study aims and hypotheses.
Research question
Does a lifestyle intervention, including supervised exercise training and 
dietary advice, have benefits on markers of cardiovascular risk in men with 
prostate cancer treated with ADT?
Study aims
To examine if 12 weeks of supervised exercise training and dietary advice 
can have a benefit on markers of cardiovascular risk in men with prostate 
cancer treated with ADT.
To examine if 12 weeks of supervised exercise training and dietary advice 
can improve physical fitness and general well-being in men with prostate 
cancer treated with ADT
To examine if any changes made over 12 weeks of supervised exercise 
training and dietary advice are maintained over a 12 week period after the 
supervision is completed.
Null hypotheses
There is no difference in markers of cardiovascular risk in men with prostate 
cancer treated with ADT after 12 weeks of supervised exercise training and 
dietary advice compared with 12 weeks of usual care
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There is no difference in physical fitness and general well-being in men with 
prostate cancer treated with ADT after 12 weeks of supervised exercise 
training and dietary advice compared with 12 weeks of usual care
Twelve weeks after removal of supervision there will be no difference in 
measures of cardiovascular risk, physical fitness or general well-being in 
comparison with those observed after 12 weeks of supervised exercise 
training
Experimental hypotheses
There is a difference in markers of cardiovascular risk in men with prostate 
cancer treated with ADT after 12 weeks of supervised exercise training and 
dietary advice compared with 12 weeks of usual care
There is difference in physical fitness and general well-being in men with 
prostate cancer treated with ADT after 12 weeks of supervised exercise 
training and dietary advice compared with 12 weeks of usual care
Twelve weeks after removal of supervision there will be differences in 
measures of cardiovascular risk, physical fitness or general well-being in 
comparison with those observed after 12 weeks of supervised exercise 
training
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7.0 METHODS: Study 2
7.1 Study design
This study used a mixed design with participants randomly allocated to 
receive either 12 weeks of exercise training and dietary advice, or 12 weeks 
of usual care. Repeat assessments were performed after 6 weeks (mid-point 
assessment) and 12 weeks of the intervention (end-point assessment) and at 
a follow-up 12 weeks after the end-point assessment (follow-up assessment). 
The patient pathway through the study is shown in Figure 7.1.
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Timeline
W eekO
Weeks 1 -6
W eek 7
W eeks 8-13
Week 14
Week 27
RANDOMISATION
Recruitment
1:1 exercise consultation
Researcher / Patient meeting 
Screening / consent / familiarisation
Supervised & home based 
exercise
Follow-up assessment
End-point assessment
Mid-point assessment
Usual Care
Baseline assessment
At university gym x 1 per week
Home based exercise x 2 per 
week
6 weeks exercise training
At university gym x 2 per week
Home based exercise x 1 per 
week
6 weeks exercise training Usual Care
Figure 7.1. Patient pathway through exercise intervention study.
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7.2 Ethics
Ethics approval was granted by the Yorkshire and Humber Research Ethics 
Committee for all procedures being carried out with men with prostate cancer 
recruited from within Sheffield Teaching Hospitals (appendix 2). To ensure 
compliance with regional policy the study was also registered with the 
Sheffield Teaching Hospitals Research and Development department. 
Procedures for this study all conformed with the Declaration of Helsinki.
7.3 Sample size calculation
Fifty men were recruited for this study and randomly allocated using the 
nQuery statistical software (nQuery Advisor 6.01, nQuery Statistical Solution, 
USA) into 2 groups of 25 men. Recruitment of this number of participants 
was calculated as being sufficient to detect an absolute difference in relative 
FMD between groups after training of 2.6 ± 3.0%, which is of similar 
magnitude to that previously reported in exercise studies in elderly patients at 
increased cardiovascular risk (Gokce et a/., 2002; Edwards et a/., 2004). This 
sample size estimate also took account of a drop-out rate of 10% which has 
been seen in gym-based exercise studies with men on ADT (Segal et al., 
2003; Galvao et al., 2006; Galvao et al., 2010; Bourke et al., 2011). Sample 
size was determined using the nQuery statistical software using 80% power 
at an alpha level of 0.05.
7.4 Participant recruitment
Men with prostate cancer being treated with ADT were identified from 
outpatient clinics at the Royal Hallamshire Hospital or Weston Park Hospital, 
Sheffield, UK. Online clinic letters and blood tests results were used for initial 
screening of patients for inclusion and exclusion criteria. In men considered 
suitable, further screening was subsequently performed using patient medical 
notes which were either seen when patients visited clinic or were requested 
for viewing through the medical records department. Patients still considered
136
eligible to participate were then approached in clinic or sent a letter inviting 
them to participate in the study (copy of letter in appendix 8). Men seen in 
clinic who showed interest in participating were provided with a participant 
information sheet and given a minimum of 5 days to consider whether they 
chose to take part prior to being contacted by a study researcher (copy of 
participant information sheet in appendix 9). Men contacted through the post 
were sent copies of the participant information sheet and asked to contact 
the research team if they were interested in participating. Data for the 
recruitment of men with prostate cancer is displayed in the consort diagram 
(Figure 7.2).
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Men on ADT identified from clinic lists 837
Patients suitable to request notes or see in clinic 454
Suitable to approach 323
Excluded (clinic letters / PSA records) 
Hormone refractory disease / rising PSA 
^  Less than 6 months of ADT 
Comorbidities
Participating in another study
Mobility problems
Painful metastases
Less than 12 months since EBRT
Active treatment for another cancer
ADT cessation
Non prostate cancer
Language barrier
Excluded (viewing patient notes) 
Comorbidities 
► Hormone refractory disease / rising PSA 
Mobility problems
Active treatment for another cancer 
ADT cessation 
Painful metastases 
Dead
Participating in another study 
Language barrier 
Not interested
Letter sent 183
No reply 69
Replied 114
Interested in participating 44
Not interested in participating 70
Approached in clinic
Interested in participating 
Not interested in participating
Insufficient time to participate 
No interest in project 
Regular exerciser
Full time work / caring commitments 
Comorbidities 
Travel constraints 
Treatment status
J
Interested in participating 95
y  Withdrew interest 39
I
Invited for familiarisation 56
Attended familiarisation 53
383
121
79
53
32
29
25
19
17
5
2
1
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53
23
21
9
8
5
4
3
3
2
86
51
35
8
7
6
5
4
3
2
Changed mind about participating 2 
Couldn't be contacted 1
Excluded at familiarisation 3 
Current health unsuitable 3
Consented to participate 50
Figure 7.2. Consort diagram for the recruitment of men with prostate cancer treated 
with ADT.
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After screening for inclusion and exclusion criteria only 38% of men identified 
on ADT were suitable to approach. The recruitment rate of all men 
approached (n = 269) was 18.6%. Although a greater number of men 
approached in clinic showed interest in taking part (60% of men approached 
requested further information compared to 24% of men sent letters), the 
percentage of men consenting to participate was the same for both 
techniques (18.6% of men approached by post or in person consented, n = 
34 and n = 16, respectively).
Men showing interest in participating in the study were invited into the 
university to meet a member of the research team to gain more details about 
the project, complete a medical questionnaire and provide informed consent 
(appendix 5 and 10, respectively). This initial visit also provided an 
opportunity to familiarise participants with the research facility and introduce 
them to all techniques to be used throughout the study.
7.5 Inclusion and exclusion criteria
Criteria for patients being included in the study:
• Histologically confirmed advanced prostate cancer, at least stage T3 
NO MO
• Been in receipt of ADT for a minimum of 6 months and due to receive 
for at least the next 6 months
• Current stable disease; defined as PSA <5 ng.ml'1 or three 
consecutive decreasing PSA readings
• Able to provide signed informed consent 
Criteria for patients being excluded from the study:
• Current participation in regular physical activity meeting the minimum 
guidelines for older adults described by the American College of 
Sports Medicine (2009), defined as moderate intensity activity for 30
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minutes at least 3 times per week, or vigorous activity for 20 minutes 
at least 3 times per week for the last 6 months
• Painful bony metastases
• Less than 12 months since completion of radiotherapy
• Having ever received chemotherapy
• Less than 2 months post-surgical treatment
• Unstable angina, uncontrolled hypertension, recent myocardial 
infarction or pacemaker
• History of sudden onset shortness of breath, blurred vision or fainting 
spells
• Any physical, neurological or psychiatric impairment or disease such 
as dementia, multiple sclerosis, severe arthritis or other condition that 
would limit the ability to understand and complete the study exercises, 
complete the required questionnaires or recall and record dietary 
information
7.6 Intervention
The intervention was designed to be the same as that used in previous 
research with men on ADT (Bourke et al., 2011). That study demonstrated 
the efficacy of this intervention with improvements in patient wellbeing and 
physical function detected over a 12 week period. Using this intervention in 
the current study therefore allowed investigation of whether changes in 
cardiovascular health were also present in an intervention proven to be well 
tolerated by this patient group. The aim of the intervention was to encourage 
participants to make healthy lifestyle changes, focussing primarily on 
increasing their physical activity and improving their diet.
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The exercise training element of the intervention involved participants being 
asked to take part in supervised gym-based exercise sessions, in addition to 
being encouraged to increase the amount of physical activity they performed 
at home. All gym sessions took place in the purpose-built exercise facility in 
the Centre for Sport and Exercise Science, Sheffield Hallam University, UK, 
where sessions were conducted in small groups of 1-4 men supervised by an 
exercise instructor. Gym sessions were tailored to each participant's ability 
and were designed to be progressive in nature with the volume and intensity 
of exercise gradually increased over the 12-week course as the patient 
became able to perform greater workloads in accordance with the guidelines 
for exercise prescription for cancer survivors published by the American 
College of Sports Medicine (Schmitz et al., 2010). Each session lasted 
approximately 1 hour and consisted of a mixture of aerobic, resistance and 
balance exercises. Sessions commenced with a 10 minute warm-up, 
including gentle treadmill walking and mobility exercises, prior to participants 
completing up to 30 minutes of aerobic exercises. Aerobic activities included 
treadmill walking, upright or recumbent cycling, rowing and arm-cranking. All 
activities were performed on Life Fitness equipment (Life Fitness UK, Ely, 
UK), with the exception of rowing (Concept 2 rowing ergometer, Concept 2, 
Nottingham, UK) and arm-cranking (Pro 2 Total Body Exerciser, SciFit, 
Binfield, UK). Exercise intensity was prescribed to elicit a heart rate of 55-85% 
of age-predicted maximum, and/or an RPE (6-20 scale Borg scale; Borg, 
1970) of 12-16. Age-predicted maximum heart rate was calculated using the 
equation:
Heart rate maximum = 220 - age
Participants subsequently completed up to 15 minutes of resistance and 
balance exercises. Resistance training focused on exercising all major 
muscle groups using body weight or thera-band for resistance. Participants 
completed 2 sets of 8-12 repetitions for each exercise. Sessions were 
concluded with a 5 minute cool-down including static-stretching to improve 
muscular flexibility. Participant heart rate (Polar F4, Polar Electro, Kempele, 
Finland) and RPE, were recorded every 5 minutes during aerobic activities.
141
Prior to commencing exercise training participants attended a 1:1 induction 
with the gym instructor for guidance on use of exercise equipment and to 
allow calculation of initial exercise training intensities. Participants were 
subsequently asked to perform 3 exercise sessions per week for the duration 
of the 12 week intervention. Through weeks 1-6 participants undertook 2 
supervised gym-based sessions per week in addition to performing 1 session 
per week at home, while for weeks 7-12 participants performed only 1 
supervised session in the gym each week, but increased the exercise at 
home to twice per week. Asking patients to maintain 3 sessions per week, 
while decreasing the time spent in instructor led sessions, was designed to 
encourage greater independence in their exercise habits. Participants were 
given advice on exercising at home including how to use RPE to monitor their 
exercise intensity. Participants were encouraged to perform at least 30 
minutes of exercise each week at an intensity between 11 ('Fairly light') and 
15 ('Hard') on the 6-20 Borg scale. A log sheet was provided to each 
participant for them to record home-based exercise (appendix 11).
In addition to engaging with exercise training, participants were encouraged 
to improve their diet over the course of the intervention. Participants were 
given advice on healthy eating when they attended exercise sessions with 
the main aims being; reduce dietary fat intake to -25%  of total calories, 
consume at least 5 portions of fruit and vegetables each day, increase fibre 
consumption, decrease intake of refined carbohydrates, and limit alcohol 
intake to moderate amounts (defined as 1-2 units per day by British Heart 
Foundation, 2013). Participants were helped to think of areas of their diet 
they would like to improve and encouraged to set themselves weekly goals 
towards achieving these targets. Participants completed 3-day diet diaries at 
baseline assessment which allowed additional feedback to be given which 
was tailored to their current diet (copy of diet diary provided in appendix 12).
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7.7 Outcome measures
Assessments were completed over two sessions held in the exercise 
physiology laboratories of the Centre for Sport and Exercise Science, 
Sheffield Hallam University. The first assessment session included body 
composition measures, vascular function assessments and blood samples, 
while at the second session participants completed questionnaires and 
performed physical function and exercise tolerance tests. Participants were 
asked to attend the first session in the fasted state having refrained from the 
consumption of food or beverages (except water) for at least 8 hours, and 
having avoided tobacco products for at least 12 hours. These sessions were 
undertaken in the morning in order to minimise the impact of fasting on 
participants' daily routine. The second assessment session was completed at 
any time of day most convenient for the participant. Where possible, 
participants were encouraged to attend assessments at the same time of day 
for each time point during the study to minimise circadian variations in 
outcome measures. Participants were asked to refrain from taking part in any 
strenuous physical activity for at least 12 hours prior to both assessment 
sessions. Where possible, participants were also asked to refrain from 
consumption of any vasoactive medications for the 12 hours prior to 
attending the vascular function assessment.
7.7.1 Assessments o f vascular function
Vascular function assessments were conducted in a similar manner as 
previously described in section 1 of this thesis (3.6.1 Assessment of vascular 
function), with the addition of proximal cuff FMD assessments after the distal 
cuff FMD test and prior to the GTN scan.
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7.7.1.1 Distal cuff FMD assessment
FMD using a distal cuff placement was performed using the same methods 
as described in section 1 (3.6.1.1 Endothelial-dependent dilatation). Use of a 
distal cuff placement provided a measure of NO-dependent arterial dilatation.
7.7.1.2 Proximal cuff FMD assessment
Endothelium-dependent dilatation was also assessed using proximal cuff 
placement. This method of FMD assessment has previously been used in 
other populations for the assessment of cardiovascular health (Shimbo et al., 
2007; Shechter et al., 2009), however, controversy still remains over the 
validity of this technique (Charakida et al., 2010). Comparison of traditional 
distal-cuff placement or proximal cuff placement techniques has not 
previously been performed in men treated with ADT for prostate cancer.
Placement of the occluding cuff proximal to the site of arterial imaging 
provides an alternative measure of endothelium-dependent dilatation not 
principally mediated by NO. Participants were given 15 minutes to rest quietly 
following completion of the distal cuff FMD assessment prior to commencing 
image acquisition for the proximal cuff test. Resting for this duration between 
scans was deemed sufficient for arterial tone to return to basal levels and 
equalled or exceeded the time given in other studies (Guazzi et al., 2004; 
Tinken et al., 2008). During this period between assessments the cuff was 
repositioned in the middle of the upper arm with ultrasound imaging 
subsequently performed distal to the site of cuff placement. Arterial occlusion 
was performed inflating the cuff to 50 mm Hg above systolic blood pressure 
with occlusion maintained for 5 minutes. Arterial dilatation was measured as 
the difference between arterial diameter during the minute of baseline 
imaging prior to cuff inflation and the peak arterial diameter achieved during 
the 3 minutes of imaging post cuff release.
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7.7.1.3 Endothelial-independent dilatation
Endothelial-independent assessments were performed in all patients in 
whom GTN administration was not contraindicated. Contraindications were 
defined in accordance with the guidelines of the British National Formulary 
(2006), and included: hypersensitivity to nitrates, hypotensive, hypovolaemia, 
mitral stenosis, marked anaemia, history of migraines, hypothyroidism, recent 
history of myocardial infarction, severe hepatic or renal impairment, or 
current use of specific medications for erectile dysfunction (Cialis, Viagra, 
Levitra), pulmonary hypertension (Adcirca), angina (Isosorbide mononitrate) 
or hypertension (Candersartan, Losartan, Valsartan, Irbesartan, Telmisartan, 
Eprosartan, Olmesartan, Enalapril, Lisinopril, Benazepril). Participants were 
given 15 minutes to rest quietly following completion of endothelial- 
dependent assessments to ensure recovery of baseline arterial diameter 
prior to commencing image acquisition. The method for GTN assessments 
were the same as previously described (3.6.1.2 Endothelial-independent 
dilatation).
7.7.1.4 Ultrasound analysis
Methods for data capture and analysis of ultrasound assessments were the 
same as previously described for section 1 in this thesis (3.6.1.3 Ultrasound 
analysis). Differences between studies were evident in blinding of 
assessments however. Baseline assessments were analysed as part of the 
cross-sectional analysis of endothelial function (study 1 in this thesis) with all 
analyses performed by the principal researcher after the video files had been 
re-coded by a researcher external to the research team to ensure blinding of 
participant identity. All subsequent scans were analysed in full by a 
researcher external to the research team who was blinded to participant 
group allocation.
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7.7.2 Anthropometry
Participant stature and body mass were measured using the same 
techniques as previously described in section 1 (3.6.2 Anthropometry). 
Similarly, body composition was also assessed using the same technique as 
previously described (Inbody 720) which has been shown to be an 
acceptable method for tracking changes in body composition over time 
(Volgyi et al., 2008; Miyatake et al., 2009).
7.7.3 Questionnaires
Disease-specific quality of life (Functional assessment of cancer therapy- 
prostate, Fact-P; Esper et al., 1995), fatigue (Functional assessment of 
cancer therapy- fatigue, Fact-F; Yellen et al., 1997) and leisure time physical 
activity (Godin LSI; Godin and Shephard, 1985) were all assessed through 
completion of questionnaires. Participants were given time to complete the 
questionnaires without interference from the study researcher. Responses 
were subsequently checked for completeness by the researcher in the 
presence of the participant.
Fact-P is a valid tool for assessment of quality of life in men undergoing 
therapy for prostate cancer (Esper et al., 1997). This tool uses a 39 item 
questionnaire with 27 questions on general wellbeing and 12 questions on 
additional concerns specific to prostate cancer and its treatment (appendix 
13). Scores can range from 0-156, with higher scores equating to a better 
quality of life. Fact-P has previously been used to assess changes in 
disease-specific quality of life over the course of exercise interventions in 
men treated with ADT (Segal et al., 2003; Bourke et al., 2011). A 6-point 
change in Fact-P has been considered the MCID (Celia et al., 2009).
Fatigue was assessed using the 13 item Fact-F questionnaire (appendix 14). 
Scores ranged from 0-52, with higher scores indicating less fatigue. Fact-F 
has been shown to have good test-retest reliability (r = 0.90) and internal 
consistency (alphas 0.93 and 0.95; Yellen et al., 1997). Celia et al. (2002)
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calculated the MCID for Fact-F as a change of 3 points. Fact-F was 
previously used to assess changes in fatigue over the duration of exercise 
interventions in men with prostate cancer treated with ADT (Segal et al., 
2003; Bourke et al., 2011).
The volume of physical activity participants completed in their leisure time 
was quantified using the Godin LSI. Participants were asked to report the 
number of times they performed more than 15 minutes of strenuous, 
moderate and mild exercise in an average week. The total leisure score 
index was subsequently calculated using the equation previously described 
(3.4 Participant recruitment).
The Godin LSI has previously been assessed for reliability and validity 
through analysis of repeated measures and comparisons against established 
physiological techniques. In studies using adult participants, reliability over 2 
weeks or 1 month varied across the different activity intensity levels of the 
Godin LSI. Correlation coefficients of 0.84-0.94 were reported for strenuous 
exercise, 0.36-0.46 for moderate exercise and 0.24-0.48 for mild exercise. 
Subsequently, total LSI showed a correlation coefficient of 0.62-0.74 (Godin 
and Shephard, 1985; Jacobs et al., 1993). Assessments of validity have 
shown similar variation, with the Godin LSI demonstrating concurrent validity 
coefficients of 0.32 with accelerometry, 0.56 with maximal oxygen 
consumption measured using expired gases, and -0.43 with percent body fat 
measured by hydrostatic weighing (Jacobs et al., 1993).
The use of Godin LSI in previous studies investigating physical activity in 
men treated with ADT demonstrates that this tool can be successfully applied 
to men in this population (Culos-Reed et al., 2007; Culos-Reed et al., 2010, 
Bourke et al., 2011). Moreover, use of this tool in the current study allows 
comparison of results between studies.
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7.7.4 Exercise tolerance and functional capacity
Exercise tolerance was assessed with a sub-maximal walking test performed 
on a treadmill (H/P/ Cosmos Pulsar Treadmill, Traunstein, Germany) using 
the BSU/Bruce protocol (Kaminskey and Whaley, 1998). This protocol was 
used in the study by Bourke et al. (2011) with no adverse events reported, 
and thus its use in the current study allowed comparison between studies. 
The BSU/Bruce protocol achieves identical intensities at 3 minute intervals as 
the traditional Bruce protocol but uses smaller and more frequent increments 
in speed and gradient making a smoother ramping of intensity. Participants 
were given time walking on a treadmill prior to undertaking the test to allow 
them to become comfortable with treadmill use. Additionally, prior to 
commencing testing a chest-strap heart rate monitor was fitted and 
participants were familiarised with the 6-20 Borg scale. During testing heart 
rate and RPE were recorded at the end of every minute of exercise with the 
test terminated when participants achieved an RPE of 15 (‘Hard’) or earlier if 
the participant requested to stop. All tests were supervised by exercise 
physiologists external to the research team ensuring participant performance 
was not influenced by researcher bias.
The 30-second sit-to-stand test was used for assessment of functional 
capacity. The test was conducted in accordance with the guidelines 
described by Rikli and Jones (1999). Participants commenced the test with 
their feet flat on the floor in front of the chair and arms across their chest. The 
same chair was used for all tests with the back positioned against the wall to 
minimise the risk of the chair falling during the assessment. Participants were 
encouraged to have three practice stands prior to commencing the test to 
ensure correct technique was used.
7.7.5 Dietary analysis
Participants completed 3-day diet diaries at baseline, end-point and at the 
follow-up assessment. Where possible, participants were asked to use the 
same three days of the week for each assessment. Nutritional intake was
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analysed using the NetWisp diet analysis software (version 3.0, Tinuviel 
Software, Anglesey, UK) with differences in energy intake and macronutrient 
content examined between time-points. Inputting diet diaries into NetWisp 
was completed by 2 pairs of researchers external to the research team who 
were blinded to the participant’s group allocation to avoid potential bias in 
analysis. Disagreement between groups was resolved by consensus opinion.
7.7.6 B lood markers
Capillary and venous bloods were sampled from all participants at baseline 
and end-point. Capillary blood was collected from a finger-prick performed on 
the middle finger of the left hand for immediate assessment of haemoglobin 
concentrations. Blood samples (10 pL) were collected on microcuvettes (B- 
Hemoglobin microcuvettes, HemoCue, Angelholm, Sweden) prior to analysis 
using a Haemoglobin Photometer (HemoCue, Angelholm, Sweden).
Venous blood (20 ml) was drawn from the antecubital vein using standard 
phlebotomy techniques. Whole blood samples were centrifuged at 3000 rpm 
for 8 minutes (Heraeus Labofuge 400R, DJB Labcare Ltd, Buckinghamshire, 
UK) for separation of plasma and serum, which was collected into 3 ml 
Eppindorf tubes and subsequently frozen at - 80°C (Sanyo VIP-series Ultra 
Low Temperature Freezer, Sanyo Biomedical, Wood Dale, IL, USA). Batch 
analyses of samples were carried out in the Department of Clinical Chemistry 
at the Royal Hallamshire Hospital, Sheffield, UK, using the Cobas 8000 
Modular Analyser (Roche Diagnostics, Basel, Switzerland). Samples were 
analysed for PSA, male sex hormones (testosterone, SHBG) and blood lipid 
profile (total cholesterol, HDL-C, LDL-C and triglycerides). In addition, free 
androgen index was calculated using the equation:
Free androgen index = 100 * (testosterone / SHBG)
Free testosterone and bioavailable testosterone were calculated in 
accordance with the equations proposed by Vermeulen et al. (1999) using
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the online calculator provided by the International Society for the Aging Male 
(2013).
7.8 Statistical analyses
Statistical analysis was performed using Statistical Package for the Social 
Sciences (SPSS) for Windows (v 19.0.0, IBM inc, NY, USA). Variation 
between groups for frequency data were examined using Pearson's Chi 
squared test. Differences in group means at baseline were examined using 
an independent groups t-test or the Mann Witney-U test after assessments of 
the distribution of data were completed using the Shapiro-Wilk test. 
Subsequently, tests of normality of distribution were also performed for 
complete data sets to be analysed for group and time interactions. Variables 
found to not be normally distributed were log transformed prior to analysis. 
Missing data were imputed using an intention-to-treat approach (Gravel etal., 
2007). In accordance with the suggestions of Engels and Diehr, (2003) data 
for participants dropping out of the study was dealt with using the 'last 
observation carried forward' method where the change over time was 
assumed to be zero.
Time by group interactions and main effects of time were assessed using 
mixed-model factorial analysis of variance (ANOVA) or, if there was a 
statistically significant difference between groups at baseline, mixed-model 
factorial analysis of covariance (ANCOVA) with baseline included as a 
covariate. Differences between groups over the 12 weeks of the intervention 
were assessed using a group by time design with baseline, mid-point and 
end-point data included as time points. Additionally, differences between 
groups from baseline to follow-up were assessed with follow-up data also 
included as a time point in the analysis. Where statistically significant main 
effects of time were present post-hoc analysis was performed using one-way 
ANOVA to examine the differences between time points within group. Effect 
sizes were calculated for variation between groups for the difference from 
baseline measures using the equations shown in section 1 (3.7 Statistical
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analyses). Thresholds were set at 0.2 for a small effect, 0.5 for a medium 
effect and 0.8 for a large effect (Cohen, 1992). Mean difference between 
groups in the change (A )  observed between time-points were also reported. 
Difference in A  was calculated as:
Mean difference in A  =  A  from baseline in the intervention group - A  from
baseline in control group.
A positive score indicated a greater change from baseline in the intervention 
group and a negative score indicated in greater change from baseline in the 
controls. In addition 95% confidence intervals (95% Cl) were also reported 
for the difference in A .
Relationships between the change in outcome measures from baseline to 
end-point and the change in exercise tolerance, quality of life and FMD over 
the same duration, were examined using correlation analysis. In cases where 
both variables were normally distributed, Pearsons bivariate correlation 
coefficient was used; however if one or more variables did not achieve 
normal distribution, Spearmans rank correlation was employed. Correlation 
coefficients <0.35 were considered weak, 0.36-0.67 moderate, 0.68-0.89 
high and >0.9 very high (Taylor, 1990). In addition, linear regression was 
performed to investigate if the change in key outcome measures (arterial 
dilatation, quality of life and fatigue) from baseline to end-point could be 
predicted by the change in selected independent variables over the same 
duration, or the baseline values of the same independent variables. To 
examine predictors of the change in arterial dilatation (logn peak - logn 
baseline), body fat mass, mean arterial pressure, triglyceride concentrations 
and exercise tolerance were included as independent variables. Predictors of 
the change in quality of life and fatigue were also examined, with exercise 
tolerance, body fat mass, mean arterial pressure and haemoglobin 
concentrations included as independent variables for both.
Data are presented as mean ± SD unless stated. P-values are displayed for 
time x group interactions unless otherwise stated. Statistical significance was 
set as P <0.05.
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7.9 Reliability of measures
Outcome measures not assessed for reliability during study 1 (treadmill test 
duration, 30-second sit to stand test) were examined in a group of 7 men (69 
± 4 years of age) who were asked to attend a second assessment session 
within 7 days of their baseline assessment. Testing procedures were 
standardized between the two trials, and where possible, participants were 
asked to attend the second session at the same time of day as they had 
attended the first.
Reliability data for exercise capacity and functional capacity assessments is 
presented in Table 7.1. ICC for these measures shows excellent reliability 
over a 7 day period (Cicchetti, 2000). This level of reliability matches or 
exceeds that previously reported for assessment of physical capacity in 
different patient groups (Minor and Johnson, 1996; Labs et al., 1999; 
Dobrovolny et al., 2003).
Table 7.1. Reliability statistics for exercise capacity and functional capacity assessments.
Outcome measure Trial 1 Trial 2 SEM rTEM (%) CV (%) ICC
Treadmill test duration (s) 445 (61) 446 (62) 6.01 0.65 0.95 0.99
Treadmill test final heart rate 
(beatsmin"1)
132 (24) 135 (20) 3.15 4.33 2.30 0.98
30 second sit to stand test 
(repetitions)
11 (3) 11 (3) 0.36 7.81 3.19 0.98
Abbreviations. CV: Coefficient of variation, ICC: Intraclass correlation coefficient, rTEM: 
Relative technical error of measurement, SEM: Standard error of measurement. Data for trials 
stated as mean (SD).
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8.0 RESULTS: Study 2
8.1 Participant demographic details
Demographic details are displayed in Table 8.1. There were no differences 
between groups for current or previous treatments received for prostate 
cancer (P >0.05). All participants were actively being treated with LHRH- 
agonists alone, or in addition to anti-androgen therapy (Bicalutamide). 
Groups were well matched for age, history of cardiovascular events and 
current medications (P >0.05). There was little difference between groups for 
current or previous smoking status (P >0.05). There were no statistically 
significant differences between groups at baseline for any outcome measures 
(P >0.05).
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Table 8.1. Intervention study demographic details: data displayed as count within group (% of group) 
unless otherwise stated.
Intervention 
(n =25)
Control 
(n =25)
P
Age: years, Mean (SD) 70 (5) 70 (9) 0.895
Treatment details
LHRH agonist alone 25(100) 23(92) 0.149
LHRH agonist + anti-androgen 0 2(8) 0.149
Months on ADT: Median (range) 19(6-138) 18(6-92) 0.454
Previous EBRT 7(28) 13(52) 0.083
Months since EBRT completion: Median (range) 17(12-95) 20(12-140) 0.550
Previous radical prostatectomy 1(4) 3(12) 0.297
Health history
Previous myocardial infarction 2(8) 2(8) 1.000
Previous stroke 0 3(12) 0.074
Arterial disease / angina 3(12) 2(8) 0.637
Diabetes Mellitus 3(12) 4(16) 0.684
Hypertension 16(64) 11 (44) 0.156
Hypertension diagnosed since ADT commencement 3(12) 2(8) 0.637
Medication
Statin therapy 14(56) 13(52) 0.777
Beta blockers 8(32) 6(24) 0.529
Aspirin 8(32) 8(32) 1.000
Calcium channel blockers 12(48) 4(16) 0.015
ACE inhibitors 9(36) 8(32) 0.765
Diuretics 4(16) 6(24) 0.480
Angiotensin-ll inhibitors 3(12) 3(12) 1.000
Prostaglandin analogues 7(28) 6(24) 0.747
Anti-coagulant therapy 2(8) 1(4) 0.552
Anti-diabetic medication 3(12) 3(12) 1.000
Lifestyle
Current smoker 1(4) 0 0.312
Previous smoker 12 (48) 11 (44) 0.777
Full time / part time employment 4(16) 5(20) 0.713
Ethnicity
White British 25(100) 22 (88) 0.074
Asian Indian 0 2(8) 0.149
Black African 0 1 (4) 0.312
Abbreviations: ADT: Androgen deprivation therapy, EBRT: External beam radiotherapy, LHRH: 
Luteinizing hormone-releasing hormone
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8.2 Compliance and attrition
Fifty men completed baseline assessments and were randomised to the 
intervention or control group. At end-point assessment 16% of the sample (8 
men) had withdrawn from the study. An additional 2 men (4% of the initial 
sample) were lost to follow-up. Four men in the control group missed the mid­
point assessment but returned to complete subsequent assessments. A flow 
diagram detailing patient attrition rates is shown in Figure 8.1.
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Randomised to 
intervention (n = 25)
Completed mid-point 
assessment (n = 24)
Randomised to control 
(n = 25)
Completed mid-point 
assessment (n = 21)
Completed follow-up 
assessment (n = 20)
Completed end-point 
assessment (n = 22)
Completed end-point 
assessment (n = 20)
Completed follow-up 
assessment (n = 20)
Completed baseline assessment 
(n = 50)
Dropped out (n = 0)
Dropped out (n = 1) 
Unrelated surgery (n = 1)
Dropped out (n = 2)
Accident at home (n = 1) 
Myocardial infarction (n = 1)
Dropped out (n = 2)
Accident at home (n = 1) 
Discomfort with exercise (n = 1)
Dropped out (n = 4)
Lost interest (n = 2)
Died- unrelated cause (n = 1) 
Developed angina (n = 1)
Dropped out (n = 1)
Change in treatment of heart 
rhythm irregularity (n = 1)
Figure 8.1. Attrition rates for men randomised to the intervention or control 
groups.
Compliance with exercise sessions for patients completing the intervention 
was good with 368 of 396 sessions completed (93% of sessions attended). 
Through weeks 1 to 6, 94% of sessions were completed (249 of 264 
sessions) and for weeks 7-12, 90% of sessions were completed (119 of 132 
sessions) (P >0.05). Home-based exercise was less well-adhered to with
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participants reporting completion of 76% of sessions (301 of 396 sessions 
completed). Participants reported completion of 83% (110 of 132 sessions) 
and 72% (191 of 264 sessions) of sessions in the first and second six weeks, 
respectively (P >0.05).
8.3 Vascular function
Data for assessment of FMD using a distal cuff are displayed in Table 8.2. 
There was no change in baseline arterial diameter in either group over the 
duration of the study (P = 0.828). There was a small effect of the intervention 
on peak arterial diameter (d = 0.47), although the difference between groups 
at end-point did not achieve statistical significance (P = 0.272, mean 
difference in A  = 0.21 mm; 95% Cl, -0.04 to 0.46). The magnitude of the 
difference between groups for peak arterial diameter decreased to follow-up 
(d = 0.17, P = 0.430). A medium effect was observed for the change from 
baseline to end-point in absolute and relative FMD (d = 0.55 and d = 0.51, 
respectively). Mean difference in A  for absolute FMD at end-point = 0.11 mm 
(95% Cl, 0.01 to 0.21) while for relative FMD mean difference in A  = 2.2% 
(95% Cl, -0.1 to 4.5). No statistically significant interaction was found for the 
change to end-point (P >0.05) but there was a main effect of time (P = 0.036). 
Post-hoc analysis demonstrated a statistically significant increase in relative 
FMD from baseline to end-point for men in the intervention group (P = 0.045). 
At follow-up the difference between groups was reduced (mean difference in 
A  for absolute FMD = 0.06 mm; 95% Cl, -0.05 to 0.18 [d = 0.30], mean 
difference in A  for relative FMD = 1.4%; 95% Cl, -1.3 to 4.1 [d = 0.29]) with 
the difference between groups remaining non-significant for the interaction 
(P >0.05) but a main effect of time remained (P = 0.007).
The change in allometrically scaled FMD between groups is displayed in 
Figure 8.2, There were no statistically significant interactions at end-point or 
follow-up after FMD was allometrically scaled for baseline diameter (P >0.05), 
but there was a main effect of time on the change in scaled FMD (P = 0.007), 
with post-hoc analysis revealing a statistically significant increase in the
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intervention group from baseline to end-point (P = 0.038). There was a 
medium effect of the intervention on change in scaled FMD at end-point (d = 
0.53).
There was no difference between groups for changes in time to peak arterial 
diameter (P >0.05 at end-point and follow-up). Similarly, no differences were 
observed at any time point for resting blood flow, peak blood flow or SR AUC 
(P >0.05).
rz- 10
Baseline Mid-point End-point Follow-up
Assessment
♦ Control " ■  Intervention
Figure 8.2. Allometrically scaled FMD for the intervention and control groups. Data 
displayed as mean for group, error bars denote 1 standard deviation. (£) denotes 
difference from baseline within the intervention group (P <0.05)
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The effects of group allocation on changes in proximal cuff FMD and GTN- 
mediated dilation are presented in Table 8.3. Data for proximal cuff FMD 
assessments are presented for 48 men because ultrasound scans were of 
insufficient quality for 1 man in each group. GTN-mediated dilation was 
assessed in 38 men (intervention = 17, control = 21). Reasons for not 
administering GTN included use of medications contraindicating GTN use (n 
= 8), previous adverse reaction to GTN (n = 1), cardiac arrhythmia (n = 1), 
history of migraines (n = 1) or refusal to undertake assessment (n = 1). Over 
the 12 weeks of the intervention no interaction effects were observed in any 
measures for proximal cuff FMD assessments (P >0.05), however, main 
effects of time were present for the change in baseline arterial diameter (P = 
0.036) and peak arterial diameter (P = 0.005). A medium effect size was 
observed for the difference in peak arterial diameter between baseline and 
follow-up (d = 0.52) although this difference was not found to be statistically 
significant (P = 0.289). Differences between groups were evident for GTN- 
mediated dilation, with an increase in the response to GTN observed at mid­
point in men in the control group (P = 0.042 for absolute change in GTN- 
mediated dilation, P = 0.057 for relative change in GTN-mediated dilation). 
No differences were observed between groups in response to GTN at end­
point or follow-up assessments (P >0.05).
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8.4 Blood pressure
Data for blood pressure measurements are displayed in Table 8.4. No 
statistically significant interactions were observed (P >0.05), however main 
effects of time were observed for diastolic blood pressure (P = 0.009), mean 
arterial pressure (P = 0.008) and heart rate (P = 0.018). Over the first six 
weeks of the study systolic and diastolic blood pressure decreased by 6.4 ± 
10.2 mm Hg and 2.6 ± 6.7 mm Hg, respectively for men in the intervention 
group, while controls showed reductions of 1.34 ± 12.4 mm Hg and 1.3 ± 3.7 
mm Hg over the same time period (mean difference in A  = -5.1 mm Hg; 95% 
Cl, -12.0 to 1.7 for systolic and -1.3 mm Hg; 95% Cl, -4.5 to 1.9 for diastolic 
blood pressure). Differences between groups were increased at end-point 
assessment with systolic and diastolic blood pressure reduced by 6.5 ±11.5 
mm Hg and 4.0 ± 6.1 for intervention and 0.4 ± 17.9 and 0.8 ± 5.2 mm Hg for 
controls (mean difference in A  = -6.0 mm Hg; 95% Cl, -14.7 to 2.6 for systolic 
and -3.1 mm Hg; 95% Cl, -6.4 to 0.2 for diastolic blood pressure). At follow- 
up systolic blood pressure showed mean difference in A  = -0.3 mm Hg (95% 
Cl, -7.7 to 7.1) and for diastolic blood pressure mean difference in A  = -0.9 
mm Hg (95% Cl, -3.7 to 1.9). At end-point, mean arterial pressure decreased 
from baseline by 5.6 ± 8.1 mm Hg for the intervention group and 1.8 ± 8.4 
mm Hg for the controls (mean difference in A  = -3.8 mm Hg; 95% Cl, -8.7 to 
1.9), while at follow-up mean arterial pressure was decreased from baseline 
by 4.5 ±11.3 mm Hg in the intervention group and 3.1 ± 8.5 mm Hg in the 
controls (mean difference in A  = -1.4 mm Hg; 95% Cl, -6.2 to 3.4). Effect 
sizes of d = 0.46 and d = 0.14 were found for the change to end-point and 
follow-up respectively.
Two-men in the control group started or increased medication to treat high 
blood pressure between the mid-point and end-point assessments, and 
hence lowered group mean blood pressure at end-point and follow-up as a 
result of pharmacological intervention. If data for these two men is removed 
from the subsequent analysis greater differences between groups are evident 
in systolic blood pressure and mean arterial pressure at end-point 
assessment (mean difference in A for systolic blood pressure = -6.2 mm Hg;
162
95% Cl, -14.9 to 2.5, P = 0.195; mean difference in A for mean arterial blood 
pressure = -4.1 mm Hg; 95% Cl, -9.3 to 1.1, P = 0.189).
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8.5 Anthropometric measures
Data for anthropometric measures are displayed in Table 8.5. There were no 
interaction effects for changes in body mass or BMI ( P  >0.05), however main 
effects of time were observed for the change in body mass at end-point and 
follow-up ( P  = 0.010 and P  = 0.013, respectively), and for the change in BMI 
at end-point ( P  = 0.021). Body mass was reduced from baseline by 0.9 ± 2.0 
kg at end-point and 1.0 ± 2.9 kg at follow-up assessment for men in the 
intervention group. Men in the control group lost 0.8 ± 2.8 kg and 0.9 ± 4.0 kg 
from baseline measures at end-point and follow-up, respectively.
At end-point assessment skeletal muscle was increased (mean difference in 
A  = 0.5 kg; 95% Cl, 0.0 to 1.0) and body fat mass (mean difference in A  =  -  
0.9 kg; 95% Cl, -2.1 to 0.4) and body fat percentage (mean difference in A  =  - 
1.1 kg; 95% Cl, -1.9 to -0.2) were decreased from baseline measures for 
men in the intervention compared to the controls. The differences between 
groups for the change in skeletal muscle mass and body fat percentage 
demonstrated a statistically significant interaction ( P  <0.05). In addition, the 
change in body fat percentage demonstrated a main effect of time for the 
change to end-point ( P  = 0.001). Changes in skeletal muscle mass occurred 
within the first 6 weeks of the intervention, with a difference between groups 
evident at the mid-point assessment (mean difference in A  = 0.4 kg; 95% Cl, 
0.0 to 0.8) ( P  = 0.022). Reduced visceral fat area was also seen at end-point 
assessment in men in the intervention compared to controls (mean difference 
in A  = -3.6 cm2; 95% Cl, -7.8 to 0.6). At follow-up assessment no interaction 
effects were evident between groups for body composition, but the effect of 
time was still present for changes in body fat percentage ( P  = 0.008).
It must be noted that one man in the control group started medication to 
achieve a reduction in fat mass during the study (prior to end-point 
assessment). If subsequent data for this participant is removed from the 
analysis greater changes are observed between groups in body fat 
percentage (mean difference in A  at end-point = -1.2%; 95% Cl, -2.0 to -0.4, 
P  = 0.017), body fat mass (mean difference in A  at end-point = -1.2 kg; 95% 
Cl, -2.0 to -0.4, P  = 0.144), BMI (mean difference in A  at end-point = -0.15
165
kg m'2; 95% Cl, -0.54 to 0.24, P = 0.293) and visceral fat area (mean 
difference in A at end-point = -4.1 cm2; 95% Cl, -8.3 to 0.1, P = 0.089).
166
Ta
ble
 
8.
5.
 A
nt
hr
op
om
et
ric
 
da
ta 
fo
r 
the
 
in
te
rv
en
tio
n 
an
d 
co
nt
ro
l 
gr
ou
ps
. 
Da
ta 
pr
es
en
te
d 
as 
m
ea
n 
(S
D
)
8.6 Exercise tests and exercise behaviour
Data for exercise tolerance test results are displayed in Figure 8.3. Treadmill 
time was increased from baseline at mid-point (A  from baseline 58.7 ± 58.6 s) 
and end-point assessments ( A  from baseline 80.3 ± 64.7 s) in men in the 
intervention group, while men in the control group showed little change in 
walking time over the same periods (reduced from baseline by 2.6 ± 52.0 s at 
mid-point and by 7.0 ±57.1 s at end-point). Accordingly, there was a large 
effect of the intervention on treadmill walking time (d = 1.46 for change from 
baseline to end-point) with the interaction demonstrating statistical 
significance at mid-point and end-point (both P <0.001, mean difference in A  
at end-point = 87.2 s; 95% Cl, 50.4 to 124.0) and a main effect of time at 
end-point assessment (P <0.001). A large effect of the intervention on the 
change in exercise tolerance from baseline was observed at follow-up (d = 
1.26) with a mean difference in A  = 73.2 s (95% Cl, 38.6 to 107.9; P <0.001 
for interaction and time).
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Figure 8.3. Treadmill time for the intervention and control groups. Data displayed as 
mean for group, error bars denote 1 standard deviation. (*) signifies interaction 
effect (P <0.05).
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Men in the intervention group demonstrated improvements in performance of 
the 30 second sit-to-stand test exceeding those shown by the controls 
(Figure 8.4). Statistically significant changes were observed at end-point (P = 
0.025) and follow-up (P = 0.048). Performance increased in the intervention 
group from a mean of 10.6 ± 2.8 repetitions at baseline to 12.7 ± 4.5 
repetitions at end-point and 13.0 ± 3.9 repetitions at follow-up. In the control 
group performance increased from 9.8 ± 3.2 repetitions at baseline to 10.4 ±
3.4 repetitions and 11.2 ± 3.8 repetitions at end-point and follow-up, 
respectively (mean difference in A at end-point = 1.5 reps; 95% Cl, 0.1 to 2.9, 
d = 0.69 for the change from baseline to end-point).
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Figure 8.4. Thirty second sit-to-stand test performance for the intervention and 
control groups. Data displayed as mean for group, error bars denote 1 standard 
deviation. (*) signifies interaction effect (P <0.05).
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Greater increases in leisure time activity were observed in the intervention 
group compared to the controls (Figure 8.5). Godin LSI score increased from 
baseline by 9.0 ± 16.1 points in the intervention group at mid-point 
assessment, while in the controls LSI score reduced by 0.2 ±8.1 points over 
the same duration ( P  = 0.013). At end-point men in the intervention 
demonstrated a 14.6 ± 24.8 point increase from baseline, in comparison with 
an increase from baseline of 3.0 ± 11.6 points in the control group (mean 
difference in A  = 11.6 points; 95% Cl, 0.5 to 22.7, d = 0.61 for the change 
from baseline to end-point, P  = 0.041). At follow-up assessment the mean 
difference in A  = 5.8 points (95% Cl, -8.1 to 19.8, P  = 0.119).
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Figure 8.5. Godin LSI results for the intervention and control groups. Data displayed 
as mean for group, error bars denote 1 standard deviation. (*) signifies difference 
between intervention and control for change from baseline (P <0.05).
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8.7 Fatigue and quality of life
Data for fatigue and quality of life were analysed as the difference between 
groups for the change from baseline. Results for the difference in fatigue 
scores from baseline are shown in Figure 8.6. There was a large effect of 
group on the change in fatigue between baseline and mid-point (d = 0.87), 
with Fact-F scores increasing by 5.0 ± 6.3 points in the intervention group 
and by 0.6 ± 3.7 points in the controls (mean difference in A  = 4.4 points; 95% 
Cl, 1.2 to 7.7, P = 0.006). At end-point assessment the change in Fact-F 
score from baseline remained greater in men undergoing the intervention 
(4.8 ± 6.5 points) than in controls (1.0 ± 5.6 points) although there was a 
slight decrease in the magnitude of the difference between groups from 
baseline (mean difference in A  = 3.8 points; 95% Cl, -0.1 to 7.7, P  = 0.044, d 
= 0.64). At follow-up assessment there was still a medium effect of group on 
fatigue (d = 0.54), however the difference in change from baseline between 
groups decreased (mean difference in A  = 3.6 points; 95% Cl, 0.0 to 7.3) and 
the effect of group on change from baseline was no longer statistically 
significant ( P  = 0.167).
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Figure 8.6. Change in fatigue (Fact-F) from baseline for the intervention and control 
groups. (*) signifies difference between intervention and control for change from 
baseline (P <0.05). Error bars denote ± 1 standard deviation
Changes in Fact-P scores from baseline are displayed in Figure 8.7. Men in 
the intervention group demonstrated improved disease-specific quality of life 
compared to men in the control group (P <0.05 for the difference between 
groups at mid-point and end-point). There was a medium effect of group (d = 
0.71) for the change in fatigue from baseline to mid-point. Fact-P scores 
increased by 6.7 ± 9.7 points in the intervention group but little change in the 
controls was observed over this period (0.5 ± 8.0 points, mean difference in A 
= 6.2 points; 95% Cl, 1.8 to 10.6, P = 0.033). At end-point Fact-P was 
increased from baseline by 7.6 ± 9.2 points in the intervention group, while 
the control group decreased from baseline by 1.8 ± 5.5 points (mean 
difference in A = 9.4 points; 95% Cl, 5.4 to 13.4, P <0.001). This represented 
a large effect of group on the difference from baseline (d = 1.3). Although 
Fact-P scores remained higher in men in the intervention group at follow-up
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(mean difference in A = 4.9 points; 95% Cl, -0.1 to 9.9), the difference 
between groups was no longer statistically significant (P = 0.316, d = 0.44).
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Figure 8.7. Change in disease-specific quality of life (Fact-P) from baseline for the 
intervention and control groups. (*) signifies difference between intervention and 
control for change from baseline (P <0.05). Error bars denote ± 1 standard deviation
8.8 Blood markers
Results for blood lipid profile are presented in Table 8.6. Data is shown for 47 
men because samples were not obtained or couldn't be analysed in 3 men (n 
= 1 intervention and n = 2 controls). No differences between groups were 
observed for changes in total cholesterol, HDL-C, LDL-C or total cholesterol / 
HDL-C ratio (P >0.05). There was a small effect of group on the change in 
triglyceride concentrations but the difference was not statistically significant 
(P = 0.136).
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Table 8.6.Blood lipid profile at baseline and end-point for the intervention and control groups.
Data presented as mean (SD)
Baseline End-point d P
Control Intervention Control Intervention A EP - BL
Total cholesterol 
(mmol-L"1)
4.71 (0.87) 5.00 (1.16) 4.69 (0.85) 4.93(1.04) 0.13 0.666
HDL-C (mmol-L"1) 1.47 (0.49) 1.42 (0.40) 1.45 (0.43) 1.44 (0.38) 0.24 0.416
LDL-C (mmol-L'1) 2.45 (0.81) 2.73(1.14) 2.50 (0.81) 2.74(1.01) 0.14 0.621
Total cholesterol / HDL-C 
ratio
3.42 (1.16) 3.74(1.2) 3.43 (0.95) 3.63(1.14) 0.24 0.416
Triglycerides (mmol-L"1) § 1.72 (0.97) 1.86 (0.72) 1.62 (0.88) 1.65 (0.74) 0.30 0.136
Abbreviations. HDL-C: High-density lipoprotein cholesterol, LDL-C: Low-density lipoprotein cholesterol. (s) 
denotes data was logn transformed prior to analysis
A reduction in haemoglobin concentration of 3 ± 8 gT1 was observed in men 
in the intervention group (from 134 ± 13 gT1 at baseline to 131 ± 1 3  g T 1 at 
end-point). This was only marginally less than the reduction in haemoglobin 
seen in the control group (4 ± 10 gT1; from 129 ± 16 gT1 at baseline to 125 ± 
18 gT1 at end-point) with the difference between groups not achieving 
statistical significance (P = 0.612, d = 0.15).
Biomarkers of disease progression are reported in Table 8.7. Data for 
testosterone, SHBG and FAI are missing for n = 4 (n = 1 intervention and n = 
3 controls). No differences between groups were observed for changes in 
serum testosterone or PSA concentrations (P >0.05). There was a medium 
effect of group on SHBG concentrations (d = 0.67) with the difference 
between groups at end-point assessment achieving statistical significance (P 
= 0.033). Similarly, there was a small effect of group on free androgen index 
(d = 0.38) which demonstrated a statistical trend (P = 0.072).
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Table 8.7 Biomarkers of disease progression at baseline and end-point for the intervention and
control groups. Data presented as mean (SD)
Baseline End-point d P
Control Intervention Control Intervention A E P -B L
Serum testosterone (nmol-L'1) 0.46 (0.17) 0.48 (0.22) 0.45 (0.18) 0.43 (0.10) 0.32 0.837
Free testosterone (nmolT1)
0.0066
(0.0036)
0.0071
(0.0034)
0.0068
(0.0042)
0.0064
(0.0030)
0.43 0.137
Bioavailable testosterone 
(nmol I'1)
0.156
(0.086)
0.166
(0.081)
0.161
(0.099)
0.149
(0.070)
0.43 0.138
SHBG (nmol-L'1) §
56.90
(31.57)
54.02
(33.00)
53.78
(30.87)
55.85
(34.26)
0.67 0.033
FAI § 1.17(1.00) 1.20 (0.77) 1.22 (1.04) 1.10(0.76) 0.38 0.072
PSA (ng-ml) § 1.50 (2.74) 2.15(4.84) 2.00 (4.05) 3.23 (8.20) 0.21 0.538
Abbreviations. SHBG: Sex-hormone binding globulin, FAI: Free androgen index, PSA: Prostate specific antigen. (s) 
denotes data logn transformed prior to analysis
8.9 Diet diaries
In total 70% of diet diaries were returned, with 88%, 66% and 58% returned 
at baseline, end-point and follow-up, respectively. No differences were 
observed between groups or over time in total energy intake, or in any of the 
macro or micronutrients examined (P >0.05; Table 8.8).
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8.10 Correlations
Relationships of variables to changes in exercise tolerance from baseline to 
end-point were examined using non-parametric correlations because data for 
the change in exercise tolerance was not normally distributed. Positive 
correlations were observed against changes in Fact-F and Fact-P, with the 
relationship between the change in exercise tolerance and the change in 
quality of life considered statistically significant (rs = 0.248, P = 0.082 and rs 
= 0.361, P = 0.010 for correlations with Fact-F and Fact-P, respectively). 
Furthermore, the change in exercise tolerance demonstrated statistically 
significant inverse relationships with changes in diastolic blood pressure (rs = 
-0.298, P = 0.036), body mass (rs = -0.303, P = 0.033) and visceral fat area 
(rs = -0.324, P = 0.022).
Relationships between changes in quality of life and changes in fatigue, 
skeletal muscle mass and body fat mass are shown in Figure 8.8. Changes 
in Fact-P score demonstrated a moderate positive correlation with changes in 
fatigue (rs = 0.551, P = <0.001). Moderate correlations were also observed 
between the change in Fact-P and the changes in skeletal muscle mass (r = 
0.479, P < 0.001), body fat mass (rs = -0.495, P < 0.001) and body fat 
percentage (r = -0.561, P <0.001). Weak inverse correlations were found 
between the change in Fact-P and systolic blood pressure (r = -0.291, P = 
0.040) and mean arterial pressure (r = -0.298, P = 0.036).
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Figure 8.8. Relationships between change in Fact-P score and change in Fact-F 
(8.8.A), skeletal muscle mass (8.8.B) and body fat mass (8.8.C) from baseline to 
end-point. Black line denotes line of best fit for each data set.
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Changes in relative FMD demonstrated a moderate positive correlation with 
changes in SHBG (rs = 0.423, P = 0.002). Changes in relative FMD did not 
demonstrate correlations with any other variables (P >0.05).
No correlation was observed between arterial dilatation measured using a 
proximal cuff placement and arterial dilatation measured using a distal cuff or 
GTN-mediated dilatation at any assessment (P >0.05).
8.11 Regression
Linear regression to investigate predictors of the change in arterial dilation for 
logn transformed data (logn peak - logn baseline) from baseline to end-point 
showed that the change in exercise capacity had a statistically significant 
effect ((3 = 0.318, P = 0.028). There was no effect of the change in mean 
arterial pressure (p = 0.112, P = 0.458), body fat mass (p = -0.009, P = 0.952) 
or triglycerides (p = 0.209, P = 0.179). This led to an overall fit for this model 
of R2 = 0.148. There was no relationship between baseline values of these 
outcomes and change in arterial dilatation (P >0.05 for all independent 
variables, R2 = 0.128).
Examining predictors of the change in Fact-P score from baseline to end­
point demonstrated that change in exercise tolerance (P  = 0.362, P = 0.004) 
and change in body fat mass (p = -0.358, P = 0.006) had statistically 
significant effects, but change in mean arterial pressure (p = -0.175, P = 
0.157) and change in haemoglobin (p = 0.203, P  = 0.100) did not (R2 for 
model = 0.380). Similarly, change in body fat mass (P  = -0.467, P  = 0.001) 
was found to be a statistically significant predictor of change in Fact-F score. 
There was no effect of change in mean arterial pressure (p = -0.163, P  = 
0.203), haemoglobin (P  = 0.070, P  = 0.558) or exercise tolerance (p = 0.194, 
P  = 0.125) for change in Fact-F. The overall model fit for change in Fact-F 
was R2 = 0.338. Including baseline values of these independent variables 
into the model for prediction of change in Fact-P or Fact-F demonstrated no
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statistically significant relationships (P >0.05 for all independent variables, R2 
= 0.41 and R2 = 0.16 for change in Fact-P and change in Fact-F, 
respectively).
8.12 Attrition analysis
Patient characteristics for men dropping out of the study prior to the end-point 
assessment are displayed in Table 8.9. Baseline exercise tolerance was 
lower in men dropping out of the study (P = 0.001). There was a trend for 
increased fatigue in patients who dropped out (P = 0.051).
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Table 8.9 Determinants of patient attrition prior to end-point assessment.
Completers 
(n = 42)
Non-completers 
(n = 8)
P
Demographic data, count within group (%) unless stated
Age, years; Mean (SD) 70 (7) 71 (9) 0.635
Duration of ADT, months; Mean (SD) 27(28) 36 (40) 0.265
Employed 9(21) 0(0) 0.148
Previous cardiovascular events 10(24) 2(25) 0.942
Flypertension 28 (67) 4(50) 0.368
Diabetes Mellitus 6(14) 1(12) 0.894
Arthritis 16(38) 4(50) 0.529
Baseline data, mean (SD)
PSA, ng-ml 2.07 (4.20) 0.51 (1.11) 0.065
Mass, kg 90.0(16.6) 88.3(16.0) 0.784
BMI, kg m'2 29.6 (5.1) 30.5 (5.7) 0.628
Exercise tolerance, s 375(137) 191 (139) 0.001
Godin LSI, points 22(16) 15(8) 0.260
Fact-F score, points 39 (8) 33(10) 0.051
Fact-P score, points 118(19) 107 (21) 0.162
Abbreviations: ADT, Androgen deprivation therapy; BMI, Body mass index; Fact-F, 
Functional assessment of cancer therapy-Fatigue; Fact-P, Functional assessment of cancer 
therapy-Prostate; PSA, Prostate-specific antigen.
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9.0 DISCUSSION: Study 2
This study demonstrates that, in this sample of men treated with ADT for 
prostate cancer, a lifestyle intervention including supervised exercise training 
and dietary advice did have significant effects on exercise tolerance, activity 
levels, fatigue and general quality of life. In addition, this intervention 
potentially had beneficial effects on risk factors for cardiovascular disease.
The primary null hypothesis for this study was that no difference would be 
found in cardiovascular risk between men with prostate cancer treated with 
ADT taking part in the intervention compared with controls. Although weak 
evidence was found for a difference between the groups for the primary 
outcome measure (relative FMD) with a mean difference of 2.2% (95% Cl, - 
0.1 to 4.5) at end-point assessment, this failed to reach the alpha of 0.05 set 
at the outset in the sample size calculation. However, there is a risk that 
accepting the null hypothesis constitutes a type II error, in that post-hoc 
analysis demonstrated differences from baseline in the intervention group of 
considerable magnitude. Similarly, the effect size for the difference between 
groups for the change from baseline to end-point is suggestive of a beneficial 
effect of the intervention on FMD. Hence, the lack of statistical significance 
for the difference between groups could reflect the relatively small number of 
completers, as the sample size was calculated assuming an attrition rate of 
10% at the end of the intervention, whereas the drop-out observed over this 
period was found to be 16%. Similarly, increased variance in the results 
could have had an effect, with a SD of 3.0% used in the sample size 
calculation and a SD of 5.3% observed for the change in relative FMD over 
the course of the intervention, thus rendering the study under-powered to 
detect a change at the 0.05 alpha.
Given the epidemiological data demonstrating a higher risk of cardiovascular 
disease in men on long-term ADT (Keating et al., 2010; Van Hemelrijck et al., 
2010), it remains important to investigate a method of reducing 
cardiovascular risk in this population. Endothelial function is considered a
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surrogate marker of cardiovascular health (Vita and Keaney, 2002), with 
dysfunction of the endothelium reported to be an important initial event in the 
development of atherosclerosis (Celermajer, 1997). Hence, longitudinal 
changes in measures of endothelial function can represent quantifiable 
evidence of alterations in cardiovascular risk. As such, the findings of the 
current study provide some evidence for healthy lifestyle changes having a 
moderate effect on endothelial function, which is suggestive of a reduction in 
cardiovascular risk in men taking part in the intervention. However, a larger 
study to confirm this would be required before such a claim can reliably be 
made.
The changes in body composition observed are congruent with 
improvements in FMD, as changes in body fat have previously been 
associated with endothelial function (Parikh et a i, 2009) and cardiovascular 
risk (Taylor et a i, 2010). Excess body fat is associated with increased 
oxidative stress (Perticone et al., 2001). Increased production of reactive 
oxygen species (including superoxide anion, hydrogen peroxide, hyroxyl 
radical, hypochlorous acid and peroxynitrite) and a concomitant reduction in 
antioxidant systems, can lead to a decrease in NO synthesis and an increase 
in NO degradation (Cai and Harrison, 2000; Higashi et a i, 2009). Similarly, 
evidence of beneficial effects of the intervention on blood pressure could also 
be influential in changes in endothelial function (Vanhoutte, 1996), with the 
effects again mediated by changes in oxidative stress (Vaziri, 2008). 
Although no statistically significant difference was found between groups, the 
magnitude of the change in diastolic blood pressure (-3.1 mm Hg; 95% Cl, -
6.4 to 0.2) is suggestive of a moderate effect of the intervention. Confirmation 
of these findings in a larger study would again be required before such an 
effect can be described with confidence however.
Changes in body composition and blood pressure might not be expected to 
account for all of the observed difference in FMD however, as Green et a i 
(2003) previously reported that changes in FMD with exercise training in 
patients with hypercholesterolemia, diabetes, coronary artery disease and 
chronic heart failure were not fully explained by changes in traditional
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cardiovascular risk factors (plasma lipids, blood pressure, blood glucose, 
waist-to-hip ratio, BMI). Thus, these findings suggest that additional 
mechanisms, independent of these cardiovascular risk factors, may account 
for the improvements in FMD seen with exercise. This could be of importance 
in the current study where regression analysis suggests a role for exercise to 
influence endothelial function independent of changes in traditional 
cardiovascular risk factors. Although no relationship was observed between 
the change in arterial dilatation and the change in established markers of 
cardiovascular health (blood pressure, body composition, blood lipids), there 
was a statistically significant effect of the change in exercise tolerance. Our 
study was not designed to explain the nature of such a relationship, however 
previous literature has described several mechanisms that could be involved.
Exercise induced up-regulation of NO synthase and a reduction in oxidative 
stress as an outcome of increased shear stress could provide one possible 
mechanism. The review by Higashi and Yoshizumi (2004) describes how 
chronic increases in arterial flow with exercise training can lead to up- 
regulation of signalling proteins, heat shock protein and hypoxia-inducible 
factor-1, resulting in an increase in endothelial NO synthase and 
consequently an increase in bioavailable NO. Furthermore, they report that 
prolonged shear stress increases production of antioxidants such as 
superoxide dismutase, leading to greater scavenging of reactive oxygen 
species and inhibition of NO degradation. These mechanisms could be 
influential in the current study, as although no changes in measures of blood 
flow or SR were observed in the intervention group at rest, the cumulative 
effects of increased arterial shear stress during exercise training could have 
mediated such an effect and contributed to the change in FMD observed in 
the intervention group.
The effects of exercise on endothelial progenitor cells could also have an 
important role in improvements in endothelial function observed in the 
intervention group. In a review of the role of endothelial progenitor cells on 
the beneficial effects of exercise, Lenk et al. (2011) describe how physical 
exercise can increase both the number and functional capacity of circulating
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endothelial progenitor cells. They suggest that exercise induced increases in 
NO concentrations activate MMP-9 within the bone marrow, which leads to 
enhanced mobilization of progenitor cells. This leads to acute increases in 
progenitor cell concentrations after a single bout of exercise, while after 
prolonged exercise training concentrations will remain elevated. Increases in 
circulating progenitor cells can subsequently lead to improvements in 
endothelial cell integrity and function due to the function of endothelial 
progenitor cells promoting endothelial cell repair (Shantsila et al., 2007). This 
is evidenced in studies demonstrating an association between endothelial 
progenitor cell concentrations and FMD in the brachial artery (Oliveras et al., 
2008; Liao et al., 2010).
Increases in dietary antioxidants could have also influenced endothelial 
function independently of changes in the traditional cardiovascular risk 
factors (Marin et al., 2011; Franzini et al., 2012). Marin et al. (2011) reported 
that consumption of a Mediterranean style diet for 4 weeks led to a decrease 
in endothelial micro-particles and an increase in endothelial progenitor cells 
in a sample of elderly men and women. Similarly, Franzini et al. (2012) found 
that consumption of a diet high in antioxidants for 2 weeks resulted in 
improved FMD in elderly men and women in comparison with a low 
antioxidant diet. Although the mechanisms behind such an association are 
not fully understood, it is believed that a higher consumption of polyphenols, 
and vitamins C and E, as would be expected in a Mediterranean style diet 
high in fruit and vegetables, could be important. Flavanols, a sub-group of 
polyphenols, have been shown to affect vascular function, causing NO- 
dependent arterial dilation (Fisher et al., 2003). This response could be an 
effect of flavanols inducing a reduction in vascular inflammation, as Landberg 
et al. (2011) reported biomarkers of vascular inflammation (CRP, IL-18, 
vascular cell adhesion molecules) were inversely associated with flavanol 
consumption.
In addition to potentially contributing to changes in FMD, the improvements 
observed in body composition are also suggestive of a decrease in 
cardiovascular risk with the intervention. The volume and distribution of body
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fat can influence cardiovascular risk, with excess fat mass and central 
adiposity shown to be associated with cardiovascular events and overall 
mortality (Taylor et al., 2010). Although the mechanisms underlying this 
association are yet to be fully described, it has been suggested that the 
hormonal and metabolic effects of excess body fat, which include the effects 
on insulin, glucose, FFA, sex steroids and glucocorticoid activity, can be 
influential in the development of hypertension and diabetes, and these could 
also increase the risk of associated cardiovascular events (Despres et al., 
1990; Jensen, 2008). Conversely, the increase in skeletal muscle mass can 
indirectly benefit cardiovascular risk by increasing resting metabolic rate 
(Zurio et al., 1990). It has been proposed that the resulting increase in daily 
energy expenditure will enable greater control of body mass, although 
evidence from studies testing this theory by examining the benefits of 
resistance training on body mass and body fat are currently inconsistent 
(Donnelly et al., 2009). In addition, greater muscle mass will facilitate 
participation in greater amounts of physical activity, which is of importance in 
consideration of the inverse relationship between physical activity and 
cardiovascular risk (Myers et al., 2004).
Although our findings of improvements in muscle mass do reflect the effects 
of exercise previously reported in men on ADT, we have provided the first 
evidence of statistically significant changes in fat mass with a lifestyle 
intervention in such a patient group. Several studies have described no 
effects or negative changes in anthropometric measures with exercise-based 
lifestyle interventions (Galvao et al., 2006; Alberga et al., 2012), however 
benefits to muscle mass were previously reported by Galvao et al. (2010). 
Over the duration of a 12 week gym-based training regime, Galvao et al.
(2010) described statistically significant improvements in lean body mass in 
comparison with a non-exercising control group (mean difference in A  = 0.76 
kg; 95% Cl, 0.01 to 1.50), but no differences were found between groups for 
the effects on body fat mass (mean difference in A  = -0.01 kg; 95% Cl, -0.82 
to 0.79) or body fat percentage (mean difference in A  = -0.34 kg; 95% Cl, - 
1.0 to 0.41).
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The reasons for greater fat loss in the current study as compared with 
previous exercise studies in men on ADT can only be speculated on; 
however, the delivery of dietary advice in addition to the exercise training 
could be important. Dietary modification has only been part of one previous 
exercise study in men on ADT (Bourke et al., 2011) which reported no 
changes in body mass, BMI or waist-to-hip ratio, but did not investigate 
further measures of body composition. Changes in dietary content can 
influence energy intake, which accounts for one side of the energy balance 
equation that describes the process of body mass management, and hence, 
provides a key modifiable factor to achieve reductions in body fat mass. 
Furthermore, small changes in dietary content may be influential in changes 
in body composition even without changes in absolute energy intake. For 
example, Fernandez de la Puebla et al. (2003) demonstrated that dietary 
modification that included reducing saturated fat consumption and increasing 
monounsaturated fat intake could decrease body fat mass in 
hypercholesterolemic males even though total calorie intake was not altered. 
Although no changes in diet were observed in the current study this could be 
due, at least in part, to a weakness in the use of diet diaries to monitor 
dietary content. Diet diaries provide a practical gauge of nutritional 
consumption; however, the current study found the level of detail with which 
participants reported food intake varied greatly. In-spite of participants being 
given clear instructions on recording food content and portion size, many diet 
diaries were completed with limited details, and thus the accuracy with which 
dietary content was measured must be questioned. This is an issue that has 
previously been shown with use of diet diaries (Myers et al., 1988), and 
hence alternative methods of dietary analysis must be considered in any 
future studies in this area.
As previously described, the evidence of an effect of the intervention on 
blood pressure could also be considered indicative of a reduction in 
cardiovascular risk. High blood pressure is a major risk factor for 
cardiovascular accidents and is considered the most important cause for 
global mortality, accounting for 13% of deaths worldwide (World Health
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Organisation, 2009). Reducing blood pressure has been associated with a 
decrease in the risk of cardiovascular events and mortality (Antonakoudis et 
al., 2007). Accordingly, the statement on management of hypertension by the 
World Health Organisation and the International Society of Hypertension 
recommends that all individuals should adopt appropriate lifestyle 
modifications to reduce blood pressure for reductions in cardiovascular risk 
(World Health Organization, International Society of Hypertension Writing 
Group. 2003).
In previous exercise studies in men on ADT, the effects on blood pressure 
has been under-reported as data for pre and post intervention has only been 
provided by two studies (Culos-Reed et al., 2010; Nobes et al., 2012). 
Although Culos-Reed et al. (2010) described statistically significant 
improvements in both systolic and diastolic blood pressure over the duration 
of their 16 week intervention for men in the exercise group (mean reduction
8.9 ± 20.9 mm Hg and 5.6 ±11 .4  mm Hg for systolic and diastolic blood 
pressure, respectively), blood pressure changes for men in the non­
exercising control group were of a similar magnitude (mean reduction 7.3 ± 
19.3 mm Hg and 6.2 ± 9.7 mm Hg for systolic and diastolic blood pressure, 
respectively), and hence no time by group effect was found. Our data clearly 
supports these findings as, although we also did not find a statistically 
significant interaction between groups, small or medium effects of the 
intervention to reduce systolic, diastolic and mean arterial blood pressure 
were observed. It is noted that the mean difference between groups in the 
change of blood pressure measures observed in the current study exceeds 
that reported by Culos-Reed et al. (2010) highlighting the greater strength of 
the current findings. Differences between groups were observed for changes 
in blood pressure in the study by Nobes et al. (2012) who found a 6.0 ± 10.1 
mm Hg decrease in systolic blood pressure in men in the intervention group 
with little change in the controls. However, the inclusion of treatment with 
Metformin as part of the intervention delivered to participants means that the 
effects attributed to lifestyle change alone cannot be deduced from these 
findings.
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Although it has already been stated that the reduction in blood pressure may 
have beneficial effects for the measures of vascular function, the reverse of 
this could also be true. Changes in endothelial function leading to an 
increase in bioavailable NO might also contribute to a reduction in blood 
pressure (Forstermann and Sessa, 2012), as the vaso-relaxing effects of NO 
decrease vascular tone and consequently reduce systemic pressure. In 
addition, exercise induced changes in vasoconstrictor concentrations might 
also be influential in the reductions in blood pressure observed. Exercise 
training has been shown to decrease expression of endothelin-1 mRNA 
(Maeda et al., 2002), while there is some speculation that training can reduce 
sympathetic nervous system activity leading to a reduction in norepinephrine 
concentrations (Mueller, 2007).
The observed increase in exercise capacity in the current study can also be 
considered in the context of evidence of a benefit to cardiovascular health 
from participation in the intervention. This association can be made in 
consideration of previous evidence of an inverse relationship between the 
volume of physical activity performed or the level of physical fitness, and the 
incidence of cardiovascular events or mortality (Lee and Skerrett, 2001; 
Myers et al., 2004; Ruiz et al., 2008). In a review of studies investigating the 
effects of fitness on mortality from cardiovascular disease, Nocon et al. (2008) 
reported a 35% risk reduction (95% Cl, 30-40%) for those with the highest 
fitness levels in comparison with those who have the lowest fitness levels.
The mechanisms behind such a reduction in cardiovascular risk with exercise 
remain incompletely understood. In a prospective study of 27,055 
participants, Mora et al., (2007) reported that the effect of exercise on 
traditional and novel cardiovascular risk factors (body mass, BMI, blood lipids, 
blood pressure, homocysteine, diabetic status and inflammatory biomarkers) 
only accounted for 59% of the reduction in risk, and hence 41% of 
cardiovascular risk reduction is mediated via other routes. Direct effects of 
exercise on endothelial function, as previously described, provided one 
potential means of a reduction in cardiovascular risk without a concomitant
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reduction in traditional risk factors, however understanding further 
mechanisms underlying this association clearly requires further investigations.
The findings of increased exercise tolerance and physical function in men 
randomised to the intervention are consistent with evidence previously 
presented on the effects of exercise on such outcomes in men on ADT 
(Galvao et al., 2006; Culos-Reed et al., 2007; Galvao et al., 2010; Bourke et 
al., 2011). Although comparisons between studies are limited by the use of 
different tests for both exercise tolerance and physical function, analysis of 
the magnitude of change in performance reported in different studies 
demonstrates the strength of the results in the present study. The change in 
both physical performance measures at the end-point assessment in the 
current study were not as large as those reported by Bourke et al. 
(improvements of 41% and 44% for exercise tolerance and physical function, 
respectively, measured using the same tests as in the current study), 
however the 23% increase in treadmill time and 20% improvement in chair 
sit-to-stand test performance found in the current study exceeded the 
changes in physical performance reported in other studies (Galvao et al., 
2006; Culos-Reed et al., 2007; Galvao et al., 2010). While Culos-Reed et al. 
(2007) reported an 11% increase in walking distance for the 6 minute walk 
test, Galvao etal. reported improvements of 7% (Galvao et al., 2006) and 4% 
(Galvao et al., 2010) for 400 m walk time. There could be a number of 
reasons for these differences in improvements in exercise performance. 
Firstly, the different tests used for measurement of physical fitness will allow 
differences in the strategy of pacing and the self-imposed physical effort on 
behalf of the participant. Use of the graded treadmill test with predefined 
speed increments in the current study and that by Bourke et al. (2011) meant 
that participants were not able to self-pace their performance in the same 
manner as they could in an assessment of time to completion such as the 
400 m walk test used by the Galvao group or the 6 minute walk test 
employed by the Culos-Reed group. Hence, exercising participants on a 
treadmill up to a pre-defined criterion for test termination could have meant 
they were encouraged to perform up to the same level of physical strain in
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repeat exercise tests, while these other forms of exercise tests could have 
been hindered by participants not feeling the need to push themselves on 
subsequent test performances. This demonstrates the importance of future 
research projects employing similar exercise tests to those previously used 
as this will allow greater comparison between studies. Additionally, the time 
spent performing aerobic exercise under supervision could also provide a 
difference between studies that could affect exercise tolerance results. In the 
current study, and that by Bourke et al. (2011), participants completed 30 
minutes of aerobic exercise in each of the 18 sessions; thus accumulating 9 
hours of supervised aerobic exercise over the duration of the study. 
Conversely, Galvao et al. (2010) asked participants to perform 15 to 20 
minutes of exercise for 24 sessions leading to completion of 6-8 hours of 
aerobic activity over the duration of the study, while in the resistance exercise 
based study of Galvao et al. (2006), and the home-based exercise studies 
performed by the Culos-Reed group, participants did not undertake 
supervised aerobic exercise. Consequently, the greater time spent 
performing aerobic exercise under supervision could be expected to have led 
to the greater increases in exercise tolerance observed, although studies 
investigating the volume of supervised activity required to gain maximum 
benefits are still warranted in this population.
In addition to evidence of increased physical performance, leisure time 
physical activity was also shown to be increased in men in the intervention 
group, with the difference between groups showing significance at the end of 
the intervention. This finding has clinical significance because Godin LSI 
quantifies the volume of activity participants were performing in addition to 
that being prescribed under the supervision of the instructor, and thus 
provides a measure of whether the increased activity they were performing 
within the supervised setting was resulting in increased activity outside of this 
environment. Being able to encourage participants to increase home-based 
activity was deemed important, as this would be the most sustainable form of 
activity for them once the intervention was completed and because previous 
evidence has shown that leisure time and household physical activity is
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associated with improvements in cardiovascular risk factors including 
hypertension, HDL-C and plasma fibrinogen concentrations (Fransson et al., 
2003). It is noted that the difference between the groups at end-point was 
removed at follow-up assessment suggesting that although participants 
would increase home-based activity while they are engaged in supervised 
sessions, the cessation of the supervision results in a decrease in activity at 
home. Clearly this provides an issue for further research as strategies must 
be employed to ensure activity levels are maintained or increased after the 
completion of supervised exercise training.
The current study also supports previous research that has shown the 
benefits of healthy lifestyle changes for overall quality of life and fatigue in 
men on ADT (Segal et al., 2003; Culos-Reed et al., 2007; Galvao et al., 2010; 
Bourke et al., 2011). Use of different measurement tools again complicates 
comparisons between studies, however, comparing the results of the current 
study against previous investigations that have used Fact-P and Fact-F 
(Segal et al., 2003; Bourke et al., 2011) shows that our findings are similar to, 
or exceed, the results reported in these studies. The difference between 
groups for quality of life at end-point assessment was greater than has 
previously been reported at the end of an exercise intervention. Bourke et al.
(2011) reported a non-significant improvement in Fact-P of 5.5 points (95% 
Cl, -4.2-15.3), while data from Segal et al. (2003) showed a statistically 
significant difference between group means at end-point assessment of a 
similar magnitude (around 5 points). Conversely, the change in fatigue at the 
end of the intervention in the current study was lower than that reported by 
Bourke and colleagues (5.4 points; 95% Cl, 0.8-10.0) but still exceeded that 
reported by Segal et al. (mean difference -1.6 points). It is worthy of note that 
our findings are the first to demonstrate mean improvements in both Fact-P 
and Fact-F exceeding the MCID after a lifestyle intervention in men on ADT.
It is of interest that change in body fat mass was found to be a strong 
predictor of the changes observed in quality of life and fatigue. Increased 
body fat mass is an established consequence of ADT (Haseen et al., 2010) 
attributed to the drastic reduction in serum testosterone concentrations with
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treatment (De Pergola, 2000), while negative changes in quality of life and 
fatigue are also accepted effects of treatment (Herr and O'Sullivan, 2000). 
Previous research however has not shown a link between these effects. 
Studies investigating predictors of the negative psychological changes with 
ADT have either not investigated, or shown no effect of body composition 
(Stone et al., 2000; Dacal et al., 2005). It could be speculated therefore that 
the difference in findings in the current study could be due to the direction of 
the association. While these previous studies have investigated whether 
body composition at a single time point predicts quality of life or fatigue at 
that time, or if negative changes in quality of life or fatigue are predicted by 
alterations in body composition, they have not examined whether positive 
changes in either psychological well-being or body composition are predictive 
of each other. With the rapid increase in body fat upon commencement of 
ADT (van Londen et al., 2008) it could be speculated that the psychological 
strain of starting more radical treatment for prostate cancer could outweigh 
the impact of increased fat mass in terms of the determinants of quality of life 
and fatigue. Conversely, it could also be possible that these results are 
simply explained by men in this population placing a greater importance on 
positive body composition changes. Further studies investigating positive or 
negative changes in psychological well-being and body composition in a 
larger cohort would be required to further understand the association 
between these effects of treatment.
Investigation of the differences in FMD cuff placement for measurement of 
changes in endothelial function in this population demonstrated large 
discrepancies between techniques. While results for the traditional distal cuff 
FMD are suggestive of reductions in cardiovascular risk across the duration 
of the study in both groups, conflicting findings were provided using the 
proximal cuff method. Furthermore, analysis of the relationship between the 
magnitude of dilatation achieved using the different techniques demonstrated 
no correlation between measures. It has previously been reported that FMD 
assessments conducted using a proximal cuff placement can be more 
challenging as a result of the occluding cuff collapsing or distorting the distal
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arterial segment being imaged (Charakida et al., 2010) and this was found to 
be the case in the current study. It was observed that arterial movement on 
cuff inflation and subsequent deflation influenced the data obtained. In such 
men use of distal cuff occlusion methods therefore provides a more reliable 
estimate of arterial dimensions.
The results from the current study support evidence that lifestyle 
interventions in men with prostate cancer treated with ADT are feasible, safe 
and well-tolerated. No changes in markers of disease progression were 
observed in the current study, which is in agreement with the findings of 
previous investigations of lifestyle interventions in men treated for prostate 
cancer (Schmitz et al., 2010). The current study did find a large effect of the 
intervention on SHBG concentrations, however this should not be deemed to 
be detrimental to prostate cancer progression. Such a decrease in SHBG 
would be expected to be responsible for the observed reduction in 
bioavailable testosterone in men in the intervention group due to the high 
affinity of SHBG to bind testosterone (Selby, 1990), and thus there should be 
a reduction in the amount of testosterone that could drive cancer progression. 
SHBG has previously been shown to increase after lifestyle interventions 
including exercise and diet in healthy adult males (Tymchuk et al., 1998; 
Longcope et al., 2000) with these effects possibly mediated by the impact of 
these interventions on insulin concentrations. Accordingly, it is noted that the 
changes observed in SHBG in the current study could also be representative 
of the effects of the intervention on insulin concentrations, and consequently 
may also be indicative of improvements in cardiovascular health. SHBG 
concentrations have been inversely associated with insulin resistance 
(Wallace et al., 2013), and thus the evidence of a difference between groups 
in SHBG at the end of the intervention could represent differences in insulin 
clearance rates and consequently variations between the groups in the risk of 
developing type II diabetes mellitus. The mechanisms that underlie such a 
relationship between SHBG and insulin levels remain incompletely 
understood however, as Wallace et al. (2013) state that it is unclear whether
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altered SHBG concentrations are a cause or a consequence of changes in 
insulin resistance.
Participant retention in the current study is comparable to that previously 
reported in exercise studies in men on ADT. Analysis of studies using 
primarily gym-based, instructor-led exercise sessions shows median 
retention rates of 89% (range 63-100%) from baseline to the end of the 
intervention (Segal et al., 2003; Galvao et al., 2006; Hansen et al., 2009; 
Galvao et al., 2010; Bourke et al., 2011), which is only marginally higher than 
that achieved in the current study (84% completed end-point assessment). It 
should also be noted that comparing retention at follow-up from the current 
study against the only other study in such a population to include a follow-up 
assessment (Bourke et al., 2011), demonstrates that loss to follow-up in the 
current study was far less than previously reported (80% completion of 
follow-up assessment in the current study compared to 56% completion 
previously reported).
Attendance at instructor-led exercise sessions was also equal to, or in 
excess of, attendance rates previously reported in exercise studies using 
instructor-led, gym-based exercise with men on ADT (Segal et al., 2003; 
Galvao et al., 2010; Bourke et al., 2011), while compliance with home-based 
exercise was marginally lower than has previously been reported (Bourke et 
al., 2011). We observed a small, but insignificant, decrease in attendance at 
instructor led sessions and compliance with home-based exercise over 
weeks 7 to 12 in comparison with weeks 1-6, which could be associated with 
a slight decrease in training impulse when participants switch from having 
contact with the instructor twice a week to only once a week. Regardless of 
this effect being observed with decreasing contact time, the current study still 
supports previous evidence suggesting that, in men with prostate cancer, 
greater benefits are accrued through supervised exercise training in 
comparison with home-based exercise (Baumann et al., 2012). Studies in 
men treated with ADT for prostate cancer using supervised exercise training 
have shown improvements in psychological well-being, physical function and 
muscle mass (Segal et al., 2003; Galvao et al., 2010; Bourke et al., 2011),
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however, only improvements in exercise test performance have been 
reported in studies using home-based activity (Culos-Reed et al., 2007; 
Culos-Reed et al., 2010). In addition, the reductions in measures of exercise 
tolerance, quality of life and fatigue observed between end-point and follow- 
up in the current study and that by Bourke et al. (2011) are suggestive of 
patients not being able to maintain performance levels, and the subsequent 
health benefits, once supervision is removed.
In conclusion, this study demonstrates that a lifestyle intervention including 
supervised exercise training and dietary advice can lead to statistically 
significant improvements in activity levels, exercise tolerance, body 
composition, quality of life and fatigue in men with prostate cancer treated 
with ADT. The current study also provides evidence that such an intervention 
can have beneficial effects on markers of cardiovascular risk, including 
endothelial function and diastolic blood pressure, although the change in 
these measures must be investigated in a larger cohort before this response 
can be confirmed. Furthermore, our findings support evidence that lifestyle 
interventions are well tolerated in this patient group and demonstrate that 
greater benefits are achieved when patients receive supervised exercise 
training compared to when they are left unsupported.
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10.0 GENERAL DISCUSSION
This general discussion is designed as an appraisal of the research studies 
completed in this thesis. The key findings are reviewed and the limitations of 
these studies are discussed with specific regards to the implications for future 
research in this area.
10.1 Main findings
The key findings of these studies are:
1. Endothelial function is reduced in men with prostate cancer treated 
with ADT in comparison with a group of matched controls. This finding is of 
scientific interest as these results directly contradict the findings of the only 
previous study investigating endothelial function in men treated with ADT 
(Herman et al., 1997), yet they are congruent with the majority of the 
scientific literature which describes an increase in cardiovascular risk in men 
treated with ADT. Although these findings must be confirmed by further 
studies using a larger sample size, evidence of endothelial dysfunction in 
men on ADT provides a possible physiological link between the evidence of 
increased prevalence of cardiovascular risk factors (e.g. increased fat mass, 
insulin resistance, hyperlipidemia) and data suggesting men on ADT are at 
increased risk of cardiovascular events. Furthermore, this evidence 
demonstrates that ultrasound assessment of FMD in the brachial artery can 
provide a suitable method for monitoring cardiovascular risk in this patient 
group. Further studies monitoring longitudinal changes in FMD in this patient 
group with baseline assessments performed prior to commencement of ADT 
would provide even greater insight into the effects of this form of treatment on 
vascular function.
2. Supervised exercise training and dietary advice could have beneficial 
effects on cardiovascular risk in men treated with ADT for prostate cancer. In
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addition to statistically significant differences being observed between groups 
in the changes in body composition over the duration of the intervention, the 
effects of the intervention on FMD and blood pressure are suggestive of a 
reduction in cardiovascular risk. Although the changes in these latter 
measures did not achieve the alpha of 0.05 required for statistical 
significance, the magnitude of the changes observed within the intervention 
group, and the evidence of meaningful effect sizes for the difference between 
groups for the change from baseline, support the notion of a benefit of 
participation in the intervention. In consideration of previous studies 
describing an increase in cardiovascular risk in men treated with ADT (Levine 
et al., 2010; Bourke et al., 2012), our data provides encouraging evidence of 
the benefits of such an intervention. Investigation of the changes in these 
measures in a larger cohort will be required before such an effect can be 
described with confidence.
3. Improvements in physical and mental well-being are observed after a 
lifestyle intervention including supervised exercise training and dietary advice 
in men with prostate cancer treated with ADT. Our findings support those 
previously reporting benefits to exercise tolerance, quality of life and 
perceptions of fatigue in men treated with ADT taking part in a lifestyle 
intervention (Segal et al., 2003; Galvao et al., 2010; Bourke et al., 2011). 
These findings are of clinical importance in consideration of the reduction in 
general well-being reported in men treated in this manner (Casey et al., 
2012). Greater promotion of physical activity is warranted in men on ADT to 
help to reduce the burden of such side effects of treatment.
4. Improvements observed over a period of supervised exercise training 
and dietary advice are not maintained after cessation of the supervision. This 
finding is of clinical importance for the development of further studies 
investigating the benefits of lifestyle interventions in this population and for 
health-care providers considering implementing lifestyle interventions in men 
on ADT. Due to the logistical and economical strains of providing on-going 
support for patients it is imperative that the benefits accrued from 
participating in interventions such as this can be maintained once the
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supervision is removed. Our finding of a reduction in activity levels and 
negative changes in measures of physical and mental well-being once the 
supervised sessions were completed could be considered a weakness of the 
implementation of the intervention in our study. Strategies to ensure that 
patients can maintain the benefits achieved over a period of supervision must 
be designed and tested in this population.
10.2 Study limitations and implications for future research
10.2.1 Study 1: Cross-sectional evaluation o f endothelial function in 
men on ADT
The case-control design of this study provides one limitation which should be 
addressed in future research. Although groups were well-matched for many 
confounding variables (e.g. age, body mass, smoking status and history of 
cardiovascular disease), comparing the results of men treated with ADT for 
prostate cancer against a separate group of control men could result in 
variables not measured in the current study and unrelated to androgen 
concentrations influencing the findings (e.g diet, personal stress levels and 
family history of cardiovascular disease). Moreover, variability of FMD is 
thought to be lower within participants rather than between individuals 
leading to possible errors in findings between groups due to FMD variation. 
Further studies should therefore investigate longitudinal changes in FMD in 
men on ADT with initial assessments undertaken before starting treatment. 
Although this was beyond the scope of the current study, our results suggest 
that FMD is a viable measure of cardiovascular risk in this population and 
thus demonstrate longitudinal assessments of FMD in men on ADT for 
prostate cancer are warranted.
In addition, the lack of a control group who have prostate cancer but are not 
treated with ADT means that the effects of the treatment cannot be 
distinguished from the effects of the disease. Recent evidence has 
demonstrated that men with prostate cancer not receiving treatment (under 
active surveillance) were at increased risk of cardiovascular disease
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compared with the general male population (Van Hemelrijck et al., 2010), 
possibly indicating a direct effect of prostate cancer on cardiovascular 
disease risk. However, risk factors for prostate cancer include factors that 
also contribute to increased cardiovascular risk, such as increased body 
mass. Thus, the evidence of increased risk of cardiovascular disease with 
prostate cancer might be the result of shared risk factors instead of a direct 
impact of prostate cancer. Controlling for the effects of disease in the current 
study was considered outside of the aims of the study which sought to 
investigate the impact of ADT in the treatment of prostate cancer on 
cardiovascular risk factors. This is considered pertinent as the use of ADT for 
reasons other than the treatment of prostate cancer would be very rare. It 
was also considered that recruitment of a suitable control group of men 
matched for disease stage and health history would provide logistical and 
ethical problems. Men with prostate cancer not treated with ADT would be 
expected to have differences in their disease or health contradicting ADT use 
making them poorly matched with the ADT group. Therefore, recruitment of 
suitably matched men would require delaying treatment initiation or 
suspending an active treatment program to allow measures to be taken; both 
of which would not be considered ethical. These are issues which further 
research studies in this area must consider in their study design.
The relatively small sample size is a limitation of our study. Only recruiting 
twenty men per group means the findings must be confirmed in studies 
investigating the effects of treatment with ADT on endothelial function in 
larger cohorts. Furthermore, future studies must ensure inclusion and 
exclusion criteria allow the results to be a generalisable as possible. Our 
sample is considered more representative of the wider population from which 
they were recruited than previous investigations of endothelial function in 
men on ADT (Herman et al., 1997) in consideration of the inclusion of men 
with cardiovascular comorbidities (American Heart Association, 2013) and 
the physically inactive nature of our sample (British Heart Foundation Health 
Promotion Research Group, 2012). However, because men with ADT were 
sampled from those entering the intervention study meeting the inclusion
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criteria for the cross-sectional evaluation, our results can only be generalised 
to a small proportion of men. Of the 837 men under treatment with ADT who 
were screened for participation only 323 met the inclusion criteria for the 
intervention study (39% of those initially screened), and then only 76% of 
men in the intervention study met the criteria for inclusion in the cross- 
sectional study. Assuming this percentage of men meeting the criteria for 
inclusion in the cross-sectional study could be found in those meeting the 
criteria for the intervention study, it would suggest that only 29% of men on 
ADT under the local Urology clinic (n = 245) would be suitable for 
participation (76% of 323, expressed as a percentage of 837). Clearly, further 
research in this area must aim to include a greater proportion of men treated 
in this manner.
10.2.2. Study 2: Lifestyle intervention in men with prostate cancer 
treated with ADT
As is discussed briefly in the experimental discussion (9.0 Discussion: Study 
2), the sample size and patient attrition rates limit the findings of the study. 
This study was powered to detect a 2.6 ± 3.0% difference in relative FMD, 
with the sample size taking account of an expected 10% attrition rate at the 
end of the intervention. However, the loss of 8 men at this stage (16% of the 
initial sample), combined with a higher than expected variance means that 
our study was under powered to detect a difference of that magnitude 
between groups. Nevertheless, the 95% Cl for the difference detected, 
suggests that an improvement in FMD of up to 4% is feasible, potentially 
resulting in a clinically meaningful reduction in cardiovascular risk in this high- 
risk group. Thus, investigation of changes in endothelial function over the 
duration of a lifestyle intervention must be performed in studies with larger 
samples. In addition to providing a clearer picture of the effects of a lifestyle 
intervention on endothelial function, a larger sample size could also provide 
greater evidence for the changes in blood pressure observed between 
groups, as here again our study was limited in its findings by lack of statistical 
power.
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The findings of the intervention study are also influenced by participants in 
the control group increasing their physical activity levels during the study. It 
can be expected that increased physical activity in the controls will have had 
knock-on effects for changes in outcomes observed in this group, and thus 
will also have influenced the differences found between groups and the 
magnitude of the effect that can be attributed to the intervention. Although 
little change was observed in exercise tolerance, Godin LSI scores for men in 
the control group increased from baseline by 3.0 ±11.6 points and 7.2 ± 24.3 
points at end-point and follow-up, respectively. These findings are of little 
surprise, as previous studies have reported that such a response is often 
found in exercise intervention studies (Courneya et al., 2004). This stands to 
reason, because for patient recruitment the potential benefits accrued 
through healthy lifestyle changes are provided to the participant as incentive 
to participate, and thus it must be expected that those not in the intervention 
will still want to achieve such benefits. It is notable however that the increase 
in activity and small improvements in outcome measures observed in the 
controls were generally found after the mid-point assessment. This leads to 
speculation that the feedback given on the change in measures between 
baseline and mid-point acted as incentive for these individuals to make such 
changes. Understanding whether such feedback was a causal factor in 
increased activity in the control group would be of interest as this information 
could help to guide those looking to increase activity in this population 
without performing supervised interventions. Clearly greater effort should go 
in to reducing such an effect in future studies, and thus, methods to achieve 
this must be considered.
Conversely however, it must also be noted that the current study may be 
limited by some participants in the exercise group having no response or 
adverse metabolic responses to the increase in physical activity in agreement 
with the work of Timmons et al. (2010) and Bouchard et al. (2012). Although 
increased physical activity has been widely associated with improvements in 
fitness and benefits to numerous cardiometabolic risk factors such as blood 
pressure, blood lipids, insulin and glucose concentrations, these recent
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studies have suggested not everyone will have such responses. The work of 
Timmons et al. (2010) demonstrated that some individuals may have a 
genetic variation limiting gains in aerobic fitness to exercise training, while 
the more recent work of Bouchard et al. (2012) has described that around 10% 
of people can have negative responses in measures of such cardiometabolic 
risk factors after exercise training. In the context of the current study these 
findings could suggest that the lack of greater difference between groups is 
not in-fact due to an increase in activity in the control group, but the result of 
no response or negative responses from some members of the intervention 
group decreasing the magnitude of the difference between groups. Although 
such limitations are difficult to overcome these issues must be considered in 
further studies in this area. Genetic testing prior to study enrolment could 
distinguish those who could be non-responders, while more tailored training 
could be beneficial for adverse responders.
As is mentioned in the limitations of the first study, the generalisability of 
results is an additional limitation of the second study. The fact that only 39% 
of men treated with ADT identified in clinic met the inclusion criteria for 
participation demonstrates that greater effort must be placed on ensuring 
future studies are as inclusive as possible. Although excluding men was 
necessary for patient safety and to increase the scientific integrity of the 
study, it means that the results are only applicable to men with prostate 
cancer treated with ADT who have stable disease, are currently inactive and 
who have no comorbidities that could have limited their participation in the 
study. To achieve greater inclusion however the methods for participant 
recruitment must also be reviewed, as it can be speculated that selection 
bias could be inherent in recruitment from clinics performed by the primary 
study researcher. It is possible that men seen in clinic could be deemed 
unsuitable to participate based upon appearance rather than medical 
information or verbal confirmation of meeting exclusion criteria.
Similarly, ensuring that the assessments and intervention undertaken in the 
study are as inclusive as possible for those consenting to participate is a 
further area for consideration for future research. The finding of lower
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baseline exercise tolerance and increased fatigue amongst men dropping out 
of the current study prior to the end-point assessment is in agreement with 
previous research on determinants of attrition from physical activity programs 
for older adults (Jancey et al., 2007). As such, this could have a number of 
implications for further research in these men. Measures of fatigue or 
exercise tolerance could be used to screen out those who were more likely to 
be non-compliant with the aim of decreasing attrition rates in such studies. 
Alternatively, greater efforts could be made to increase retention of patient 
groups with low baseline fitness and higher fatigue. This would seem the 
preferable option, as it is the participants with the lowest exercise capacity 
and greatest fatigue at baseline that could be expected to gain the greatest 
benefits from participation in such studies.
It is evident that further research is also warranted to investigate the volume 
of exercise training required to gain health improvements in such a 
population. Our intervention was designed to be clinically relevant and so the 
duration and intensity of exercise completed within the exercise sessions was 
tailored to the ability and tolerance of individual participants to elicit a heart 
rate within a specified range, and then progressed as the participants 
changing fitness and strength permitted. However, the weakness inherent in 
such an approach is that the intensity and duration of exercise required to 
achieve this response varied greatly between participants meaning the exact 
volume of activity performed cannot be specifically noted. This is also the 
case with home-based activity where participants were asked to use RPE to 
monitor exercise intensity. Although use of RPE provides a guide for 
monitoring exercise intensity suitable for this population who would be 
unlikely to have access to more sophisticated equipment for intensity 
monitoring, and despite participants been given instructions as to how to use 
RPE to monitor activity, this again means the activity volume cannot be 
specifically calculated.
Furthermore, while this study and that of Bourke et al. (2011) demonstrate 
benefits from a lifestyle intervention with progressively decreasing contact 
time, the ideal frequency and duration of supervised sessions cannot be
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deduced from these studies. It has been shown that greater benefits are 
gained by prostate cancer patients participating in supervised exercise 
training compared with unsupervised home-based activity (Baumann et al., 
2012). However, for such exercise interventions to be adopted as part of 
standard clinical practice, further information on the volume of training 
needed is required to understand the supervision patients will require to gain 
health benefits, and to enable health authorities to ascertain whether 
supplying such additional care would be cost effective.
Lastly, the duration of follow-up can be considered an additional limitation of 
the current study and one that further research in this area could look to 
address. Although this is only the second exercise study in this population to 
include a follow-up assessment (Bourke et al., 2011), it would be of interest 
for follow-up to be conducted over a longer duration as this could allow 
investigation of whether or not participation in such an intervention can lead 
to long-term reductions in the incidence of cardiovascular events and 
mortality. Furthermore, undertaking long-term follow-up of patients could 
provide greater evidence on whether increasing activity levels through 
participation in such an intervention can reduce prostate cancer specific 
mortality, as retrospective studies have shown that men with higher activity 
levels have a reduced rate of disease progression or mortality (Kenfield eta l., 
2011; Richman et al., 2011).
10.3 Summary
These studies provide novel data on markers of cardiovascular health in men 
treated with ADT for prostate cancer. The findings of our studies and their 
implication for future research demonstrate that the cardiovascular health of 
this patient group remains an area of scientific interest. Further research in 
this area is clearly warranted to build on the data we have presented.
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Participants needed...
Participants needed for a research study undertaken by Sheffield 
Hallam University in collaboration with Sheffield University and 
Sheffield Teaching Hospitals.
Men aged 60 years or older are needed to form part of a control 
group, whose results will be compared to patients with prostate
cancer.
The study aims to investigate cardiovascular health in men with 
prostate cancer on androgen deprivation therapy. This study 
hopes to advance knowledge on the cardiovascular effects of 
treatment options for prostate cancer patients.
Men willing and eligible to take part will be required to attend 1 
testing session lasting approximately 90 minutes. During this 
session your vascular function wiii be assessed and a venous 
blood sample will be taken.
Testing will take place at the Centre for Sport and Exercise 
Science, Sheffield Hallam University, Collegiate Campus, 
Ecclesall Road, Sheffield.
If you are interested in volunteering to take part in this project, or 
would like any further information, please contact Stephen Gilbert,
study researcher.
Telephone: 0114 225 5413
Email: s.gilbert@shu.ac.uk
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Participant Information Sheet- Controls Sheffield Hallam university
Version 1: 8th June 2010
Cardiovascular health in prostate cancer patients on androgen 
deprivation therapy
Q: What is the main purpose of this study?
A: Men with prostate cancer often have treatment to reduce the level of testosterone (male 
hormones) in their blood (Androgen Deprivation Therapy). Some men who are receiving this 
treatment experience side effects such as deterioration o f cardiovascular health. The aim of this 
study is to see whether men receiving androgen deprivation therapy experience decreased arterial ' 
function which might be associated with increased risk of cardiovascular events.
Q: Why have I been approached about this study?
A: To investigate the effects prostate cancer and its drugs on cardiovascular health a group of 
participants without these conditions are required to act as controls. You have been approached to 
be a member o f this control group.
Q: What does being in the ’control group' mean?
A: Being in the 'control group' simply means your results will be compared against those of 
patients who have prostate cancer and are on androgen deprivation therapy. This will allow us to 
assess differences in results brought about by cancer or by the type of treatment.
Q: What is required of me if I decide to take part in this study?
A: All participants who are interested in entering the study will be invited to meet a researcher 
from The Centre for Sport and Exercise Science at Sheffield Hallam University. You will have 
the opportunity to go through this information sheet again and ask any questions you might have 
about the study. You will be given a consent form to take home and complete. This is so you can 
take time to decide whether or not you want to take part in the study.
The assessment:
If you decide to take part you will be asked to attend the assessment session which will be held at 
The Centre for Sport and Exercise Science at Sheffield Hallam University, Collegiate Crescent, 
Sheffield. You should bring your completed consent form with you. The researcher will take your 
medical history and your vascular function will be examined. You will be asked to come to this 
session in the morning, following an overnight fast and having avoided products containing 
vitamin C, tobacco and caffeine for 6 hours beforehand. Assessment of vascular function requires 
a pneumatic blood pressure cuff to be inflated around the forearm for 5 minutes and then released.
For 1 minute before cuff inflation, and 5 minutes after cuff deflation, an ultrasound probe will be 
placed on the skin just above the elbow to image the artery inside the upper arm. Inflation of the
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cuff around the arm can result in a 'pins and needles' sensation in the fingers, but once the cuff is 
released this feeling quickly goes away. After 15 minutes of rest a second scan will be performed 
for 7 minutes. This time the cuff will not be used, but after the first minute of scanning you will 
be asked to take 400 pi of glyceryl trinitrate (GTN). GTN is taken via a spray under the tongue 
and may cause slight feelings of nausea or light headedness, but these feelings should go away 
within 10 minutes. Throughout the vascular function tests blood pressure will be taken from an 
additional cuff around the opposite arm.
After the vascular function testing a venous blood sample will be drawn from your arm and a 
finger tip sample will also be taken for analysis of biomarkers of cardiovascular health. 
Additionally your body composition, body weight and height will also all be assessed.
Q: How long will the study last?
A: The study will only require the one assessment visit. This assessment will take approximately 
90 minutes to complete.
Q: What are the possible benefits of taking part in this study?
A: We cannot promise that the study will help you, but the information which we obtain might 
help improve the rehabilitation of prostate cancer patients.
Q: Are there any side-effects of taking part?
A: Taking glyceryl trinitrate during the assessment visit can make some people feel light headed 
or nauseous for around 10 minutes afterwards. However, we will ensure you are lying down 
when you take this and stay lying down until the symptoms have subsided.
Blood sampling can also make some people feel light headed, but you will remain lying down 
until this process has been completed. Venous blood sampling can result in bruising in some 
people but this will be minimised through maintaining pressure on the site after sampling.
Q: What are the possible disadvantages and risks of taking part?
A: The potential for risks to occur will be minimised.
In the event that something does go wrong during the research study, there are no special 
compensation arrangements. If you are harmed then you would have access to the normal 
university complaints mechanism (see below).
If you are harmed and this is due to someone's negligence then you might have grounds for legal 
action for compensation, but you could have to pay your legal costs.
Q: Do I have to take part?
A: It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form.
Q: What if I do not wish to take part?
A: Your participation is entirely voluntary. If you decide not to take part, this will not affect the 
standard of care you receive from any other health professional.
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Q: What if I change my mind during the study?
A: You are free to withdraw from the study at any time without giving a reason.
Q: What will happen to the information from the study?
A: The overall conclusions of the study will be available to you, however it will not be possible 
to produce an individualised report of your results.
Q: Will my taking part in this study be kept confidential?
A: The confidentiality o f our participants and the data which this study will generate is o f utmost 
importance. All data from this study will be annonymised. In brief, you will be allocated a 
number during the study. We will need to obtain your permission to allow the research team 
access to your information collected during the study. This is one of the clauses, which you will 
sign in agreement on the official consent form.
Our procedures for handling, processing and storage of and destruction of data are compliant 
with the Data Protection Act 1998.
Q: Who is organising and funding the research?
A: The research is organised and sponsored by The Centre for Sport and Exercise Science, 
Sheffield Hallam University in collaboration with the University of Sheffield Medical School and 
Sheffield Teaching Hospitals NHS Foundation Trust.
Q: Who has reviewed this study?
A: The Sheffield Hallam University Research Ethics Committee has reviewed this study.
Q: What if I have further questions?
A: If you have any further questions with regards to this study you may phone:- 
Name: Professor Edward Winter (Primary investigator) Tel: 0114 225 4333 
Name: Stephen Gilbert (Project co-ordinator) Tel: 0114 225 5413
Q: What if I wish to complain about the way this study has been conducted?
A: If you have any cause to complain about any aspect of the way in which you have been 
approached or treated during the course of this study, you will be able to contact the normal 
University complaints procedure
Liz Winders (University Secretary and Registrar) Tel: 0114 225 2051 
You can also complain to any individual of the research team 
Name: Professor. Edward Winter (Primary investigator) Tel: 0114 225 4333 
Name: Stephen Gilbert (Project co-ordinator) Tel: 0114 225 5413
Thank you for taking the tim e to consider participating in this study 
Mr Stephen Gilbert (Project co-ordinator)
Telephone number: 0114 225 5413 
Email: s.gilbert@shu.ac.uk
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APPENDIX 5
PARTICIPANT SCREENING QUESTIONNAIRE
Cardiovascular health in prostate cancer patients on androgen deprivation
therapy
Sheffield Hallam University
Please answer each of the following questions
Name:
Address:
Postcode:
Telephone:.
GP:
Date of Birth:
Email:
Practice:
Are you currently taking any medication? Yes | | N o | |
If yes, please list your medication and dosage in the table below.
Medication name Dose Frequency, e.g. times per 
day/wk/month
Duration of medication, e.g. 
’initiated 6 months ago'
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Have you ever Y N Have any immediate Y N Have you recently Y N
had? family had? had?
High blood □ □ Heart attacks □ □ Chest pain/ □ □
pressure discomfort
Any heart trouble □ □ High blood pressure □ □ Shortness of □ □
breath
Arterial disease □ □ High Cholesterol □ □ Heart palpitations □ □
Lung disease □ □ Stroke □ □ Dizzy spells □ □
Asthma □ □ Diabetes □ □ Frequent □ □
headaches
Diabetes □ □ Early death □ □ Frequent colds □ □
Epilepsy □ □ Other family illness □ □ Back pain □ □
Arthritis □ □ Orthopaedic □ □
problems
If you answered yes to any of the above, please give brief details
Do you currently have any form of muscle or joint injury? Yes Q  No
If yes, please give details _______________________________________________________
Have you ever had an adverse reaction to nitrates? Yes Q  No
As far as you are aware, is there anything that might prevent you Yes Q  No
from successfully completing the assessments outlined to you?
If blood is being taken please also answer the following questions in the box.
Yes No
Are you currently suffering from any known infection or illness?
Have you had jaundice within the previous year?
Have you ever had any form of hepatitis?
Are you HIV antibody positive?
Have you had unprotected sexual intercourse with any
person from an HIV high-risk population?
Have you ever been involved in intravenous drug use?
Are you hemophiliac?
3. Do you currently engage in any physical activity?
If yes, what type?
On average.. How often? times
/week
4. a. Are you currently a smoker?
b. If yes, how many do you smoke?
c. If no, are you a previous smoker?
d. How long is it since you stopped?
How long?
Yes
Yes
time/
session
No
per day
No
years
a. Do you drink alcohol? Yes / No
b. If yes, do you usually have?
An occasional 
drink
A drink 
everyday
More than one 
drink a day
As far as I am aware the information I have given is accurate.
Print nam e:.................................................................. D ate :....... / ........../
Signature: ............................................................................................
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APPENDIX 6
Sheffield Hallam University
PARTICIPANT CONSENT FORM
Version 1: 8th June 2010 
Cardiovascular health in prostate cancer patients on androgen deprivation therapy.
Participant Identification Number for this study:
Investigators: Mr. Derek Rosario, Professor Edward Winter, Dr Garry Tew, Dr Liam 
Bourke, Professor John Saxton, Stephen Gilbert
Name of researcher: Mr Stephen Gilbert Tick box
1. I confirm that I have read and understood the information sheet dated —
08/06/2010 (Version 1) for the above study. I have had the opportunity to _____
consider the information, ask questions and have had these answered
satisfactorily.
2. I understand that my participation is voluntary and that I am free to
withdraw at any time, without giving any reason, without my medical_____________
care or legal rights being affected.
3. I understand that relevant sections of any of my data collected during the 
study may be looked at by responsible individuals o f the research team, 
where it is relevant to my taking part in this research. I give permission for 
these individuals to have access to this data.
4. I agree to take part in the above study.
Name o f  Participant Date Signature
Name o f individual taking consent (if  
not researcher)
Date Signature
Researcher Date Signature
2 copies to be kept: 1 for site file; 1 for participant.
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APPENDIX 7
Godin Leisure-Time Exercise Questionnaire
During a typical 7-Day period (a week), how many times on the average do 
you do the following kinds of exercise for more than 15 minutes during your 
free time (write on each line the appropriate number).
a) STRENUOUS EXERCISE 
(HEART BEATS RAPIDLY)
(e.g., running, jogging, hockey, football, soccer, 
squash, basketball, cross country skiing, judo, 
roller skating, vigorous swimming, vigorous long 
distance bicycling)
b) MODERATE EXERCISE 
(NOT EXHAUSTING)
(e.g., fast walking, baseball, tennis, easy 
bicycling, volleyball, badminton, easy swimming, 
alpine skiing, popular and folk dancing)
c) MILD EXERCISE 
(MINIMAL EFFORT)
(e.g., yoga, archery, fishing from river bank, 
bowling, horseshoes, golf, snow-mobiling, easy 
walking)
During a typical 7-Day period (a week), in your leisure time, how often do 
you engage in any regular activity long enough to work up a sweat (heart 
beats rapidly)?
Times Per 
Week
Often Sometimes Rarely/Never
i - D 2 - D 3 - D
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APPENDIX 8
Sheffield Teaching Hospitals h)lr$\
NHS Foundation Trust
Date Sheffield Hallam
Dear
We would like to inform you about a new research study for men who are 
undergoing hormonal treatment for prostate cancer. Consultants from the urology 
unit at The Royal Hallamshire Hospital and health researchers at Sheffield Hallam 
University are working together to investigate how exercise and diet can affect men's 
health and quality o f life.
This study will be asking men with a diagnosis o f prostate cancer to undertake a 
period o f exercise training - under the guidance of a trained exercise specialist. 
Dietary advice will also be offered. We hope to gain a better understanding o f the 
effects o f exercise and diet on prostate cancer related health.
Please find enclosed a patient information sheet, which describes the study in detail 
and answers the most frequently asked questions.
If you are interested in participating in this study, please return the tear-off slip 
below, in the envelope provided, as soon as possible. One o f the study researchers 
(Stephen Gilbert 0114 225 5413 or Liam Bourke 0114 225 5865) will then contact 
you and will gladly answer any further questions you may have.
Yours sincerely,
Mr. Derek Rosario
Consultant Urologist, Academic Urology Unit, The Royal Hallamshire Hospital.
THE FEASIBILITY OF A COMBINED PROGRAMME OF EXERCISE AND 
DIETARY ADVICE IN THE TREATMENT OF PROSTATE CANCER 
PATIENTS.
Yes, I am interested in taking part in the above named study. I understand 
that a member of staff will be contacting me, regarding this study.
No, I am not interested in taking part in the study
Full Name (please print): 
Telephone Number: __
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APPENDIX 9
Sheffield Teaching Hospitals l/Vr/*")
NHS Foundation Trust Sheffield Hallam University
The feasibility of a combined programme of exercise and 
dietary advice in the treatment of prostate cancer patients.
Patient Information Sheet
Version 6: 19th November 2010
Q: What is the main purpose of this study?
A: The aim of this study is to see whether men receiving androgen deprivation 
therapy (ADT) for prostate cancer might benefit from a supervised programme of 
exercise over twelve weeks. We would like to assess the effects o f regular 
exercise on cardiovascular function, general feeling o f well-being and on the 
body's ability to fight off cancer cells.
Q: Why have I been approached about this study?
A: You have been identified by the doctors treating you at the Royal Hallamshire 
Hospital as a suitable patient for this study because you are being treated for 
prostate cancer.
Q: What is required of me if I decide to take part in this study?
A: All patients who are interested in entering the study will be invited to meet a 
researcher from The Centre for Sport and Exercise Science at Sheffield Hallam 
University. You will have the opportunity to go through this information sheet 
again and ask any questions you might have about the study. You will be given a 
consent form to take home and complete. This is so you can take time to decide 
whether or not you want to take part in the study.
Your initial assessment:
If you decide to take part you will be asked to attend The Centre for Sport and 
Exercise Science at Sheffield Hallam University on Collegiate Crescent, 
Sheffield. You should bring your completed consent form with you. The 
researcher will take your medical history, your vascular function will be 
examined and a blood sample will be taken. You will be asked to come to this 
session in the morning, following an overnight fast and having avoided products 
containing vitamin C, tobacco and caffeine for 6 hours beforehand. During the 
vascular function tests you will be required to lie as still as possible whilst the 
ability of the artery in your upper arm to contract and relax is examined. The artery 
in your upper arm will be imaged using ultrasound whilst a blood pressure cuff is 
inflated around your forearm for 5 minutes and a small hand-gripping exercise is 
performed. Inflation of the cuff may result in a 'pins and needles' sensation in the 
fingers and slight discomfort in the wrist, but this will go away when the cuff is
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released. Once the cuff is deflated arterial scanning will be maintained for a further 
5 minutes. After a 15 minute rest period a second scan will be performed where 
you will take 400 pi of glyceryl trinitrate (GTN), followed by a further 6 minutes 
of arterial scanning. GTN is taken by a spray under the tongue and may cause 
slight feelings of nausea or light headedness, but these feelings should go away 
within 10 minutes. Throughout the vascular function tests blood pressure will be 
taken from an additional cuff around the opposite arm.
You will be asked to attend a second session at the centre within the same week 
to complete a series of physical tests. These will include walking on a treadmill, 
performing a sitting-to-standing task, measuring your upper limb strength, taking 
your blood pressure, body weight, body composition and height. You will be 
asked to complete a set of questionnaires. Two brief questionnaires will ask you 
about your physical activity habits. Additionally there will be three 
questionnaires to complete that will ask about your feelings of fatigue, your 
quality of life and your physical function at the moment. We will also ask you to 
complete a questionnaire about your food intake. The questionnaires will take 
approximately 15 minutes to complete. We will ask you to take home and wear a 
small device (accelerometer) which measures your level of physical activity 
throughout the day. It needs no adjustment or setting, you simply wear it on a 
belt around your waist (from first thing in the morning, until going to bed at 
night).
Q. What checks take place before I exercise?
A. You will be asked to fill out a medical screening questionnaire before you 
undergo any assessments or partake in any exercise.
Q. What happens after the initial assessment?
A. Half the men taking part will be allocated to an exercise programme and the other 
half will be allocated to their ‘usual care’. This is a process called 
‘randomisation’ which is routine in such studies. Figure 1 on the last page gives 
further details of the randomisation process.
Q: What will I have to do if I am allocated to the exercise and dietary advice 
group?
A: You will be asked to attend The Centre for Sport and Exercise Science at 
Sheffield Hallam University, Collegiate Crescent Campus (off Ecclesall Road) 
twice-weekly for six weeks. You will perform a range of aerobic exercises 
(indoor walking, cycling etc) and resistance exercises under the supervision of a 
trained therapist. You will also receive infonnation about how to achieve a 
healthy diet. In addition you will be asked to perfonn a set of exercises at home 
once per week during this period. After six weeks, you will attend the centre 
once per week and to exercise at home twice per week for a further six weeks. 
You will be asked to wear your accelerometer during certain weeks.
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Q: What will I have to do if I am allocated to the usual care group?
A: You will be asked to continue with your usual daily routine. You will only be 
required to attend the Centre for Sport and Exercise Science for assessment 
visits which will be at the beginning, middle and end of the 12-week study 
period and at 27 weeks for a follow up. We will monitor your physical activity 
by telephoning you a few times and by asking you to wear an accelerometer 
during certain weeks.
Q: What will the assessment visits entail?
A: All patients will attend regular assessments throughout the study - at the
beginning of the study, the 7th and 13th weeks and at follow up. At each 
assessment we repeat all the measurements that are described in the previous 
section “...your initial assessment”.
Q: How long will I have to exercise for?
A: Patients randomised to the exercise group will be asked to exercise continuously 
for up to ten minutes at a time, accumulating thirty minutes of moderate 
intensity aerobic exercise, plus up to ten minutes of resistance exercise. Each 
exercise session will last for approximately 40-50 minutes in total. All exercises 
will be tailored to your level of ability and be carefully supervised and you will 
be shown how to use the equipment.
Q: How long will the study last?
A: The exercise programme will last for 12 weeks and you will remain in the study 
for 26 weeks. We will monitor your progress throughout the study with regular 
assessments.
Q: What are the possible benefits of taking part in this study?
A: We cannot promise that the study will help you, but the information which we 
obtain might help improve the care of prostate cancer patients.
Q: Are there any side-effects of taking part?
A: If you haven't exercised for a while, exercise might initially make you feel tired 
and you could feel slightly breathless, but as you do it more regularly you will 
feel increasingly better. Such exercise might improve your walking ability and 
quality of life.
Additionally, taking glyceryl trinitrate in the initial assessment can make some 
people feel light headed or nauseous for around 10 minutes afterwards. 
However, we will ensure you are lying down when you take this and stay lying 
down until the symptoms have subsided.
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Q: What are the possible disadvantages and risks of taking part?
A: The potential for risks to occur will be minimised by careful assessment before 
and supervision whilst you exercise. The likelihood o f anything untoward 
happening during the exercise will be minimal. Trained personnel will take a 
blood sample from you which may cause slight temporary discomfort.
In the event that something does go wrong during the research study, there are no 
special compensation arrangements. If you are harmed then you would have 
access to the normal NHS complaints mechanism (see below). If you are harmed 
and this is due to someone's negligence then you might have grounds for legal 
action for compensation, but you could have to pay your legal costs.
Q: If I decide to participate, will my GP be notified?
A: With your consent, we will write and inform your family doctor that you are 
taking part in this study.
Q: What if I do not wish to take part?
A: There is no compulsion on you to take part. Your participation is entirely
voluntary. If you decide not to take part, this will not affect the care you receive 
from the hospital or any other health professional.
Q: What if I change my mind during the study?
A: You are free to withdraw from the study at any time without it affecting your 
future treatment.
Q: What will happen to the information collected during the study?
A: The overall conclusions o f the study will be available to you; however it will not 
be possible to produce an individualised report o f your performance.
Q: Will my taking part in this study be kept confidential?
A: The confidentiality o f our patients and the data which this study will generate is 
of utmost importance. All data from this study will be anonymised. In brief, you 
will be allocated a number during the study. We will need to obtain your 
permission to allow the research team access to your medical records and to 
information collected during the study. This is one o f the clauses, which you will 
sign in agreement on the official consent form.
Our procedures for handling, processing and storage o f and destruction of data 
are compliant with the Data Protection Act 1998.
Q: Who is organising and funding the research?
A: The research is organised and sponsored by The Centre for Sport and Exercise 
Science, Sheffield Hallam University in collaboration with the University of  
Sheffield Medical School and Sheffield Teaching Hospitals NHS Foundation 
Trust.
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Q: Who has reviewed this study?
A: The Sheffield Research Ethics Committee has reviewed this study.
Q: What if I have further questions?
A: If you have any further questions with regards to this study then please phone 
Name: Helen Crank or Stephen Gilbert (Study researchers) tel. 0114 225 5413 
Name: Mr. Derek Rosario (Consultant Urologist) Tel: 0114 226 1229
Q: What if I wish to complain about the way this study has been conducted?
A: If you have any cause to complain about any aspect of the way in which you
have been approached or treated during the course o f this study, the normal 
National Health Service complaints mechanisms are available to you and are 
not compromised in any way because you have taken part in a research study. 
The normal hospital complaints procedure applies and you should contact the 
following person:
Name: Professor Mike Richmond (Medical Director) Tel: 0114 271 1900 
You can also complain to any individual of the research team:
Name: Dr Liam Bourke (Study researcher) tel. 0114 225 5865 
Name: Mr. Derek Rosario (Consultant Urologist) Tel: 0114 226 8840
Thank you for taking the time to consider participating in this study 
Mr Derek J Rosario (Project co-ordinator)
303
Figure 1 Study flow chart
Randomly allocated to either
Hospital Visit: Urology 
clinic medical screening
University VISIT: Assessment
University VISIT: Meet the Research team, read 
information and ask questions, confirm your 
consent
VISIT: Assessment
12 weeks later University VISIT: Follow up Assessment
VISIT: Baseline assessment (tests & questionnaires)
Researcher phones you 
bi-weekly to record 
activity levels
Usual Care 6 wks
2 x p/week exercise at home
1 x p/week for 6 weeks visit 
university &
University VISIT: x 6
Exercise 6wks
bi-weekly to record activity 
levels
Researcher phones you
Usual care: 6wks
University VISIT: x 12
Exercise: 6wks
1 per week exercise session 
at home
supervised exercise at 
university
2 per week for
6 weeks
304
APPENDIX 10
Sheffield Teaching Hospitals
Sheffield Hallam University
PATIENT CONSENT FORM
Version 3: 21st A p r il 2010 
Study: The feasibility of a combined programme of exercise and dietary advice
in the treatment in prostate cancer patients 
Patient Identification Number for this study:..................
Investigators: Mr. Derek Rosario, Dr. John Saxton, Helen Crank, Stephen Gilbert
Please initial the boxes
1. I confirm that I have read and understood the information sheet, version 6
dated 19-11 -2010 for the above study. I have had the opportunity to consider ____
the information, ask questions and have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw
at any time, without giving any reason, without my medical care or legal rights ____
being affected.
3. I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals of the
research team, where it is relevant to my taking part in this research. -------
I give permission for these individuals to have access to my records.
4. I agree to my G.P. being informed of my participation in the study.
5. I agree to take part in the above study.
Name o f  Patient Date Signature
Name o f  ind ividual taking consent 
( i f  not researcher)
Date Signature
Researcher Date Signature
3 copies to be kept; original for site file; 1 for patient; 1 for medical notes
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APPENDIX 11
EXERCISE AND DIETARY ADVICE IN THE TREATMENT OF PROSTATE
CANCER 
STH NUMBER: 07/Q2305/3
Week 1 Date:
Activity Duration RPE Intensity Feelings
E.g. Hill walking 30 minutes 14 Happy, energetic.
Week 2 Date:
Activity Duration RPE Intensity Feelings
Week 3 Date:
Activity Duration RPE Intensity Feelings
Week 4 Date:
Activity Duration RPE Intensity Feelings
Week 5 Date:
Activity Duration RPE Intensity Feelings
Week 6 Date:
Activity Duration RPE Intensity Feelings
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APPENDIX 12
Three Day Diet Diary
I t  is important that you note down everything that you eat and drink in the 
three days covered by this diary, including things consumed away from home, 
e.g. snacks or alcohol. This is important because if items are missed out the 
resulting analysis will not produce a true picture of your diet and we will not be 
able to compare it to the other diaries you will complete over the course of this 
study. Try to be as honest as possible, your responses will not be shown to the 
group.
When recording items in the diary you should enter the type of food or drink 
consumed and approximate quantity, e.g. two slices of toast or a can of coke. 
Where possible try  to list the d iffe ren t food items separately and in as much 
detail as possible, e.g. two slices of toast with a thin layer of butter and two 
teaspoonfuls of jam. Quantities can be reported as common measures where 
applicable, such as a cup/mug of tea or a spoonful of jam, otherwise please try  
and estimate the weight, e.g. 8oz steak. For ready meals, please note the pack 
weight and proportion consumed, e.g. half an 800g lasagne.
Also, please record the approximate time you consumed the item and whether it 
was a snack or part of a meal. This will help us build a picture of your daily 
eating pattern.
To save you from having to note down how you take your tea and coffee every 
time please complete the following two statements:
I  usually drink my tea with milk /  no milk and teaspoonfuls of sugar
I  usually drink my coffee with milk /  no milk and teaspoonfuls of sugar
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Date Time Meal or 
Snack?
Food Consumed Quantity
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APPENDIX 13
FACT-P (Version 4)
Below is a list of statements that other people with your illness have 
said are important. Please circle or mark one number per line to 
indicate your response as it applies to the past 7 days.
PHYSICAL WELL-BEING Not at all
A little 
bit
Some
-what
Quite 
a bit
Very
much
GP1 I have a lack of energy.................................... 0 1 2 3 4
GP2 I have nausea.................................................. 0 1 2 3 4
GP3 Because of my physical condition, I have 
trouble meeting the needs of my family 0 1 2 3 4
GP4 I have pa in........................................................ 0 1 2 3 4
GP5 I am bothered by side effects of treatment.... 0 1 2 3 4
GP6 I feel ill............................................................... 0 1 2 3 4
GP7 I am forced to spend time in bed.................... 0 1 2 3 4
SOCIAL/FAMILY WELL-BEING Not at 
all
A little 
bit
Some­
what
Quite 
a bit
Very
much
GS1 I feel close to my friends.................................. 0 1 2 3 4
GS2 I get emotional support from my fam ily.......... 0 1 2 3 4
GS3 I get support from my friends.......................... 0 1 2 3 4
GS4 My family has accepted my illness................. 0 1 2 3 4
GS5 I am satisfied with family communication 
about my illness................................................ 0 1 2 3 4
GS6 I feel close to my partner (or the person who 
is my main support).......................................... 0 1 2 3 4
Q1 Regardless of your current level of sexual 
activity, please answer the following question. If 
you prefer not to answer it, please mark this box □
GS7 I am satisfied with my sex life ......................... 0 1 2 3 4
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Very
much
4
4
4
4
4
4
Very
much
4
4
4
4
4
4
4
Please circle or mark one number per line to indicate your
response as it applies to the past 7 days.
EMOTIONAL WELL-BEING Not at A little Some Quite 
all bit -what a bit
I feel sad..................................................................  0
I am satisfied with how I am coping with my 
illness.......................................................................
I am losing hope in the fight against my illness... 0
I feel nervous..........................................................  0
I worry about dying.................................................  0
I worry that my condition will get worse.............  0
FUNCTIONAL WELL-BEING Not at A little Some Quite 
all bit -what a bit
I am able to work (include work at home)  0
My work (include work at home) is fulfilling  0
I am able to enjoy life......................................... 0
I have accepted my illness................................ 0
I am sleeping well..............................................  0
I am enjoying the things I usually do for fun.... 0
I am content with the quality of my life right 0
2
2
2
2
2
2
2
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44
4
4
4
4
4
4
4
4
4
4
Please circle or mark one num ber per line to indicate your
response as it applies to the past 7 days.
ADDITIONAL CONCERNS Not A little Some
at all bit -what
I am losing weight  0 1 2
I have a good appetite  0 1 2
I have aches and pains that bother me  0 1 2
I have certain parts of my body where I 0 1 2
experience pa in .........................................................
My pain keeps me from doing things I want to do.. 0 1 2
I am satisfied with my present comfort level  0 1 2
I am able to feel like a man  0 1 2
I have trouble moving my bowels  0 1 2
I have difficulty urinating  0 1 2
I urinate more frequently than usual  0 1 2
My problems with urinating limit my activities  0 1 2
I am able to have and maintain an erection  0 1 2
Quite 
a bit
3
3
3
3
3
3
3
3
3
3
3
3
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4
4
4
4
4
4
4
4
4
4
4
APPENDIX 14
FACIT Fatigue Scale (Version 4)
Below is a list o f statements that other people with your illness have said are 
important. Please circle or m ark one num ber per line to indicate your 
response as it applies to the past 7 days.
Quite 
a bit
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3
3 
3
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Not at A little Some-
all bit what
I feel fatigued..................................................................  0 1 2
I feel weak all over.........................................................  0 1 2
I feel listless (“washed out”) .........................................  0 1 2
I feel tired......................................................................... 0 1 2
I have trouble starting things because I am tired   0 1 2
I have trouble finishing things because I am tired   0 1 2
I have energy...................................................................  0 1 2
I am able to do my usual activities...............................  0 1 2
I need to sleep during the d ay .......................................  0 1 2
I am too tired to ea t........................................................  0 1 2
I need help doing my usual activities...........................  0 1 2
I am frustrated by being too tired to do the things I
want to do...........................................................................  0 1 2
I have to limit my social activity because I am tired . . 0  1 2
